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Abstract 
 
Calcium/Calmodulin dependent protein kinase kinase beta (CaMKKβ) is a serine/threonine 
kinase involved in the Calcium/Calmodulin dependent protein kinase (CaMK) cascade. In 
2005, CaMKKβ was shown to phosphorylate and activate AMP-activated protein kinase 
(AMPK), a master regulator of metabolism. Activation of AMPK has previously been reported 
to inhibit vascular smooth muscle myosin light chain (MLC) phosphorylation. The 
phosphorylation state of MLC in smooth muscle is known to directly control the contractility of 
blood vessels and the maintenance of blood pressure.        
 
This thesis describes the characterisation of the global CaMKKβ knockout (CaMKK KO) 
mice, as well as the investigation of CaMKKβ signalling pathways involved in blood pressure 
regulation using CaMKK KO mice in a model of lipopolysaccharide induced septic shock. 
Septic shock is a syndrome defined by persistently reduced blood pressure despite fluid 
resuscitation leading to multiple organ failure resulting from overwhelming infection. Using 
implantable telemetry probes, aortic blood pressure was recorded in age matched male wild-
type (WT) and CaMKK KO mice under both basal conditions and during lipopolysaccharide 
induced septic shock. In mice with global deletion of CaMKKβ, basal blood pressure was 
found to be increased compared to their WT littermates. In addition, when treated with 
intraperitoneally injected bacterial lipopolysaccharide, the lack of CaMKKβ appears to confer 
protection against hypotension, with significantly higher blood pressure seen in CaMKK KO 
mice, as well as improved mobility and general physiological state, compared to WT mice. To 
investigate the mechanism for the increased blood pressure in CaMKK KO mice, aorta lysate 
MLC kinase activity and MLC phosphorylation were measured and found to be increased in 
lipopolysaccharide treated CaMKK KO mice compared to WT mice.  In contrast to a recent 
independent study, no indication of altered inflammatory response was found in CaMKK KO 
mice compared to WT littermates following intraperitoneal lipopolysaccharide injection. Ex 
vivo lipopolysaccharide treatment induced similar levels of nitric oxide production and 
phagocytosis in primary peritoneal macrophages isolated from WT and CaMKK KO mice.    
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In summary, CaMKKβ appears to be involved in the regulation of blood pressure.  Loss of 
CaMKKβ in mice protects against septic shock through increased phosphorylation of MLC 
and the maintenance of blood pressure.  Currently, septic shock is associated with a high 
mortality rate despite the available pharmacological treatments; inhibition of CaMKKβ could 
provide an alternative strategy to assist with the maintenance of blood pressure during 
sepsis.   
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Chapter 1. Introduction 
 
Protein phosphorylation is one of the critical mechanisms within biological organisms. 
Proteins are phosphorylated by kinases and dephosphorylated by phosphatases. The 
phosphorylation of a protein can either activate or inactivate the protein.  
The discovery of protein phosphorylation begins in the early 1940s.  The conversion between 
an active and inactive form of glycogen phosphorylase was shown in a series of publications 
on glycogen metabolism (Cori and Green, 1943). Following on from this, research by Fischer 
and Krebs in 1955 presented evidence for the regulation of glycogen phosphorylase by 
reversible phosphorylation, and the identification of the first protein kinase as the cause of the 
conversion between the active and inactive forms of glycogen phosphorylase (Fischer and 
Krebs, 1955; Krebs and Fischer, 1955).  Since then, protein phosphorylation has been the 
focus of a large body of research.  In 2002, Manning et al. identified 518 putative human 
kinase genes which have been collectively described as the human kinome (Manning et al. 
2002). 
 
A considerable amount of literature has been published on the phosphorylation of proteins 
and protein phosphorylation has been shown to play a significant role in the regulation of a 
wide range of cellular processes.  For example, the mitogen-activated protein kinase (MAPK) 
cascade is initially activated by Mitogen-activated protein kinase kinase kinase; the cascade 
has been shown to function in cell proliferation, cell differentiation, and cell death (Junttila et 
al. 2008; Raman et al. 2007; Turjanski et al. 2007). In humans, the dysregulation of one of 
the subgroups of MAPK, p38 MAPK, has been shown to be associated with advanced stage 
and reduced mortality in several cancers including prostate cancer (Khandrika et al. 2009), 
liver cell cancer (Iyoda et al. 2003), and non small cell lung cancer (Greenberg et al. 2002).   
Protein phosphorylation has been shown to be involved in biological functions ranging from 
energy homeostasis (Carling et al. 1997; Kahn et al. 2005), leukocyte cytokine production 
(Van der Bruggen et al. 1999; Rosengart et al. 2002), to smooth muscle contraction in blood 
pressure regulation (Adelstein and Conti 1975; Somlyo and Somlyo 1994).  
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The contractility of smooth muscle myosin light chain (MLC) is important for establishing 
vessel tone and therefore the maintenance of systemic blood pressure (Haslett et al. 2002). 
In 1975, Adelstein and Conti discovered that smooth muscle myosin light chain contractility 
was regulated by a calcium dependent reversible protein phosphorylation mechanism 
(Adelstein and Conti 1975).   
In the area of metabolism, AMP-activated protein kinase (AMPK), has been shown to be a 
regulator of cellular and whole body energy homeostasis in response to stress conditions 
(Carling et al. 1997; Kahn et al. 2005 ).  In 2005,  In addition to activation by liver kinase B1 
(LKB1) (Hong et al. 2003), AMPK was found to be activated by the protein kinase 
Ca2+/Calmodulin dependent protein kinase kinase β (CaMKKβ) (Woods et al. 2005; Hawley 
et al. 2005).  
With the exception of long term memory formation (Peters et al. 2003), very little is known 
regarding the physiological functions of CaMKKβ in other biological systems.  In this study, 
the function of CaMKKβ is investigated using a mouse knockout model, under basal 
conditions as well as under the stress condition of hypotension resulting from sepsis.  
 
1.1 Ca2+/Calmodulin dependent protein kinase kinase β  
 
There are two isoforms of Ca2+/Calmodulin dependent protein kinase kinase: 
Ca2+/Calmodulin dependent protein kinase kinase α (CaMKKα) and Ca2+/Calmodulin 
dependent protein kinase kinase β (CaMKKβ), encoded by different genes.  Human CaMKKβ 
shares 65% protein sequence homology with CaMKKα; with the greatest heterogeneity seen 
at the two termini outside the central kinase domain (Anderson et al. 1998). Although 
CaMKKβ and CaMKKα have common downstream targets, both of the CaMKKs can 
phosphorylate Ca2+/Calmodulin dependent protein kinase I (CaMK I) and Ca2+/Calmodulin 
dependent protein kinase IV (CaMK IV); the evidence suggests only CaMKKβ is capable of 
phosphorylating AMP-activated protein kinase (AMPK), a master regulator of metabolism 
(Woods et al.  2005).  
 
CaMKKβ is a serine/threonine kinase also known as CaMKK2. CaMKKβ show greater than 
90% amino acid conservation between mice, rats and men, with heterogeneity present in the 
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3’ non-coding termini (Vinet et al. 2003). The human CaMKKβ locus maps to chromosome 
12q24.2, and consists of 18 exons and 17 introns. Multiple transcripts have been found 
including two main transcripts generated through the usage of polyadenylation sites located 
in the last two exons, as well as additional transcripts from alternative splicing of the internal 
exons (Hsu et al. 2001).    
 
1.1.1 CaMKKβ and the CaMK cascade 
 
 CaMKKβ and CaMKKα can both activate CaMK I and/or CaMK IV as part of the CaMK 
cascade.  In cells, an influx of Ca2+ leads to a greater amount of Ca2+ bound calmodulin 
(Ca/CaM), allowing binding of Ca/CaM to all the members of the CaMK cascade including the 
CaMKKs, CaMK I and CaMK IV.  Following binding of Ca/CaM, CaMK I and CaMK IV adopt 
conformation changes which allow access for the activated CaMKKs to phosphorylate their 
activating residues at Thr177 and Thr200 respectively and enhance their activity by 10-20 
fold (Nairn and Picciotto 1994; Soderling 1996; Wayman et al. 1997).  
 
 CaMKKα and CaMKKβ are themselves activated by the binding of Ca/CaM through 
conformation change; however there are important differences in the regulation of their 
activation.  CaMKKα is known to be inhibited by PKA phosphorylation, both directly through 
phosphorylation at Thr108 and Ser458, and also through the recruitment of 14-3-3 following 
phosphorylation of Ser74 (Davare et al. 2004).  Whereas CaMKKα is entirely dependent on 
the binding of Ca/CaM for its activation; studies using CaMKKβ purified from both bacterial 
and mammalian sources show varying amounts of Ca/CaM independent activity (Anderson et 
al. 1996; Tokumitsu et al. 2001; Woods et al. 2005).   
 
Two studies published in 2011 investigated the autonomous activity seen in recombinant 
CaMKKβ expressed in bacteria.  Tokumitsu et al identified Thr482 in the regulatory domain 
as an autophosphorylation site in bacterially expressed CaMKKβ; mutation of the residue to 
alanine led to the loss of 65% of total activity (Tokumitsu et al. 2011).  A separate study 
identified the sequential phosphorylation of three inhibitory sites, first Ser137, followed by 
Ser133 and Ser129, to regulate the autonomous activity of CaMKKβ from mammalian 
sources (Green et al. 2011). Mutating all three residues to alanine more than doubled the 
autonomous activity of mammalian CaMKKβ, from 20% to 50% maximum activity compared 
to bacterially expressed CaMKKβ which was shown to have 70% maximum activity 
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(measured in the presnce of calcium and calmodulin).  The same study also showed cyclin-
dependent kinase 5 (CDK5) and glycogen synthase kinase 3 (GSK3) to be the upstream 
kinases in human embryonic kidney (HEK293) cells; however in neurones from CDK5 
conditional knockout mice, the authors reported reduced CaMKKβ protein expression but no 
result was shown for CaMKKβ phosphorylation or activity (Green et al. 2011). 
 
1.1.2 Tissue specific activation of the CaMK cascade  
 
The CaMK cascade is known to regulate cAMP response-element binding protein (CREB) 
dependent transcriptional activity in vivo, which is important for hippocampal long term 
memory formation (Lonze and Ginty. 2002).  CaMKKα and CaMKKβ are both highly 
expressed in the brain (Anderson et al. 1996), and have been shown to be important in the 
formation of memory and neuronal plasticity (Wayman et al. 2008).  In addition, studies show 
the CaMK cascade is essential for axon and dendrite elongation in cortical neurons (Ageta-
Ishihara et al. 2009; Davare et al. 2009), as well as synaptogenesis in hippocampal neurons 
(Saneyoshi et al. 2008).   
 
Global CaMKKβ KO mice generated by Peters et al were found to have male specific 
impaired spatial memory formation secondary to reduced spatial-training induced CREB 
activation, as well as impaired long term memory for the social transmission of food 
preferences secondary to the lack of late long term potentiation at the hippocampal area CA1 
synapses (Peters et al. 2003; Mizuno et al. 2007).  No difference was found in other types of 
hippocampus dependent long term memory, including contextual fear memory and passive 
avoidance, compared to wild-type mice suggesting that the formation of these long term 
memory types do not require the activation of CREB by CaMKKβ.  In contrast, CaMKKα KO 
mice have impaired contextual fear memory, also male specific, with no difference found in 
spatial memory or social transmission of food preferences (Mizuno et al. 2006).  The cause of 
the different long term memory impairments seen between the CaMKKα and CaMKKβ KO 
mice is currently unclear.   
 
CaMKKs have also been shown to function in non-neuronal systems through the CaMK 
cascade.  In the immune and inflammatory system, CaMKK function has been shown to be 
required for the development of T lymphocytes, through the phosphorylation of CaMK IV 
following T lymphocyte receptor binding leading to nuclear translocation of CaMK IV, 
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transcription of interleukin 2, CD25 upregulation and thymocyte development (Racioppi and 
Means. 2008). CaMK IV has also been shown to be important in the maintenance of bone 
turnover, Oury et al showed both CaMKKβ and CaMK IV deletion in Steroidogenic Factor 1 
(SF1) expressing hypothalamic neurones are associated with increased osteoblast 
proliferation and reduced bone mass (Oury et al. 2010).   
 
CaMK I can be found in most tissues where it is predominantly cytosolic (Piccioto et al. 
1995).  In addition to axonal growth, CaMK I has also been found to phosphorylate substrates 
involved in transcription initiation and cytoskeleton regulation (See table 1.1).  The 
physiological consequence of regulation by CaMK I is currently unclear as is the role of 
phosphorylation on the function of several of its identified substrates.  
 
 
 
 Table 1.1   Substrates of CaMK I identified in vitro and/or in situ. (Wayman et al. 2008). 
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1.1.3 CaMKKβ and AMPK phosphorylation 
 
CaMKKβ was shown to be an upstream activator of AMP-activated protein kinase (AMPK) by 
several groups (Hawley et al. 2005; Hurley et al. 2005; Woods et al. 2005) (See Figure 1.1).  
CaMKKβ phosphorylates AMPK at Thr172, the same site phosphorylated by the previously 
identified upstream kinase of AMPK, liver kinase B1 (LKB1) (Hong et al. 2003).  Hurley et al 
show reduced AMPK activity in Hela cells transfected with CaMKKα small interfering RNA 
suggesting CaMKKα may also activate AMPK (Hurley et al. 2005); however, this is not 
consistent with work previously published from other groups,where CaMKKα does not 
significantly activate AMPK either in vitro or in mammalian cells (e.g. Hawley et al. 2005; 
Woods et al. 2005; Stahmann et al. 2006).  
  
AMPK is a serine/threonine protein kinase conserved throughout eukaryotes. It is a regulator 
of energy balance and monitors cellular energy status in response to various stresses.  Once 
activated by low energy status it, switches on adenosine triphosphate (ATP) producing 
catabolic pathways such as fatty acid oxidation and glycolysis, and switches off ATP 
consuming anabolic pathways such as lipogenesis.  It does this both by immediate effects 
through targeted phosphorylation of substrates such as acetyl CoA carboxylase (ACC) (Kahn 
et al. 2005), and by long-term effects on transcription and gene expression (Carling et al. 
1997). AMPK also controls whole body energy homeostasis by integrating, at the 
hypothalamic level, nutrient and hormonal signals that regulate food intake and energy 
expenditure (Schneeberger and Claret. 2012). AMPK is a well studied cellular energy sensor 
with many known substrates (see Appendix 1). 
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Figure 1.1 Diagram of the downstream targets of CaMKK. The influx of Ca2+ into cells 
leads to the activation of the CaMK cascade through binding of Ca/CaM to all the members of 
the CaMK cascade including the CaMKKs, CaMK I and CaMK IV. Both CaMKKα and 
CaMKKβ can phosphorylate CaMK I and CaMK IV.  In addition, CaMKKβ can activate AMP 
kinase (AMPK) through phosphorylation of Thr172 on the α subunit of AMPK, the same site 
phosphorylated by the known kinase of AMPK, liver kinase B1 (LKB1). AMPK is a monitor of 
cellular energy status. Once activated, AMPK functions to restore energy balance at the 
cellular level and controls whole body energy homeostasis.  
 
 
 
1.1.4 Structure and function of AMPK complexes 
 
AMPK is a heterotrimeric complex consisting of a catalytic α subunit and two regulatory 
subunits, β and γ. The α subunit contains the activation loop where phosphorylation of the 
residue Thr172 by LKB1 or CaMKKβ leads to activation of AMPK through a conformational 
change (Carling et al. 2012).  The γ subunit contains tandem repeats known as cystathionine 
β-synthase (CBS) motifs which can bind AMP, ADP or ATP in a mutually exclusive manner 
(Xiao et al. 2011).  The binding of AMP to the γ subunit can allosterically activate AMPK 
 27 
(Carling et al. 1989).  It was originally proposed that AMP binding promoted the 
phosphorylation of AMPK by the upstream kinases LKB1 and CaMKKβ; however recent 
studies show that the binding of ADP, rather than AMP, to the γ subunit retains AMPK activity 
by protecting against the dephosphorylation of Thr172 (Xiao et al. 2011).  
 
In mammals, different genes encode isoforms for each of the subunits (α1 and α2; β1 and β2; 
γ1,γ2 and γ3), giving rise to twelve possible heterotrimeric combinations (Carling et al. 2012).  
Differences in the tissue distribution of catalytic and regulatory isoforms expression patterns 
have been reported.  In comparison to equivalent expression of AMPKα1 and α2 containing 
complexes in the liver; erythrocytes, endothelial cells and bone cells mainly express AMPK 
complexes containing α1 subunits, whereas skeletal and cardiac muscles mainly express 
AMPK complexes containing α2 subunits (Kahn et al. 2005; Viollet et al. 2009; Jeyabalan et 
al. 2012). In addition to tissue distribution, the distribution of AMPK complexes also varies at 
the intracellular level.  AMPK complexes with α1 subunits are predominantly localized in the 
cytoplasm, but have also been noted at the plasma membrane in airway epithelial cells and 
carotid body cells (Viollet et al. 2009).  In comparison, AMPK complexes with α2 subunits can 
be found in the nucleus as well as the cytoplasm (Jager et al. 2007). These differences 
between the tissue expression and intracellular localisation of AMPKα1 and α2 subunit 
complexes hint at differential regulation of the α subunits, potentially through the upstream 
kinases.  
 
Knockout mouse model studies also suggest possible specificity in the upstream kinases for 
the catalytic isoforms.  Lack of AMPKα2 activity was seen in mice with skeletal muscle 
specific deletion of LKB1, associated with impaired 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) and contraction stimulated muscle glucose uptake (Sakamoto et al. 
2005).   In cardiomyocyte specific LKB1 KO mice, ischaemia in the heart led to the loss of 
AMPKα2 activity whereas AMPKα1 activity was minimally affected, indicating a different 
kinase, potentially CaMKKβ, may be the upstream kinase for complexes containing AMPKα1 
subunits (Sakamoto et al. 2006).  The functional significance of the different AMPK isoform 
combinations and their upstream kinase specificity is currently unclear and remains an 
interesting area of study.  
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1.1.5 Tissue specific roles for AMPK and CaMKKβ 
 
Many studies have been carried out to elucidate the function of AMPK in different tissues but 
the role of the upstream kinase is often unclear.  Summaries of AMPK function have been 
categorised into the main organs where they occur, and are presented below with an 
emphasis on pathways that could potentially be activated by CaMKKβ. It is important to note 
that many of the AMPK functions occur in most tissues and the interaction between different 
tissues is essential in the control and regulation of metabolism. 
 
1.1.5.1 Brain 
 
CaMKKβ is highly expressed in many regions of the brain.  The involvement of CaMKKβ in 
the formation of long term memory through the CaMK cascade has already been discussed 
(See section 1.1.2).  CaMKKβ also appears to play a role in the hypothalamic control for 
whole body energy balance through the activation of AMPK; however, the details of the 
mechanism are currently under debate.   
 
In the hypothalamus, AMPK is known to regulate feeding behaviour in response to multiple 
hormonal and nutritional signals. It is activated by fasting, hypoglycaemia and ghrelin, and 
inhibited by hyperglycaemia, insulin and leptin (Schneeberger and Claret 2012).  Ghrelin is a 
hormone secreted by the stomach prior to meals and during periods of fasting or starvation.  
The central effects of ghrelin on increased food intake and body weight have been shown to 
be mediated by AMPK activation in neuropeptide Y (NPY)/agouti-related protein (AgRP) 
neurons in the arcuate nucleus of the hypothalamus. Under fasting conditions, ghrelin was 
shown to increase presynaptic AMPK activity through intracellular Ca2+ release and 
subsequent CamKKβ activation, leading to further Ca2+ release and setting up a positive 
feedback loop which activates the AgRP neurons (Yang et al 2011).  
However, conflicting data have been published in KO mouse models regarding the role of 
CaMKKβ in grehlin induced feeding.  In 2008, Anderson et al showed reduced food intake in 
the global CaMKKβ KO mice on a high fat diet associated with reduced AMPK activation and 
up regulation of NPY and AgRP gene expression in the hypothalamus.  Recently, Claret et al 
showed no difference between weight gain, food intake, glucose tolerance and insulin 
resistance in a separate cohort of high fat diet fed global CaMKKβ KO mice compared to WT 
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controls (Claret et al. 2011).  The reason for the discrepancy between the results is currently 
unknown.   
 
1.1.5.2 Liver 
 
Hepatic metabolism plays an important role in the control of whole body energy status.  
Evidence from mouse models confirms the importance of AMPK in the regulation of glucose 
production and fatty acid synthesis.  LKB1 has been shown to be involved in hepatic glucose 
production (Shaw et al. 2005). 
 
The involvement of hepatic AMPK in whole body glucose homeostasis was suggested by 
liver specific AMPKα2 KO mice, with hyperglycaemia and glucose intolerance through 
increased hepatic glucose production (Andreelli et al. 2006).  Pharmacological activation of 
AMPK by AICAR in normal as well as insulin resistant obese rats was found to inhibit hepatic 
glucose production (Bergeron et al.  2001).   It has also been shown that in liver specific 
LKB1 KO mice, increased hepatic glucose production was associated with negligible AMPK 
activity; in addition, the hypoglycaemic effect of metformin was also found to be absent 
(Shaw et al. 2005).  However, recent studies have questioned the involvement of AMPK in 
AICAR and metformin induced inhibition of hepatic glucose production.  Metformin and 
AICAR were still able to lower glucose production in AMPKα1α 2 null hepatocytes (Foretz et 
al 2010, Guigas et al. 2006); suggesting the hypoglycaemic effect seen following metformin 
and AICAR treatment does not occur through hepatic AMPK activation.   AICAR was found to 
inhibit the expression of gluconeogenic genes including glucose-6-phosphatase and 
phosphoenolpyruvate carboxykinase (PEPCK) independently of AMPK activity (Foretz et al. 
2010).  The mechanism underlying the hypoglycaemic effect of hepatic AMPK remains 
unclear.   
 
AMPK has been shown to control the balance between hepatic fatty acid synthesis and 
mitochondrial β-oxidation, the breakdown of fatty acids to acetyl-CoA.   Acetyl-CoA 
carboxylase (ACC) is an important rate controlling enzyme for the synthesis of malonyl-CoA 
from acetyl-CoA.  AMPK can phosphorylate both isoforms of ACC, at Ser79 on ACC1 and 
Ser221 on ACC2 respectively, and inhibit their function (Carling et al. 1989).  Malonyl-CoA is 
both a precursor for the biosynthesis of fatty acids, and also an inhibitor of mitochondrial β-
oxidation through the inhibition of fatty acid transport into the mitochondria by carnitine 
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palmitoyltransferase  1 (CPT1).  Activation of AMPK leads to reduced triglyceride synthesis 
concurrent with an increase in β-oxidation, as seen following the pharmacological activation 
of rat hepatocytes by AICAR treatment (Muoio et al. 1999).  Further support comes from 
mouse models where liver specific overexpression of a constitutively active version of the 
catalytic domain of AMPKα2 decreases plasma triglyceride levels and increases plasma 
ketone bodies, a surrogate marker for hepatic β-oxidation (Foretz et al. 2005); and 
conversely, deletion of AMPKα2 in the liver leads to increased plasma triglyceride levels and 
reduced plasma ketone body levels (Viollet et al. 2009).  
 
AMPK also regulates cholesterol synthesis through the phosphorylation, at Ser871, and 
inhibition of hydroxyl-3-methylglutaryl-CoA (HMG-CoA) reductase (Carling et al. 1987).  
Inhibition of HMG-CoA reductase prevents the conversion of HMG-CoA to mevalonate, and is 
the rate limiting step targeted by statins, frequently used cholesterol reducing drugs. In both 
total and liver specific AMPKα2 KO mice, both total plasma cholesterol and high density 
lipoprotein (HDL) concentrations were found to be similar to WT mice (Viollet et al. 2009), 
suggesting that HMG-CoA is likely a target for AMPK complexes containing the α1 subunit.   
 
AMPK has also been reported to regulate mitochondrial function through the regulation of 
transcription factors and co-activators including peroxisome proliferator activated receptor γ 
coactivator 1α (PGC1α) and nuclear respiratory factors (NRF) (Guigas et al. 2007; Jäger et 
al. 2007). Liver specific double KO of AMPKα1 and α2 was shown to have reduced 
mitochondrial respiration as well as mitochondrial biogenesis as measured by reduced 
transcript and proteins expression of PGC1α and cytochrome c (Guigas et al. 2007).  It is 
likely that the control of mitochondrial function will not be limited only to hepatocytes, 
providing another layer of regulation by AMPK in the maintenance of cellular energy 
homeostasis.  
 
1.1.5.3 Adipose tissue 
 
Adipocytes provide energy storage for periods of increased energy expenditure or reduced 
food availability.  In addition to the inhibition of fatty acid synthesis by AMPK phosphorylation 
of ACC, AICAR activation of AMPK has also been shown to inhibit lipolysis where 
triglycerides are hydrolyzed into fatty acids and glycerol (Sullivan et al. 1994, Daval et al. 
2005).  The mechanism of inhibition is not entirely clear.   AMPK has been shown to 
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phosphorylate Ser565 on hormone sensitive lipase (HSL) which then abolishes the activating 
phosphorylation by protein kinase A on the adjacent S563, leading to a reduction in HSL 
activity and lipolysis (Garton et al. 1989).  An alternative mechanism has also been shown in 
adipocytes, where AMPK activation by AICAR leads to a reduction in isoproterenol induced 
HSL translocation to the lipid droplet; reversible by viral overexpression of the dominant 
negative form of AMPK (Daval et al. 2005).  
 
Consistent with this, adipocytes from mice with AMPKα1 global deletion show reduced size 
and increased lipolysis (Daval et al. 2005).  Interestingly, although adipocytes contain 
predominantly AMPKα1 complexes, mice with AMPKα2 global deletion on a high fat diet 
show increased lipid accumulation in their pre-existing adipocytes compared to WT mice 
(Villena et al. 2004); indicating different downstream targets between AMPKα 1 and AMPKα2 
complexes in the regulation of adipocyte metabolism. 
 
To complicate matters, a recent study showed increased adiposity and adipocyte size in 
global CaMKKβ KO mice on a standard diet, opposite to the AMPKα 1 KO phenotype (Fumin 
et al. 2011).  They show increased adipogenic gene expression and enhanced differentiation 
in CaMKKβ KO adipocytes which can be reversed by AICAR activation of AMPK, suggesting 
CaMKKβ enhances lipolysis through AMPK dependent expression of adipocyte differentiation 
genes.  
 
1.1.5.4 Skeletal muscle 
 
In skeletal muscle, the activation of AMPK by acute exercise is dependent on the intensity of 
the exercise in both rodents and humans (Treebak et al. 2008).  AMPK activation during 
exercise appears to be confined locally as AMPK activation in human skeletal muscle during 
one-legged exercise occurs only in the exercising muscle (Kristensen et al. 2007).   Exercise 
at 60-70% of maximum oxygen consumption is required for AMPK activation, and the 
regulation of AMPK in skeletal muscle have been shown to occur mainly through AMPKα2 
complexes (Birk et al. 2006; Jorgensen et al; 2005, Klein et al; 2007).  As the regulation of 
glucose uptake during muscle contraction has been shown to be regulated by LKB1 through 
AMPKα2 complexes (Sakamoto et al. 2005), the contribution of CaMKKβ in muscle 
metabolism during contraction is likely limited.  
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AMPK can regulate glucose uptake in skeletal muscle both under resting conditions and 
following contraction stimulation (Lee et al. 2002).  AICAR or hypoxia stimulated glucose 
uptake is abolished in muscles from AMPKα2 global KO mice, where the AICAR induced 
phosphorylation of Akt substrates of 160kDa (AS160), an important protein in the regulation 
of insulin dependent glucose transporter type 4 (GLUT4) transport and glucose uptake, is lost 
(Treebak et al. 2006, Kramer et al. 2006).  Contraction induced phosphorylation of AS160 
has also been shown to occur mainly through AMPKα2 complexes, specifically α2β2γ1 
(Treebak et al. 2008).  In addition, lack of AMPKα2 phosphorylation is seen in muscle LKB1 
KO mice in association with impaired AICAR and contraction stimulated glucose uptake 
(Sakamoto et al. 2005). 
 
Muscle fatty acid metabolism is also partially regulated by AMPK activity.  AMPK activation in 
muscle by AICAR or contraction leads to increasing rates of fatty acid β-oxidation through 
phosphorylation and inhibition of ACC (Mirrell et al. 1997; Barnes et al. 2004).  However, the 
increase in β-oxidation resulting from muscle contraction have been shown to be AMPK 
independent at low exercise intensity (Raney and Turcotte 2006), indicating alternative 
pathways are also present.   
 
In addition to glucose and fatty acid, glycogen provides another major source of energy in 
skeletal muscle during muscle contraction.  In skeletal muscle, AMPKα2 but not AMPKα1, 
has been shown to phosphorylate and inhibit glycogen synthase (Jorgensen et al. 2004), the 
rate limiting enzyme in glycogen synthesis. However increased muscle glycogen content and 
exercise capacity was found in AMPKγ3 over expression mutants where AMPK activity is 
increased in skeletal muscle (Barnes et al. 2005).  
 
1.1.5.5 Heart 
 
The activation of CaMKI by CaMKKβ has been reported in hog heart lysates (Uemura et al. 
1998) but its physiological function is unknown.  AMPKα2, the predominant subunit 
expressed in the murine heart, and is known to play a major role in cardiac metabolism 
including glucose uptake, fatty acid oxidation, and ischaemia induced glycolysis (Russell et 
al. 2004; Zarrinpashneh et al. 2006). AMPKα2 activation in cardiac muscle is known to be 
regulated by LKB1 (Sakamoto et al. 2006); the physiological function of the small proportion 
of AMPKα 1 subunit and the involvement of CaMKKβ is unclear. 
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1.1.5.6 Blood cells 
 
Erythrocytes, macrophages, neutrophils and lymphocytes all predominantly express the 
AMPKα1 subunit (Tamas et al. 2006; Foretz et al. 2010; Bae et al. 2011), suggesting AMPK 
subunit specificity in the haematopoietic lineage.  The activation of AMPK by CaMKKβ has 
been shown in T lymphocytes following T cell antigen receptor (TCR) binding and is 
suggested to provide ATP for the cell proliferation and differentiation that follows TCR 
activation (Tamas et al. 2006). In erythrocytes, AMPK is essential for the maintenance of cell 
membrane flexibility, as Global AMPKα1 KO mice have anaemia and splenomegaly due to 
lysis of rigid erythrocytes sequestered in the spleen (Foretz et al. 2010).  AMPK is also 
important for phagocytosis by macrophages and neutrophils.  Activation of AMPK by AICAR 
and metformin was shown to increase phagocytosis by both macrophages and neutrophils 
through increased microtubule formation and actin polymerization (Bae et al. 2011). 
 
Several studies have been carried out investigating the involvement of CaMKKβ and CaMK 
IV in T lymphocytes.  CaMKKβ was shown to activate CaMK IV following TCR binding in 
cultured human lymphocytes (Park and Soderling. 1995), and the activation of CaMK IV has 
been shown to be required for CREB phosphorylation and transcription activation following 
TCR binding (Westphal et al. 1998).  CaMK IV has also been found to be involved in the 
thymocyte transition from double positive (DP) (CD4+CD8+) to single positive (SP) (CD4+ or 
CD8+) during lymphocyte development through an unknown mechanism, with CaMK IV KO 
mice showing a decrease in the percentage of SP cells accompanied by a corresponding 
increase in the percentage of DP cells (Raman et al. 2001). It is currently unclear whether 
CaMKKα and/or CaMKKβ is the responsible kinase for the activation of CaMK IV during 
lymphocyte development.  
 
1.1.5.7 Bone 
 
Recent studies suggest the involvement of CaMKKβ in the regulation of bone turnover.  
CaMK I was shown to be involved in the proliferation of osteoblasts in vitro, with deletion by 
siRNA in osteoblasts leading to reduced osteoblast proliferation (Pedersen et al. 2008).  More 
recently, Oury et al showed both CaMKK β and CaMK IV deletion in Steroidogenic Factor 1 
(SF1) expressing hypothalamic neurones are associated with increased osteoblast 
proliferation and reduced bone mass (Oury et a. 2010), the opposite phenotype to that seen 
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in CaMK1 osteoblast deletion.  In addition, global AMPKα1 KO mice have been shown to 
have reduced trabecular bone mass and density, with the AMPKα1 subunit being the 
predominant subunit expressed in both osteoblasts and osteoclasts (Jeyabalanet et al.  
2012). If CaMKKβ is the upstream kinase for AMPKα 1 subunit, deletion of CaMKKβ should 
result in a similar phenotype to that seen in the AMPKα1 KO mice. 
 
1.1.5.8 Kidneys 
 
Sodium transport is known to be the major energy requiring process in the kidney (Kiil et al. 
1961). Indications that AMPK is involved in regulation of sodium transport by the kidneys 
came from the finding that kidney AMPK activity was increased in rodents fed either a high 
salt or a low salt diet for two weeks, with reduced AMPKα1 expression seen following the low 
salt diet only (Fraser et al. 2005).  Since then, AMPK has been found to phosphorylate the 
kidney specific Na+-K+-2Cl- co-transporter 2 (NKCC2) on Ser126 and shown to reduce the 
activity of NKCC2 in Xenopus laevis oocytes under basal conditions (Fraser et al. 2007).  
NKCC2 activity results in salt reabsorption, transporting Na+, K+, and Cl-, across the luminal 
membrane in the ascending limb of the loop of Henle and the macula densa (Yang et al. 
1996).  Currently, there is no data on the physiological function of NKCC2 activation by 
AMPK in the kidneys. 
 
1.1.6 Pharmacological activators and inhibitors 
 
As CaMKKβ is activated by an increase in the concentration of Ca2+, any pharmacological 
agent that causes an increase in intracellular Ca2+, whether through activation of ion 
channels or release from intracellular stores, can potentially result in activation of CaMKKβ.  
Cytoplasmic Ca2+ is normally maintained in the range of 10-100 nM, compared to millimolar 
levels in the extracellular space, with Ca2+ being actively pumped from the cytosol into the 
extracellular space, the endoplasmic reticulum, and the mitochondria (Clapham et al. 2007).  
Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus that acts as 
a mobile ion carrier transporting Ca2+ across and into the cytoplasm down the concentration 
gradient (Liu et al. 1978) and has been shown  to activate CaMKKβ leading to the activation 
of AMPK in Hela cells (Woods et al. 2005).   
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STO-609 was originally thought to be a specific inhibitor of both CaMKKα and CaMKKβ, with 
IC50 values of 120 ng/ml and 40 ng/ml, respectively (Tokumitsu et al. 2002).  It is not a 
Calmodulin antagonist such as trifluoperazine, instead it targets the catalytic domains of the 
CaMKKs.  At a concentration of 10µg/ml, STO-609 show 50% inhibition of CaMK II, 46% 
inhibition of myosin light chain kinase (MLCK), and less than 25% inhibition of CaMK I and 
CaMK IV (Tokumitsu et al. 2002).  Used at high concentrations, STO-609 is also known to 
directly inhibit AMPK activity (Bain et al. 2007). 
 
 
1.2 The Regulation of Blood Pressure 
 
Although a few recent studies have suggested the involvement of AMPK in vasodilation 
through nitric oxide production (Chen et al. 1999; Morrow et al. 2003) and its involvement in 
the establishment of blood vessel tone (Horman et al. 2008), the role of CaMKKβ in blood 
pressure regulation and sepsis had not been previously investigated.  In this study, the 
function of CaMKKβ in blood pressure regulation is investigated both under basal conditions 
and during hypotension induced in a mouse sepsis model. 
 
Blood pressure (BP) describes the pressure exerted by the circulating blood on the blood 
vessel walls, and will be used to refer to arterial blood pressure unless further specified.  It 
oscillates between a high systolic pressure (SBP) during cardiac contraction to a low diastolic 
pressure (DBP) during cardiac relaxation (Haslett et al. 2002).  Blood pressure is tightly 
regulated within a range optimised for tissue perfusion and oxygenation.  Low blood pressure 
predisposes to faints and falls, and persistently low blood pressure refractory to treatment as 
seen during sepsis is associated with a high risk of 45-50% mortality (Sakr et al. 2006; 
Esteban et al. 2007).  On the other hand, high blood pressure is the major risk factor for the 
development of cardiovascular disease (Haslett et al. 2002).     
 
In keeping with the importance of blood pressure maintenance, a complex regulatory network 
involving many systems exists to maintain blood pressure within the optimal range (See 
Figure 1.2).   Blood pressure is regulated by altering a number of contributing factors: 
systemic vascular resistance, cardiac output and blood volume.  Blood pressure can be 
raised by increasing any one or a combination of these three interconnected factors.  Intrinsic 
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to the blood vessels, systemic vascular resistance is controlled by the constriction and 
dilation of the vessels through the phosphorylation state of vascular smooth muscle myosin 
light chain (MLC) in the vessel walls (See section 1.2.3.1).  Cardiac output is controlled by 
both heart rate and the end diastolic volume (EDV) which is the blood volume filling the 
ventricle prior to being pumped out of the heart during systole.  Blood volume itself, is 
controlled mainly by kidneys through the renin-angiotensin-aldosterone system, and also by 
vasopressin released from the hypothalamus in response to increased plasma osmolarity 
(Haslett et al. 2002).  An increase in blood volume not only has direct effects on the blood 
pressure, it also increases cardiac output following Starling’s Law.  According to Starling’s 
Law, cardiac output is directly proportional to EDV up to certain physiological limits; whereas 
the ratio between cardiac output and EDV is determined by cardiac contractility and vascular 
resistance (Haslett et al. 2002).   
 
1.2.1 Blood pressure regulation 
 
Regulatory systems important for the maintenance of blood pressure include the autonomic 
nervous system as well as the renin-angiotensin-aldosterone system (Haslett et al. 2002). 
The autonomic nervous system continuously monitors arterial blood pressure through the 
baroreceptors situated in the aortic arch and the carotid sinuses of internal carotid arteries.  
These baroreceptors are sensory nerve endings that respond to stretching of the blood 
vessel wall; triggered action potentials are conducted to the brain stem with connections to 
the solitary nucleus in the medulla oblongata (Spyer. 1982; Haslett et al. 2002)   A decrease 
in blood pressure causes rapid activation of the sympathetic nervous system resulting in the 
release of epinephrine and norepinephrine (also known as adrenaline and noradrenaline 
respectively) from the adrenal medulla.  The release of epinephrine and norepinephrine 
returns blood pressure to within normal ranges through activation of adrenergic receptors, 
present in cardiomyocytes to increase heart rate and muscle contractility, as well as in 
smooth muscle cells in the vessel walls leading to constriction of the blood vessels and 
increased peripheral vascular resistance. 
 
Produced in the kidneys, the importance of renin and angiotensin in the regulation of blood 
pressure has been known for many years (Haslett et al. 2002). During low blood pressure, 
renin is released from the juxtaglomerular cells in the kidney macular densa in response to 
reduced perfusion of the juxtaglomerular apparatus and/or reduced filtrate NaCl 
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concentration. Renin cleaves the inactive angiotensinogen released from the liver to 
angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme 
present mainly in lung capillaries.   
 
Angiotensin II acts to increase blood pressure through several pathways:  
1 In the adrenal cortex, it stimulates the release of aldosterone which causes increased blood 
volume by increasing reabsorption of sodium and water in both the distal convoluted tubules 
and the collecting ducts in the kidneys. 
2 In the posterior pituitary gland, it increases the release of vasopressin which not only further 
increases water absorption in the kidneys but also acts on the central nervous system to 
increase thirst and therefore water intake. 
3 Angiotensin II also acts on smooth muscle cells in the blood vessel wall to cause 
vasoconstriction and directly increase blood pressure.  
 
 
 
Figure 1.2  The regulation of blood pressure by central and renal mediate pathways.   
The sympathetic nervous system and the mainly renal mediated renin-angiotensin 
aldosterone system function together to maintain blood pressure through the regulation of 
vascular resistance, cardiac output and fluid volume. 
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1.2.2 The regulation of vascular resistance 
 
1.2.2.1 Establishment of vessel tone 
 
Intrinsic to the blood vessels, the contractile state of vascular smooth muscle determines the 
vessel lumen size and therefore has a significant effect on blood pressure.    The main 
regulatory mechanism of smooth muscle contraction is the phosphorylation state of the 
20kDa MLC (Somlyo and Somlyo 1994). MLC is phosphorylated by the Ca2+/calmodulin 
activated smooth muscle myosin light chain kinase (MLCK) on Ser19 and dephosphorylated 
by myosin light chain phosphatase (MLCP) (Adelstein and Conti 1975).  MLC 
phosphorylation triggers the formation of myosin cross bridges on the actin filaments, and is 
sufficient for the initiation of muscle contraction (Rembold et al. 1992).   Therefore, raised 
cytosolic Ca2+ concentration leads to smooth muscle contraction through activation of MLCK 
and consequently phosphorylation of MLC.  
 
The activation of MLC by Ca2+/calmodulin has been shown to be regulated by 
phosphorylation of MLCK, with several kinases suggested to phosphorylate MLCK at 
Ser1760, including protein kinase A (PKA), protein kinase C and Ca2+/calmodulin dependent 
kinase II (CAMKII), resulting in reduced affinity of MLCK for Ca2+/calmodulin (Hashimoto and 
Soderling. 1990; Klemke et al. 1997).  Two transcripts of MLCK exist. The shorter form (150 
kDa) present in smooth muscle and the longer form (210 kDa) present in non-muscle cells 
including endothelial cells (Kamm and Stull. 2001).  The longer form of MLCK is involved in 
endothelial cell gap formation, vascular permeability, cell motility and morphology (Kamm and 
Stull. 2001).   
 
MLC phosphorylation during vascular contraction has also been shown to be induced 
independently of changes in cytosolic Ca2+ concentration (Somlyo and Somlyo. 2004).  
Agonists such as norepinephrine, vasopressin, angiotensin etc, bind to G-protein coupled 
receptors and produce smooth muscle contraction by increasing both the cytosolic Ca2+ 
concentration and the Ca2+ sensitivity of the contractile apparatus. The increased sensitivity 
of vascular smooth muscle toward Ca2+ has been attributed to inhibition of MLCP activity 
leading to increased MLC phosphorylation and tension at a constant Ca2+ concentration. 
Several studies suggest sensitization to Ca2+ occurs through activation of Rho-associated 
kinase (ROCK) through the small GTPase RhoA, which in turn, phosphorylates the regulatory 
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subunit of MLCP (MYPT1) at Thr696 and Thr853, resulting in inhibition of MLCP activity and 
increased MLC phoshorylation (Uehata et al.1997; Feng et al. 1999).  
 
1.2.2.2 AMPK and MLC phosphorylation 
 
Recent studies suggest AMPK may be involved in the regulation of vascular tone. The 
pharmacological activation of AMPK by AICAR induces endothelium independent relaxation 
of murine aortic rings, which is abolished in aortic rings from global AMPKα1 KO but not 
AMPKα2 KO mice (Goirand et al. 2007).   In vitro, AMPK α1β1γ1 complex was shown to 
phosphorylate MLCK at the same site as PKA, protein kinase C (PKC) and CaMK II 
(Ser1760), leading to reduced affinity of MLCK for Ca2+/calmodulin binding (Horman et al. 
2008).  The treatment of aortic smooth muscle cells with 10µM STO-609 accelerated 
Vasopressin induced MLC phosphorylation (Horman et al. 2008), suggesting CaMKKβ may 
also act upstream of MLC in smooth muscle.  
 
The AMPK subunit distribution in vascular smooth muscle appears to differ depending on the 
origin of the vessel.  In murine pulmonary arterial smooth muscle, both AMPKα1 and 
AMPKα2 subunits have been found, with higher expression of AMPKα1 subunits and the 
majority of AMPK activity from complexes containing AMPKα1 subunits (Evans et al. 2005).   
AMPKα1 subunit complexes have been suggested to account for 90% of total AMPK activity 
in aortic smooth muscle cell lysates (Horman et al. 2008).   
 
1.2.2.3 Nitric oxide and vasodilation 
 
Nitric oxide (NO) is endogenously produced from L-arginine by nitric oxide synthase (NOS) 
(Bredt and Snyder. 1990). Three forms of NOS exist; endothelial NOS (eNOS), neuronal 
NOS (nNOS), and inducible NOS (iNOS).NO has been known as a vasodilator for many 
years (Furchgott et al. 1980) and more recent studies have shown that the vasodilation is 
achieved through MLCP activation and MLC dephosphorylation  (Nakamura et al. 2007)  
Smooth muscle is not known to produce NO; NO produced by the eNOS present in the 
endothelial layer of blood vessels diffuses into smooth muscle leading to activation of soluble 
guanylate cyclase resulting in increased cyclic-guanosine monophosphate (cGMP) 
production (Hofmann et al. 2000).  The mechanism of vasodilation caused by cGMP is not 
entirely clear.  Increased concentration of cGMP has been shown to correlate with increased 
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T696 MLCP phosphorylation and induce Ca2+ concentration independent MLC 
dephosphorylation (Nakamura et al. 2007), suggesting the RhoA/ROCK pathway may be 
activated.  The expression of iNOS is induced during sepsis and is important for the 
inflammatory response; this will be described in more detail in section 1.2.4.7. 
 
1.2.2.4 AMPK and eNOS 
 
In vascular endothelial cells, where AMPKα1 is the predominant subunit expressed (Davis et 
al. 2006), there appear to be two separate sets of signals for the activation of AMPK which 
determines whether AMPK goes on to phosphorylate eNOS.   In vitro, AMPK has been 
demonstrated to phosphorylate both cardiac and endothelial eNOS at Ser1177, leading to 
activation of eNOS and increased NO production (Chen et al. 1999).   AMPK activation by 
AICAR in human aortic endothelial cells has also been shown to increase eNOS 
phosphorylation and NO synthesis (Morrow et al. 2003).   However, recent studies show 
activation of AMPK may also occur independently from the phosphorylation and activation of 
eNOS.  Bradykinin, thrombin and vascular endothelial growth factor (VEGF) have all been 
shown to activate AMPK in endothelial cells through calcium dependent CaMKKβ pathways 
(Stahmann et al. 2006; Mount et al. 2008; Stahmann et al. 2010).  In all three cases, 
activation of the CaMKKβ/AMPK pathway led to downstream ACC phosphorylation; in 
contrast, eNOS phosphorylation and NO production was shown to occur independently of 
AMPK activation by CaMKKβ.    In addition, AMPKα1 was shown to be essential in VEGF 
induced matrigel plug angiogenesis assays in WT and global AMPKα1 KO mice (Stahmann 
et al. 2010).   
 
1.2.3 Pathophysiology of Septic Shock 
 
Blood pressure is normally tightly regulated within a range optimised for tissue perfusion and 
oxygenation.  Low blood pressure predisposes to faints and falls, and persistently low blood 
pressure refractory to treatment as seen during sepsis is associated with a high risk of 45-
50% mortality (Sakr et al. 2006; Esteban et al. 2007).  Sepsis is defined as the systemic 
inflammatory response by the body to the presence of infection, and severe sepsis describes 
sepsis associated with organ dysfunction or tissue hypoperfusion (Bone 1992).  Septic shock 
is defined as sepsis with refractory hypotension despite adequate fluid resuscitation (Bone 
1992).  Complex events that occur in septic shock can be broadly divided into 
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microorganism-related components as well as host-related components including 
inflammatory dysfunction and cardiocirculatory dysfunction.  
 
1.2.3.1 Pathogenic microbes  
 
Severe sepsis and septic shock are initiated by the invasion of normally sterile tissue by 
pathogenic microbes including bacteria, viruses, or fungi.  The interactions between the host 
immune system and the pathogen involved may result in either a contained infectious 
process with minimal tissue injury or severe sepsis and septic shock.  Bacterial virulence 
factors can confer advantages to pathogens via one of several mechanisms including 
modulation of host defence mechanisms, promoting attachment to host cell surfaces, 
invasion of host tissue, and evasion of host immune systems. One of the virulence factors 
able to modulate host inflammatory responses is lipopolysaccharide (Nduka and Parrilo 
2009).   
 
1.2.3.2 Lipopolysaccharide (LPS) 
Lipopolysaccharide (Also known as endotoxin) is a component of the outer cell membranes 
of Gram-negative bacteria such as Escherichia coli (E coli), Salmonella, Shigella, 
Pseudomonas, Neisseria, Haemophilus influenza, Bordetella pertussis and Vibrio cholera.   
Although it is known that small amounts of LPS may be released in a soluble form by young 
cultures grown in the laboratory (Zhang et al. 1998); LPS is more commonly associated with 
the cell membrane and released into the host tissue upon destruction of the pathogen.  LPS 
release can result from autolysis, external lysis mediated by complement and lysozyme, and 
phagocytic digestion of bacterial cells (Nduka and Parrillo. 2009).  
LPS are complex amphiphilic molecules with a molecular weight of around 10kDa.Chemical 
composition can vary greatly both between and among bacterial species. However all LPS 
consists of three regions: a hydrophilic membrane anchoring lipid; a region attached to a core 
polysaccharide region similar within a specie; and an O-antigen region consisting of repeating 
oligosaccharide subunits with varying length and variation in saccharide composition 
(Rietschel et al. 2009).  The virulence of E coli O111:B4, including its capacity to resist 
phagocytosis, has been shown to be dependent on the saccharide composition of its cell 
membrane LPS (Medearis Jr et al. 1968); with similar results seen from multiple batches of 
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LPS isolated from log-phase cultures, and reduced virulence seen in strains with altered 
saccharide composition.    
 
LPS elicits a variety of inflammatory responses in the host.  It is recognised by toll-like 
receptor 4-CD14 complex (TLR4) which is one of the pattern recognition receptors expressed 
by immune cells to identify the presence of invading pathogens (Takeuchi et al. 1999).  
These receptors initiate the innate immune response and regulate the adaptive immune 
responses to infection or tissue injury. Upregulation of toll-like receptor (TLR) expression is 
seen following the activation of the immune response by the presence of LPS (Mollen et al 
2006; Uematsu and Akira. 2007).   Positive feedback loops may be set up where TLR4 
interaction with LPS leads to enhanced TLR reactivity, resulting in excessive inflammatory 
response and mortality (Paterson et al 2003).   In contrast, single nucleotide polymorphisms 
(SNPs) identified in TLR4 have been linked to LPS hyporesponsiveness, predisposing 
carriers of these SNPs to high rates of Gram-negative septic shock following inadequate 
inflammatory responses (Gibot et al 2002). 
 
1.2.3.3 Inflammatory signal transduction network 
 
The mechanism of LPS induced signalling events mediated by TLR4 has been extensively 
studied over recent years. Much work has been carried out to elucidate the role of specific 
molecules comprising the signalling pathways and to identify the negative regulators of the 
LPS signalling.  A summary of the more important pathways are described below, and the 
links within provide further information on the mechanisms of TLR4 activation by LPS.  
 
The binding of LPS to TLR4 on the outer membrane of immune cells recruits myeloid 
differentiation factor (MyD88), activating  intracellular signalling pathways leading to the 
activation of transcription activators such as interferon regulatory factors (IRF), 
phosphoinositol-3-kinase (PI3K) and its downstream kinase Akt, as well as cytosolic nuclear 
factor κ B (NFκB).  Activated NFκB moves into the nucleus and: binds to transcription sites; 
induces the expression of a range of inflammatory proteins and mediators including: acute 
phase proteins, iNOS, coagulation factors, proinflammatory cytokines, and adhesion 
molecules; initiates the enzymatic activation of cellular proteases (Cinel et al. 2009 Review).  
PI3K acts at several positions downstream of TLR4, and can function either as a positive or 
negative regulator depending on the cell type and/or the regulatory signal (Cinel et al. 2009). 
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The downstream targets of PI3K/Akt signalling include activation of mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway important for tumour 
necrosis factor α (TNFα) production; as well as regulation of neutrophil functioning through 
p38 signalling including cytokine production, chemotaxis, adhesion, and apoptosis (Peck-
Palmer et al. 2008).   IRF has been shown to regulate the expression of not only interferon β, 
but also iNOS and chemokines, following TLR4 binding (Negishi et al. 2006).  There is 
significant crosstalk between these signalling pathways with IRF1 known to interact with 
NFκB and PI3K signalling also known to activate NFκB. 
  
The recruitment of MyD88 is essential for the expression of inflammatory cytokines including 
interleukin 1β (IL1β), interleukin 6 (IL6) and TNFα; these cytokines are not produced in mice 
lacking MyD88 in response to LPS; instead, IRF3 was found to be activated following LPS 
binding to TLR4 resulting in the NKκB dependent expression of interferon stimulated 
regulatory elements such as IP10 (Kawai et al. 2001).  
 
1.2.3.4 Cytokine release 
 
The progression of sepsis is driven by the synthesis and release of many inflammatory 
mediators and cytokines following TLR4 activation (See Table 1.1). This sets up a systemic 
environment that promotes destruction of pathogens by a variety of means including: 
resetting the thermoregulator in the hypothalamus to a higher temperature; blood vessel 
dilation to improve tissue oxygenation; the recruitment and activation of increasing numbers 
of immune cells; and increased vascular permeability to increase tissue infiltration by the 
phagocytic cells.     
 
Cytokine cascade describes the sequential release pattern of mediators with the initial 
release of pro-inflammatory cytokines IL1β and TNFα, leading to the concomitant release of a 
range of cytokines including IL6, interleukin 8 (IL8), macrophage inhibitory factor (MIF), as 
well as NO produced by iNOS (Nduka and Parrillo. 2009).  Interleukin 10 (IL10) is a 
regulatory anti-inflammatory cytokines released by monocytes and T-cells following the 
initiation of the cytokine cascade leading to inhibition of pro-inflammatory cytokine synthesis 
(Banchereau et al. 2012). Cytokines are normally present in the circulation at very low 
concentrations and can increase by >1000 fold following TLR4 activation (Damas et al. 
1997).  Very high but transient cytokine concentrations of IL6 and IL8 were associated with 
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the development of septic shock rather than severe sepsis, suggesting both the concentration 
and the time course of the cytokine production is important for sepsis severity (Blackwell and 
Christman. 1996; Damas et al 1997). 
 
Class Mediator Source Role in sepsis 
Pro-
inflammatory 
cytokines 
Interleukin 1β Monocytes 
Macrophages 
Lymphocytes 
Endothelial cells 
Altered  thermoregulation. 
Hypotension. 
T lymphocyte and macrophage activation. 
Tumor necrosis 
factor α 
Activated 
macrophages 
Altered thermoregulation. 
Hypotension. 
Neutrophil and endothelial cell activation. 
Interleukin 6 T lymphocytes 
B lymphocytes 
Endothelial cells 
Induction of lymphocyte proliferation. 
Interleukin 8 Activated 
macrophages and 
monocytes 
Chemotactic for neutrophils and T 
lymphocytes. 
Interleukin 18 Activated 
macrophages 
Increased secretion of interferon γ. 
Initiates cell mediated immune response 
with interleukin 12. 
Interferon γ Natural killer cells Macrophage priming. 
Defense against viral and intracellular 
bacterial pathogens. 
Macrophage 
inhibitory factor 
Activated 
macrophages 
Increased tumor necrosis factor expression. 
Increased TLR4 expression. 
Anti-
inflammatory 
cytokines 
Interleukin 10 Epithelial cells 
Monocytes 
Lymphocytes 
Downregulation of macrophage function. 
Decreased tumor necrosis factor α 
Interleukin 4 unknown Induces differentiation of naive helper T 
lymphocytes to Th2 cells. 
Interleukin 1Ra Monocytes Inhibits interleukin 1 activity. 
Endothelial 
factors 
Induced Nitric 
oxide 
Activated 
macrophages 
Endothelial cells 
Vasodilation. 
Myocardial depression. 
Increases vascular permeability. 
Inhibition of platelet function. 
Others Platelet 
activating factor 
Macrophages 
Neutrophils 
Endothelial cells 
Activation of endothelial cells. 
Histamine release from platelets. 
Complement 
proteins C3a-
C5a 
 Increased capillary permeability. 
Histamine release. 
Table 1.2  Cytokine and non-cytokine mediators of sepsis and septic shock (adapted from 
Nduka and Parrilo. 2009). 
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1.2.3.5 TLR4 activation in endothelial cells 
 
The endothelium also plays a major role in the pathogenesis of sepsis and septic shock.  
Endothelial cells line the inner wall of blood vessels and functions to regulate angiogenesis, 
vascular permeability, vessel contractility, as well as providing an anticoagulant surface.   
Vascular dysfunction occurs both as a result of the direct effects of LPS and also in response 
to the released inflammatory mediators including TNFα, IL1β, and interferons (IFN) from 
macrophages and immune cells (Salgado et al. 1994).  
 
1.2.3.6 Neutrophils and macrophages 
 
Myeloid cells including neutrophils and macrophages contain vesicles of proteolytic enzymes 
and are capable of phagocytosing and degrading internalized pathogens.   Neutrophils are 
proapoptotic and in addition to their antimicrobial function, they are associated with the 
potential for host tissue damage when they are activated during sepsis (Brown et al. 2006).  
Host tissue damage in severe sepsis can occur through a variety of mechanisms including 
premature neutrophil activation, extracellular release of cytotoxic molecules during microbial 
killing, removal of infected or damaged host cells, and failure to terminate the acute 
inflammatory response.   
 
Phagocytosis of the apoptotic neutrophils by macrophages inhibits the release of 
proinflammatory cytokines and promotes the secretion of anti-inflammatory cytokines (Fadok 
et al. 1998).   The capacity of activated macrophages to clear expanded apoptotic 
populations of neutrophils has been shown to contribute to immune suppression during 
sepsis (Swan et al. 2007). 
 
1.2.3.7 The progression to septic shock 
 
The development of septic shock involves both cardiac and vascular dysfunction.  Many 
mechanisms have been proposed to explain the myocardial depression present in sepsis, 
including coronary ischaemia, interstitial myocarditis, and pathways initiated by several of the 
inflammatory mediators (Fernandes et al. 2008); however the importance of any of these 
mechanisms is currently unclear.  Better understood is the importance of NO in the 
development of hypotension seen in septic shock (Petros et al. 1991; Cauwels. 2007).  The 
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cytokines TNFα and IL1β induce the expression of iNOS, leading to the release of NO by 
neutrophils, macrophages and endothelial cells (Nduka and Parrillo. 2009).  In addition to 
causing vasodilation through the dephosphorylation of MLC (See section 1.2.3.3), NO has 
also been shown to impair cardiomyocyte contractile function (Baumgarten et al. 2006), 
suggesting it may be the main mediator for both the cardiac and vascular aspects of septic 
shock. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
1.3 Project aims  
 
CaMKKβ is known to phosphorylate and activate CaMKI, CaMKIV as well as the master 
regulator of metabolism, AMPK.  Recent research in AMPKα subunit KO mice suggests the 
involvement of AMPK and potentially CaMKKβ in the regulation of systemic blood pressure.  
With the exception of long term memory formation, very little is known regarding the 
physiological functions of CaMKKβ in other biological systems.   
 
This project aims to further current understanding of CaMKKβ function using the global 
CaMKKβ KO mice;  
 
1. To clarify the involvement of CaMKKβ in the downstream metabolic effects following AMPK 
activation. To assess the effect of global loss of CaMKKβ on systemic AMPK activation.  
 
2. To investigate the function of CaMKKβ in the immune system using a mouse model of LPS 
sepsis. 
 
3. To determine the involvement of CaMKKβ in blood pressure regulation duing LPS sepsis and 
establish the mechanism through which CaMKKβ regulates blood pressure. 
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Chapter 2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 General reagents  
 
Adenosine monophosphate (AMP), Adenosine diphosphate (ADP), Adenosine triphosphate 
(ATP), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Tris(hydroxymethyl)aminomethane (Tris), ethylene glycol tetraacetic acid (EGTA), ammonium 
persulphate, magnesium chloride (MgCl2), sodium fluoride (NaF), sodium pyrophosphate 
(NaPP), dithiothreitol (DTT),  N,N,N’,N’-tetramethylethylenedamine (TEMED), protein A/G-
sepharose, sorbitol, β-mercaptoethanol, water soluble dexamethasone, 3,3’,5-Triiodo-L-
tyronine sodium salt (T3), bovine serum albumin (BSA), agarose, ionomycin, Taq DNA 
polymerase, NP-40, Dimethyl sulfoxide (DMSO), Triton X-100, Ponceau S solution, and 1-
1,dimethyl biguanide hydrochloride (metformin) were obtained from Sigma (Poole, UK).  
Glucose oxidase kit was from Thermo Fisher Scientific (Leicestershire, UK).  10x 
Tris/glycine/SDS buffer, Protogel bisacrylamide and Ecoscint scintillant were purchased from 
National Diagnostics (Yorkshire, UK).  Polyvinylidene difluoride (PVDF) membrane was from 
Perkin Elmer (Beaconsfield, UK).  AICA-Riboside was purchased from Calbiochem 
(Nottingham, UK).  Primers were generated by Sigma-Genosys (Havrehill, UK).   NaOH, 
sodium lauryl sulfate (SDS), NaCl, Tween 20, glycerol, ethylenediaminetetraacetic acid 
(EDTA), ethanol, methanol, KCl, KH2PO4, NaHCO3, choloroform and glucose were from 
VWR (West Sussex, UK).   RNeasy columns, quantitect primers and quantitative reverse 
transcription PCR (qRT-PCR) kit were from Qiagen (Crawley, UK).  3MM chromatography 
paper and P81 phosphocellulose paper were obtained from Whatman (Maidstone, UK).  
DMEM, M199, Penicillin/Streptomycin, insulin, sodium pyruvate were from Gibco, Invitrogen 
(Paisley, UK).     PageRuler Plus Prestained protein marker was from Fermentas (York, UK).   
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2.1.2 Antibodies 
 
All antibodies were used at 1:1000 dilution for western blot. 
Anti-pThr172 AMPKα raised in rabbit was from Cell Signalling (2535).  
Anti-β actin raised in rabbit was from Sigma (A5060). 
Anti-GAPDH raised in rabbit was from Abcam (ab9485). 
Anti-iNOS raised in rabbit was from Santa Cruz (NOS2 N-20, sc-651). 
Anti-total MLC raised in rabbit was from Cell Signalling (MLC2, 36725). 
Anti-pSer19 MLC raised in rabbit was from Cell Signalling (pMLC2, 36755). 
Anti-total MLCK raised in mouse was from Sigma (Clone K36, M7905). 
Anti-pSer1760 MLCK raised in rabbit was from Invitrogen (441085G). 
Anti-PKG raised in rabbit was from GeneTex (PRKG1, GTX111610). 
Antibodies against CaMKKβ and LKB1 were generated in house. Anti-CaMKKβ raised in 
rabbit was used at 1:66 dilution for immunoprecipitation.  Anti-LKB1 raised in rabbit was used 
at 1:100 dilution for immunoprecipitation. 
Antibodies targeting the AMPKβ subunit, α1 subunit and α2 subunit were generated in house. 
Anti-AMPKβ raised in rabbit was used at 1:400 dilution for immunoprecipitation.  Anti-
AMPKα1 and AMPKα2 were separately raised in sheep were used at 1:100 dilution for 
immunoprecipitation.   
Antibodies against total NKCC2 and pSer126 NKCC2 were kind gifts from Prof Dario Alessi, 
Dundee.  
APC efluor 780 conjugated anti-mouse CD3e was from eBioscience (clone 17A2, 47-0032-
80), used at 1:66 dilution to identify all mature T lymphocytes through flow cytometry. 
PerCP conjugated anti-mouse CD4 was from Biolegend (clone GK1.5, 100431), used at 
1:200 dilution to identify CD4 positive T lymphocytes through flow cytometry. 
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PE conjugated anti-mouse CD8a was from eBioscience (clone 53-6.7, 12-0081-81), used at 
1000 dilution to identify CD8 positive T lymphocytes through flow cytometry. 
PerCP-Cy5.5 conjugated anti-mouse CD45R (B220) was from eBioscience (clone RA3-6B2, 
45-0452-80), used at 1:100 dilution to identify B lymphocytes through flow cytometry. 
FITC conjugated anti-mouse CD25 was from Biolegend (clone 3c7, 101907), used at 1:100 
dilution to identify CD25 positive thymocytes through flow cytometry. 
APC conjugated anti-mouse CD44 (Pgp-1, Ly-24) was from Pharmigen (559250), used at 
1:200 dilution to identify CD44 positive thymocytes through flow cytometry. 
PE conjugated anti-mouse F4/80 was from eBioscience (clone BM8, 12-4801-80), used at 
1:2000 dilution to identify mature macrophages through flow cytometry. 
FITC conjugated anti-mouse Ly-6G (Gr-1) was from Pharmigen (553126), used at 1:200 
dilution to identify neutrophils through flow cytometry. 
 
2.1.3 Protein 
 
Recombinant AMPK complex (α1β1γ1) was expressed in Eschericha coli and purified by Dr 
Faith Mayer and Dr Angela Woods as described in Sanders et al. 2007.   
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2.1.4 Mice  
 
CaMKKβ KO mice with global deletion of exon 5 generated as described in Peters et al. 
2003.  CaMKKα KO mice with global deletion of exons 2 to 5 generated as described in 
Blaeser et al. 2006.  AMPKα1 and AMPKα2 global KO mice were generated as described in 
Jorgensen et al. 2004 and Viollet et al. 2003 respectively.  All mice were maintained on a 12 
hour light/dark cycle with free access to water and standard mouse chow and housed in 
specific-pathogen free barrier facilities, unless otherwise stated. All in vivo studies were 
performed in accordance to the Animal Scientific Procedures Act (1986) with approval from 
Home Office, UK.  Male mice were used unless otherwise stated.  All mice used were 8-10 
weeks old unless otherwise stated.   
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2.2 Methods 
 
2.2.1 Genotyping 
 
DNA from ear snip or tail tip biopsies was extracted by heating to 100ºC with 100mM NaOH 
for 15 min, followed by addition of 1M Tris pH 8 to adjust the pH to 8.  DNA was amplified by 
polymerase chain reactions (PCR) using Reddymix (2x Reddymix mastermix containing Taq 
DNA polymerase, Thermo Scientific) and the appropriate primers (Table 2.1) in the presence 
of 5% DMSO.   
Following amplification, DNA was analysed by agarose gel electrophoresis at 120V for 30 
min on 3% (w/v) agarose gel, and bands visualised by ultra-violet light exposure (Gene 
Genius, Syngene). 
 
Genotyping primers CaMKKβ WT 5’ CAGCACTCAGCTCCAATCAA 3’ 
5’ GCCACCTATTGCCTTGTTTG 3’ 
CaMKKβ KO 5’ CAGCACTCAGCTCCAATCAA 3’ 
5’ TAAGCACAAGCACTCATTCC 3’ 
CaMKKα WT 5’ GAATGTGGCTGTGTCTTGAG 3’ 
5’ GACACAGAGCAGGAACTGTA 3’ 
CaMKKα KO 5’ GTGGAGGTATTGAGGCAGTC 3’ 
5’ GACACAGAGCAGGAACTGTA 3’ 
Real-Time PCR primers 
 
LKB1 
short and long form 
5’ TGGACTCCGAGACCTTATGC 3’ 
5’ CATTGTACAGCACGTCCACA 3’ 
CaMKKβ 5’ CCCCACAGTCCTCTCCCCGG 3’ 
5’ CGACGTGGGAAGCCAGCCTG 3’ 
GAPDH 5’ AGGTCGGTGTGAACGGATTTG 3’ 
5’ TGTAGACCATGTAGTTGAGGTCA 3’ 
Table 2.1  List of primers used in PCR and real-time PCR reactions.  
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2.2.2  Body composition and serum measurements 
 
For serum metabolite measurements, tail vein blood was collected in heparinized microvettes 
(Sarstedt) and centrifuged at 3000g for 30 min at 4°C.  Serum was stored at -80°C until all 
samples had been collected.  Serum levels of total cholesterol, low density lipoprotein (LDL), 
high density lipoprotein (HDL), free fatty acids, triglycerides, and alanine transaminase (ALT) 
were determined by the Mouse Biochemistry Laboratories, Cambridge, UK.   To measure 
fasting glucose, mice were fasted overnight before tail vein blood collection and 
measurement of blood glucose using a Glucometer Elite (Bayer Corporation). 
Body composition measurement of anaesthetized mice was kindly carried out by Mr Phill 
Muckett by quantitative magnetic resonance imaging using EchoMRI (Houston Medical 
Systems). 
 
2.2.3 Tissue lysate preparation 
 
Tissue was snap frozen in liquid nitrogen immediately following extraction.  Adipose tissue 
was collected from peritesticular and perirenal areas.  Lung and muscle were ground in liquid 
nitrogen with pestle and mortar. All tissues were homogenised (IKA T10 basic ULTRA-
TURRAX using dispersing tool S10N-5G) for 1 min on ice, in HBA (50mM Tris-HCl pH 7.4, 
50mM NaF, 5mM NaPP, 1mM EDTA, 0.25M sucrose with 1% (v/v) triton-100, 1mM DTT, 
0.1mM phenylmethylsulfonyl fluoride (PMSF), 1mM benzamidine, 4µg/ml Trypsin inhibitor).  
Supernatant was collected following centrifugation at 13000g at 4°C for 15-20 min.  Protein 
concentrations were measured by Bradford protein assay (Bio-Rad) (Bradford, 1976). 
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2.2.4 Immunoprecipitation 
 
Tissue lysate was incubated with antibody and protein A/G slurry (Sigma) in HBA for 2 h at 
4°C.  Immune complexes were washed once in HBA, followed by a second wash in HGE 
(HBA without NaF and NaPP).    
 
2.2.5 AMPK activity assay 
 
Immunoprecipitation was carried out from 50µg tissue or cell lysate incubated with antibody 
against AMPKβ (Woods et al. 1996). To measure non-specific antibody binding, 
immunoprecipitation was also carried out with no antibody.  Immune complexes were added 
to 30µl SAMS assay mix (333µM AMP and 333µM SAMS peptide [HMRSAMSGLHLVKRR] 
(In house synthesis, MRC Peptide Synthesis Unit) in HGE), 10µl HGE and 10µl γ-32P-
ATP/MgCl2 (1mM γ-
32P -ATP (Perkin Elmer), 25mM MgCl2, 1mM ATP), before incubating for 
20min at 37°C.  Immune complexes were then centrifuged at 13000g and 20µl supernatant 
spotted onto P81 paper (Whatman). P81 paper was washed in 1% (v/v) orthophosphoric 
acid, blotted dry, then counted for 30 seconds in Tri-Carb Liquid Scintillation Counter (Perkin 
Elmer). 
 
2.2.6 LKB1 and CaMKKβ activity assays 
 
50µg tissue lysate was incubated with rabbit antiserum against LKB1 (Denison et al. 2009) or 
rabbit antiserum against CaMKKβ (Stahmann et al. 2006) for 2 h at 4°C.  The resulting 
immune complexes were incubated with 800ng bacterially expressed AMPK α1β1γ1 complex 
(Neumann et al. 2003) and 10mM HGE, 100µM ATP, 5mM MgCl2, 2mM DTT, with or without 
2mM CaCl2, 2µM Bovine Brain Calmodulin (Calbiochem) for CaMKKβ or LKB1 activation of 
AMPK respectively, for 10 min at 37°C.  200ng activated AMPK was added to 30µl SAMS 
assay mix with 10µl γ-32P -ATP/MgCl2, incubated for 15min at 30°C, and 20µl spotted onto 
P81 paper.  To measure non-specific binding of P81 paper, 200ng activated AMPK was 
 55 
added to 30µl SAMS Blank mix (1mM AMP, HGE with 1% (v/v) Triton-100 in 1:2 ratio) with 
10µl γ-32P -ATP/MgCl2, incubated for 15min at 30°C, and 20µl spotted onto P81 paper. P81 
paper was washed and activity counted as for measuring AMPK activity above. Background 
incorporation into SAMS peptide in the absence of upstream kinase was subtracted from 
LKB1/CaMKKβ activity for all results.   
 
2.2.7 Primary hepatocyte isolation and culture  
 
Hepatocytes were isolated by collagenase (Collagenase H, Roche) perfusion of the liver in 
situ under terminal anaesthesia (Foretz et al. 1998).  Perfusion was carried out by Dr Angela 
Woods. Cells were collected by centrifugation for 3 min at 500g, and washed in perfusion 
buffer (Carboxygenated sterile HBSS buffer, pH 7.4 at 37°C containing 138mM NaCl, 50mM 
Hepes, 5.6mM Glucose, 5.4mM KCl, 0.34mM anhydrous Na2HPO4, 0.44mM KH2PO4, 
4.17mM NaHCO3, 0.5mM EGTA, 0.2µM CaCl2 ). Cell viability was assessed by Trypan Blue 
prior to plating at 1.5 × 106 cells per well in collagen pre-coated 6 well tissue culture plates 
(Sigma) or 4 x 104 cells in collagen (Invitrogen) coated 24 well Seahorse plates (Seahorse 
Bioscience) in M199 with Earle’s salts (Invitrogen) supplemented with 100 units/ml penicillin, 
100 μg/ml streptomycin, 0.1% (w/v) bovine serum albumin, 2% (v/v) Ultroser G (Pall 
BioSepra), 100 nM dexamethasone (Sigma), 100 nM insulin (Invitrogen), 100 nM 
triiodothyronine (T3) (Sigma). After 4 hrs at 37°C in a 5% CO2 incubator, attached 
hepatocytes were changed into media with reduced insulin (1nM) and cultured overnight prior 
to treatments.   
Hepatocyte treatments used include 0.6M sortibol for 10mins, 500µM AICAR for 30mins, and 
2mM metformin for 2 h.  Following treatment, hepatocytes were collected into 50mM Hepes 
pH7.4, 50mM NaF, 5mM NaPP, 1mM EDTA, 10% (v/v) glycerol with 1% (v/v) triton-100, 1mM 
DTT, 0.1mM PMSF, 1mM benzamidine, 4µg/ml trypsin inhibitor (HBA), lysed by freeze-thaw 
from -80°C, centrifuged for 15mins at 13000g at 4°C, and supernatant assayed for AMPK 
activity.  
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2.2.8 Glucose output measurement 
 
Cultured hepatocytes were changed into Dulbecco’s Modified Eagle’s Medium (DMEM) 
without glucose (Sigma), 3.7g/l NaHCO3, 2mM sodium pyruvate (Invitrogen), 20mM lactate 
(Invitrogen).  Media was taken at various times following treatment.  Glucose concentration in 
media was measured by a colorimetric glucose oxidase method using Enzymatic Glucose 
Reagent (Thermo Scientific) and calibrated using known glucose concentration standards. 
 
2.2.9 Mitochondrial function 
 
Hepatocyte mitochondrial function was assessed using the Seahorse XF24 System 
(Seahorse Bioscience). 24 well Seahorse plates (Seahorse Bioscience) were coated with 
30µl per well of 0.3mg/ml of collagen (Collagen I rat tail, Invitrogen) in 0.02M acetic acid and 
dried overnight in laminar flow hood prior to plating of hepatocytes.  Hepatocytes were 
cultured overnight following isolation at 37ºC with 5% CO2.  XF sensor cartridges (Seahorse 
Bioscience) were hydrated in 1ml per well of calibrant (Seahorse Bioscience) and incubated 
at 37ºC overnight without CO2.  Hepatocytes were washed and changed into Glycolysis 
Assay Medium pH 7.4 containing DMEM D5030 (Sigma), 143mM NaCl, 5mM glucose, 1nM 
insulin, and 100nM dexamethasone 1 h prior to assay and cultured at 37ºC without CO2. 
Using the Seahorse XF24 system, Oxygen Consumption Rate (OCR) was measured at 
baseline, as well as following the sequential addition of respiratory chain inhibitors/uncouplers 
including 2µg/ml oligomycin, 0.5µM p-trifluoromethoxy carbonyl cyanide phenylhydrazone 
(FCCP), 20mM ascorbate with 5mM N,N,N',N'- 
tetramethyl-1,4-phenylene diamine (TMPD), and 5µM each of antimycin A and rotenone.  
OCR readings for each animal were taken from four hepatocyte wells and normalized to 
protein concentration in each well as measured by Bradford protein assay (Bio-Rad) 
(Bradford. 1976) following cell lysis. 
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2.2.10 Bone measurements  
 
Long bones and tail vertebrae from 13-16 week old male mice were dissected and stored at 
4°C in 70% (v/v) ethanol.  Soft tissue was removed by gentle scraping.  Digital X-ray images 
were recorded at 10-μm resolution using a Qados Faxitron MX20 variable kV point projection 
x-ray source (Cross Technologies plc.).  Bone length was determined using ImageJ 1.41 
software (http://rsb.info.nih.gov/ij/) (Bassett et al. 2010) and measurements calibrated by 
imaging a digital micrometer. Femoral cortical thickness was determined by averaging 5 
measurements mid shaft.  
 
2.2.11 Faxitron analysis of bone mineral density  
 
Bone mineral density was measured by faxitron analysis (Bassett et al. 2010).  Digital images 
were taken as described for bone measurements above, with the addition of a 1 mm thick 
steel plate, a 1 mm diameter spectrographically pure aluminium wire, and a 1 mm diameter 
polyester fiber.  Images were converted to 8-bit Tiff format using ImageJ.  Bone mineral 
density was measured by setting the grey level of the polyester to 0, and the grey level of 
steel to 255, then dividing the grey levels between 0 and 255 into 16 levels through 
converting to a pseudocolour scheme. The number of pixels of a particular colour 
representing a particular bone mineral density range is then counted using ImageJ 1.41 
software.    
 
2.2.12 Bone RNA extraction and reverse transcription 
 
Following isolation of murine femur, soft tissue was immediately stripped off the bone which 
was then snap frozen in liquid nitrogen and stored at -80ºC.  Bone was crushed using a 
pulverizer (BioSpec 59013N, Fisher Scientific) frozen by dipping in liquid nitrogen and kept 
cold on a block of dry ice.  1ml Trizol (Invitrogen) was added to each powdered bone prior to 
3 min homogenisation on dry ice followed by a further 5 min homogenisation at room 
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temperature.  Supernatant was collected following centrifugation at 12000g for 10 min at 4ºC.  
200µl chloroform was added to the supernatant and thoroughly mixed by shaking for 15 sec 
before incubating at room temperature for 3 min and centrifugation at 12000g for 10 min at 4 
ºC.  The upper aqueous phase containing RNA was mixed with 0.53 volume of absolute 
ethanol and transferred onto an RNeasy column (Qiagen).  RNA was extracted according to 
the RNeasy column protocol including on column DNase treatment.  Concentration and purity 
of RNA was measured using the Nanodrop spectrophotometer (Nanodrop ND-1000, Thermo 
Scientific). A minimum absorbance ratio of 1.8 measured at 260/280 nm and 260/230 nm was 
set for all samples, any sample falling below this level was repurified.   
 
Synthesis of cDNA was carried out with equal amounts of total bone RNA (1-2µg) using 
SuperScript II reverse transcriptase (Invitrogen) according to manufacturer’s instructions in 
the presence of 200ng random primers and 500µM mixed dNTP.   
 
2.2.13 Quantitative real-time PCR 
 
Quantitative real-time PCR was carried out using 1 in 10 diluted cDNA added to 5µM each of 
the appropriate primers as well as 1x SensiMix SYBR (Bioline) containing SYBR Green I dye, 
3mM MgCl2 and dNTPs on a real-time thermo-cylcer (DNA Engine Opticon, Bio-Rad).  
Following polymerase activation at 95ºC for 10 min, 40 PCR cycles were performed  with 15 s 
each of denaturation at 95ºC, annealing at 60ºC and extension at 72ºC. Primers were 
selected to produce 100-200bp amplicons spanning at least one exon-exon junction in the 
target mRNA (See Table 2.1).  Satisfactory melting curves were obtained for all primers used.   
 
All samples were analyzed in duplicate with Ct values measured in the exponential phase of 
the PCR reaction (OpticonMonitor Analysis Software Version 3.1, Bio-Rad), and relative 
expressions calculated using the 2-ΔΔCt method (Schmittgen 2008).  Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as the internal control for the quantification of 
gene expression. Samples treated without reverse transcriptase enzyme were used as 
negative controls. 
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2.2.14 Erythrocyte fragility test 
 
Blood was collected in heparinized microvettes (Sarstedt), mixed and tested within 1 hour of 
collection.  10µl of blood was added to 2.5ml of increasing concentrations of NaCl2 solution 
and incubated at room temperature for 30 min before centrifugation at 3000g for 5 min.  
Optical Density (OD) of the supernatant was measured at 540nm, and the percentage 
haemolysis calculated from OD measurements taking OD of distilled water as equivalent to 
100% haemolysis. 
 
2.2.15 Lipopolysaccharide (LPS) induction of sepsis 
 
16-20 week old individually caged male animals were used for the induction of sepsis.  E.coli 
LPS 0111:B4 (Sigma) was injected intraperitoneally at a dose of 8mg/kg.  Temperature 
transponders (IPTT-300, BMDS) were inserted subcutaneously in the right flanks of animals 
7 days prior to LPS induction to allow temperature reading using a scanner (Small Smart 
Reader IPTT, BMDS).  Core body temperature was recorded both prior to LPS been given 
and 12 hours post sepsis induction either using the temperature transponder scanner or 
using the flexible temperature probe from Homeothermic Blanket System (Harvard 
Apparatus).  All animals were monitored every 2-3 hours and assessed for sepsis severity.  
Following temperature measurement at 12 hours post induction, animals were sacrificed by 
cervical dislocation and blood was collected through cardiac puncture.   
 
2.2.16 Serum cytokine measurements  
 
Blood was collected in heparinized microvettes (Sarstedt) and centrifuged at 3000g for 30 
min at 4°C.  Serum was stored at -80°C until all samples collected. The concentration of 
cytokines including IL1β, IL6, IL10, TNFα and granulocyte macrophage colony stimulating 
factor (GM-CSF) were prepared in a multiplexed ELISA assay using fluorescent-coded 
magnetic beads according to kit instructions (Mouse Cytokine/Chemokine Magnetic Bead 
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Panel, Milliplex MAG Kit, Millipore), and analyzed on the MAGPIX plate reader (Millipore). 
Satisfactory results were obtained from quality control samples containing known 
concentrations of all measured cytokines provided as part of the kit. 
 
2.2.17 Nitric oxide measurement 
 
Greiss assay was used to determine nitrite formed by the spontaneous oxidation of NO under 
physiological conditions (Ignarro et al. 1987) in cell culture supernatant.  Samples were 
incubated with 30µg/ml N-(1-naphthyl) ethylenediamine dihydrochloride and 300µg/ml 
sulfanilic acid in 0.17% (v/v) phosphoric acid for 30 min at room temperature. Absorbance 
was measured at 548nm on a spectrophotometer (SpectraMax Gemini, Molecular Probes) 
and nitrite concentration was calculated using sodium nitrite standards.   
In serum samples, as NO is usually present in the form of nitrate, equal volume of 8mg/ml 
vanadium trichloride was added to serum prior to incubating with the components of the 
Greiss assay for 30 min at 37ºC.  Absorbance was measured at 548nm on a 
spectrophotometer (SpectraMax Gemini, Molecular Probes) and nitrite concentration was 
calculated using sodium nitrate standards.   
 
2.2.18 cGMP measurement 
 
cGMP concentration in the serum and in the isolated aorta was measured using the cGMP 
complete Enzyme ImmunoAssay Kit (Enzo Life Sciences) according to kit instructions. The kit 
utilises a competitive binding assay using alkaline phosphatase conjugated cGMP and a 
pNpp substrate that is catalyzed by alkaline phosphatase to produce colourimetric readout.  
The acetylated format was used in the aorta samples to increase sensitivity.  cGMP 
concentration was calculated from the standards supplied.   
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2.2.19 White cell count by flow cytometry 
 
Cell viability was assessed by Trypan blue staining and cells aliquoted into 1-2 × 106 cells in 
100µl Fluorescence-activated cell sorting (FACS) buffer (PBS+ 5% fetal calf seum) for 
antibody staining. Fluorescent antibody was added at a pre-determined, optimised 
concentration and the mixture incubated with shaking in the dark for 30min at 4ºC.  Stained 
cells were washed twice in FACS buffer, then resuspended in 500µl FACS buffer and 
analysed on BD LSR II Flow Cytometer (BD Biosciences).   
 
2.2.20 Splenocyte, thymocyte and lymph node cell isolation  
 
Spleen, thymus and lymph nodes (axillary, inguinal and iliac) were isolated under aseptic 
conditions and stored in DMEM (Invitrogen) at 4ºC until ready to process.  The spleen was  
forced through a 70µm cell strainer (BD Falcon) using a 5ml syringe plunger, washed  twice 
with DMEM and the cells collected by centrifugation at 500g for 5 min.  To lyse red blood 
cells, the packed cell pellet was resuspended in 1ml ACK lysis buffer (150mM NH4Cl, 10mM 
KHCO3, 130mM EDTA, pH7.4) and incubated for 5min at room temperature.  The cell pellet 
was washed once more and resuspended in 1ml of DMEM or FACS buffer (PBS + 5% (v/v) 
fetal bovine serum).   
 
2.2.21 Peritoneal macrophage isolation and culture 
 
Primary macrophages were isolated by peritoneal PBS wash as described in Zhang et al. 
2008.  Following cervical dislocation, 5-8ml cold PBS was carefully injected into the 
peritoneal cavity then aspirated and cells in the peritoneal exudates were collected by 5min 
centrifugation at 400g.  The isolated cells were stained with Trypan Blue to confirm viability 
and 2 × 105 nucleated cells were plated per well of 96 well tissue culture plates in 
macrophage culture media containing DMEM/F12 (Invitrogen), 10% (v/v) fetal bovine serum, 
100units/ml penicillin, and 100ug/ml streptomycin. After incubation for 2h at 37°C in a 5% 
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CO2 incubator, attached macrophages were washed three times with PBS to remove non-
adherent cells leaving 1 × 105 macrophages per well for culture overnight prior to treatments 
as stated in the figure legends.    
 
2.2.22 Macrophage activation  
 
Cultured primary macrophages were primed overnight with IFNγ (eBioscience) and activated 
with E.coli LPS 0111:B4 (Sigma) (Mosser and Zhang, 2008).  Macrophage activation was 
confirmed by measurement of NO production into the culture media using Greiss assay.  
Optimization with a range of IFNγ and LPS concentration show clear activation as measured 
by NO production was achieved with 200U/ml of IFNγ, and activated by 24 h treatment with 
10ng/ml LPS (See Figure 2.1). Cultured macrophages are activated under these conditions 
unless otherwise stated.   
 
 
 
 
 
 
 
 
 
 
Figure 2.1  Optimization of primary macrophage activation with overnight IFNγ priming and 
LPS treatment.  
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2.2.23 Macrophage phagocytosis assay 
 
The Vybrant Phagocytosis Assay Kit (Molecular Probes) was used to measure phagocytosis 
in activated primary macrophages.  Cultured primary macrophages were activated by 24 h 
treatment with a range of LPS concentrations with or without priming with IFNγ.  To measure 
phagocytosis, the macrophage culture media was aspirated and replaced with 100µg of 
fluorescent BioParticle suspension in 100µl Hanks’ balanced salt solution (HBSS) and 
incubated for 2 h at 37ºC with 5% CO2 in the dark.  The macrophages are washed with 100µl 
Trypan Blue solution to remove non-phagocytosed BioParticles prior to measurement using a 
spectrophotometer at excitation/emission wavelength of 480nm and 520nm respectively. 
Macrophage samples from each mouse were run in triplicate.   
 
2.2.24 Macrophage migration assay 
 
Primary macrophages were plated on Transwell inserts (Corning) at a density of 1 x 105 cells 
per insert. 5µm pore size translucent polycarbonate 24 well Transwell inserts were used with 
an equivalent growth area of a 96 well plate well.  10ng/ml recombinant human Vascular 
Endothelial Growth Factor (VEGF) (PeproTech) was added to 600µl of macrophage culture 
media in the lower chamber of the Transwell and cells cultured for 6 h at 37ºC with 5% CO2.  
Following VEGF stimulated macrophage migration, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was used to measure the number of cells 
remaining on the insert.  Macrophage samples from each mouse were run in duplicate.   
 
2.2.25 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
 
MTT is converted to insoluble formazan following reduction of the tetrazolium ring by the 
mitochondria in living cells, dissolving the formazan crystals in DMSO produces a colour 
change that can be measured between absorbance 500nm and 600nm on a 
spectrophotometer (Mosmann 1983).  20µl of 5mg/ml MTT reagent (Sigma) was added to 
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each well of cultured primary macrophages on a 96 well plate, equivalent to each of the 
upper chambers of 24 well Transwell plate.   Following incubation at 37ºC for 1h, the media 
was carefully removed and 100µl DMSO added.  The absorbance of formazan dissolved in 
DMSO was measured at 590nm (Bio-Rad Model 680 Microplate reader). 
 
2.2.26 Human umbilical vein endothelial cell (HUVEC) culture 
 
HUVEC stock (Invitrogen) was found to be approximately 60% viable by staining with Trypan 
Blue solution (Sigma) and cultured at 37ºC with 5% CO2 in Phenol red free Medium 200 
(Invitrogen) with Low Serum Growth Supplement (Invitrogen).  Final supplemented media 
contained 2% (v/v) fetal bovine serum, 1µg/ml hydrocortisone, 10ng/ml human epidermal 
growth factor, 3ng/ml basic fibroblast growth factor and 10µg/ml heparin.  Cultured HUVEC 
was found to have a doubling time of around 24 hours.  Cells were detached using 0.25% 
Trypsin-EDTA (Invitrogen) and split once they reached 70-80% confluency.  All experiments 
were performed using HUVEC from passages 2-3.   
 
2.2.27 HUVEC permeability assay 
 
Transwell inserts (Corning) were coated with 100µl 125µg/ml Matrigel (BD Biosciences) and 
dried overnight in a laminar flow hood.  5µm pore size translucent polycarbonate 24 well 
Transwell inserts were used with an equivalent growth area of a 96 well plate well.  5 x 104 
HUVEC cells were plated on the Matrigel-coated inserts and cultured for 72 h in HUVEC 
media to form a monolayer.  100µg of high molecular weight FITC-dextran (Sigma) was 
added to the HUVEC culture media in the insert and 600µl of HUVEC media was added to 
the lower chamber.  The cells were cultured for 4 h before 50µl of the media in the lower 
chamber was collected and the fluorescence measured at the absorption/emission 
wavelength of 492/520nm on a spectrophotometer (SpectraMax Gemini, Molecular Probes).   
The presence of the Matrigel layer was found to be essential for the formation of a HUVEC 
monolayer on the Transwell inserts.   
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2.2.28 Haematocrit measurement 
 
Whole blood was obtained from incisions into the left ventricle of the heart following sacrifice 
of the animal and stored in heparinised eppendorfs (Microvette CB300 LH, Sarstedt) until all 
samples were collected.  Micro-haematocrit tubes (Hawksley and Sons) were filled by 
capillary action and sealed on one end before centrifuged for 10 min at 12000 RPM at room 
temperature in a micro-haematocrit centrifuge (Microspin, Hawksley and Sons).  The length 
of the red blood cell fraction along the tube as well as the total length of red blood cell, white 
blood cell and serum fractions was measured using a ruler.  The haematocrit was calculated 
as the ratio between red blood cell fraction length and total length.   
 
2.2.29 LPS sepsis study with STO-609 pretreatment 
 
16-20 week old individually caged male animals were used for the induction of sepsis. 
Treatment animals were injected intraperitoneally with 10µg/kg of STO-609 (Tocris 
Bioscience) in 55-65µl 10mM NaOH both 18 h prior to LPS sepsis induction and again just 
prior to the LPS injection.  Control animals were injected twice with 60µl 10mM NaOH only.  
STO-609 is commonly dissolved in DMSO, however 2 intraperitoneal injections of 100µl 
DMSO, the volume required for STO-609 treatment at 10µg/kg, was found to effect the 
severity of LPS sepsis and reduce the temperature drop seen over 12 h.  In addition to 
DMSO and NaOH, STO-609 is also known to be soluble in ethanol. 
Following treatment with STO-609, or NaOH only in control animals, E.coli LPS 0111:B4 
(Sigma) was injected intraperitoneally at a dose of 8mg/kg, and animals were monitored 
every 2-3 hours and assessed for sepsis severity. Core body temperature was taken both 
prior to LPS administration and 12 h post sepsis induction using the flexible probe from 
Homeothermic Blanket System (Harvard Apparatus).  Following temperature measurement at 
12 h post induction, animals were sacrificed by cervical dislocation and blood was collected 
through cardiac puncture.   
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2.2.30 Telemetry transmitter implantation 
 
Implantable mouse BP transmitters (TA11PA-C10, Data Sciences International) were used to 
measure heart rate, arterial pressure and activity level in 16-18 week old individually caged 
male animals. The surgical implantation of the telemetry transmitters was kindly carried out 
by Dr Zhen Wang (Nitric Oxide Signalling Group, MRC Clinical Sciences Centre). Briefly, the 
mice were anaesthetized with inhaled isofluorane (Abbott); the carotid artery of the mouse 
was accessed with a ventral midline incision; the left carotid artery was isolated with fine-
tipped vessel dilation forceps then punctured with a catheter introducer and the telemetry 
catheter was inserted into the vessel; 3-4mm of the catheter was advanced into the thoracic 
aorta and the catheter was secured in place with sutures around the aorta.  Through the 
same incision a subcutaneous tunnel was formed along the right flank and enlarged to form a 
pocket where the body of the transmitter containing the battery pack was placed. 0.05mg/kg 
buprenorphine (Alstoe Animal Health) was given by subcutaneous injection just before suture 
closure of the ventral incision.   
 
2.2.31 Telemetry recording 
 
The animals were left to recover for at least 7 days before telemetry recordings were made 
using receiver pads (RPC1, Data Sciences International) connected via a data exchange 
matrix to the Dataquest A.R.T acquisition system and analysis system (Data Sciences 
International).  Heart rate, systolic and diastolic blood pressure, and activity level were 
recorded from each animal every 10 seconds for 50-60 hours under control conditions and 
over 8 hours during LPS treatment. For high salt treatment, recordings were made for 2 days 
prior to and 7 days following the start of the high salt diet, as well as on days 13 and 14 of the 
high salt diet.   
Statistical analysis of telemetry data performed by the Imperial statistics department.  Curve 
fitted by quadratic model, polynomial of degree two, and analysis carried out using SPSS 
V21.  
 
 67 
2.2.32 Aorta lysate preparation 
 
Following isolation of murine thoracic and abdominal aorta down to the celiac trunk, the outer 
layer of fat and adventitia was immediately stripped off in 4ºC PBS under the dissecting 
microscope, prior to snap freezing the aorta in liquid nitrogen and storage at -80ºC.  Frozen 
aorta samples were crushed in liquid nitrogen using pestle and mortar before homogenization 
in HBA.  Following centrifugation, the supernatant was collected for activity assays.  The 
pellet was further extracted by dissolving in urea lysis buffer (0.57g/ml urea, 5% (v/v) β-
mercaptoethanol, 2% (v/v) Igepal CA-630 (Sigma), 1% (v/v) Pharmalytes buffer pH 3-10 (GE 
Healthcare), Halt Protease and Phosphatase Inhibitor Cocktail (Pierce)) for 2 min at room 
temperature.  Supernatant was collected following centrifugation at 13000g at 4°C for 15-
20min and used for polyacrylamide gel electrophoresis and western blotting.   
 
2.2.33 Polyacrylamide gel electrophoresis 
 
Between 30-75ug of each tissue lysate sample was denatured for 10min at 70ºC with sample 
buffer (25mM Tris-HCl pH 7.4, 2.5% (v/v) SDS, 1% (v/v) β-mercaptoethanol, 10% (v/v) 
glycerol, 0.05% (v/v) bromophenol blue), loaded onto Precast Bis-Tris 4-12% polyacrylamide 
gels (Bio-Rad), and electrophoresed at 200V for 50-60 min in 1x SDS-PAGE running buffer 
(10x SDS-PAGE Running Buffer, National Diagnostics) in the XCell SureLock Mini-Cell 
electrophoresis System (Invitrogen).  At least one well per gel was loaded with a protein 
ladder (PageRuler or PageRuler Plus Prestained Protein Ladder, Thermo Scientific).   
 
2.2.34 Western blotting 
 
Proteins separated by polyacrylamide gel electrophoresis were transferred onto PVDF 
membrane (Millipore Immobilon-FL Transfer Membrane, pore size 0.45µM) by wet transfer 
using Mini Trans-Blot Cell (Bio-Rad).  Both polyacrylamide gel and methanol pre-soaked 
PVDF were sandwiched between chromatography paper (Whatman) and foam pads inside 
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the transfer cassette (Bio-Rad).  Protein transfer was carried out at 100V for 80 min at 4ºC in 
transfer buffer (25mM Tris-HCl pH 7.4, 192mM glycine, 20% (v/v)  methanol), and protein 
transfer was confirmed with 0.2% (v/v) ponceau red stain (Sigma). 
Following transfer, membranes were blocked with TBS (10mM Tris-HCl pH 7.4, 150mM 
NaCl, 0.1% Tween 20) with 3% (w/v) BSA for 60 min at room temperature, prior to blotting 
with primary antibody in TBS with 3% (w/v) BSA overnight at 4ºC.  Membranes were washed 
in TBS and blotted with the appropriate secondary antibody against the primary antibody in 
HST (10mM Tris-HCl pH 7.4, 500mM NaCl, 0.5% (v/v) Tween 20) with 2% (w/v) milk powder 
for 60 min at room temperature.  Membranes were washed before visualisation using the 
Odyssey Imaging System (LI-COR Biosciences).  
 
2.2.35 MLCK activity assay 
 
Immunoprecipitation from 30µg tissue incubated with mouse antibody against total MLCK 
(Clone K36, ascites fluid, Sigma).  To measure non-specific antibody binding, 
immunoprecipitation also carried out with no antibody.  Immune complexes were added to 
30µl MLCK assay mix (1mM AMP, 1mM CaCl2, 1µM Bovine Brain Calmodulin (Calbiochem), 
1mM MLCK smooth muscle substrate peptide [KKRAARATSNVFA] (Sigma),  HGE with 1% 
(v/v) Triton-100), 10µl HGE and 10µl [γ-32P]ATP/MgCl2 (1mM ATP (Perkin Elmer), 25mM 
MgCl2,), before incubating for 30min at 30°C.  Immune complexes then spun down at 13000g 
and 20µl supernatant spotted onto P81 paper (Whatman). P81 paper washed in 1% (v/v) 
orthophosphoric acid, blotted dry, then counted for 30 s in Tri-Carb Liquid Scintillation 
Counter (Perkin Elmer). 
 
2.2.36 Aorta immunohistochemistry 
 
Whole animal perfusion and fixation was carried out in CO2 sacrificed animals with first 
phosphate buffered saline (PBS) then 4% (w/v) formaldehyde prior to tissue isolation.  Aortas 
were paraffin mounted, sectioned and stained by C&C Lab Services, High Wycombe, UK.   
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Images were captured using a Zeiss upright microscope (Axiophot, Zeiss) at the specified 
magnifications.  All measurements were taken using ImageJ 1.41 software. 
 
2.2.37 Urinary epinephrine and electrolyte measurements 
 
Urine samples were collected between 9AM and 10AM from 14-18 week old male mice and 
spun down to remove cells before storage at -80°C until all samples collected.  Urinary 
epinephrine and creatinine levels as well as sodium and potassium concentrations were 
determined by the Mouse Biochemistry Laboratories, Cambridge, UK.  
 
2.2.38 High salt study 
 
Mouse BP transmitters (TA11PA-C10, Data Sciences International) were implanted in the 
thoracic aortas of 16-20 week old individually caged male animals as described previously.  
The mice were fed control diet (0.32 % NaCl) made by soaking the standard mouse chow 
pellets (Rat and Mouse No. 3 Breeding Diet, Special Diet Services) in distilled water (150 ml 
distilled water per 100g of pellets) at 4ºC overnight.  Animals were left for at least 7 days 
before telemetry recordings were made for 48 h to measure baseline heart rates, arterial 
pressures and activity levels.   
 
A high salt diet (8.32 % NaCl) was made by dissolving 8g of NaCl (VWR International) in the 
150ml distilled water prior to soaking 100g of pellets at 4ºC overnight.  All animals were given 
free access to water.  Telemetry recordings were made over the course of two weeks to 
measure baseline heart rates, arterial pressures and activity levels.  Animals tolerated both 
control and the high salt diet as seen by maintenance of bodyweight over the course of two 
weeks.   
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2.2.39 Wire myography 
 
14-16 weeks old male mice were used for the assessment of aorta contractility by wire 
myography kindly carried out by Miss Anna Slaviero (MRC Clinical Sciences Centre).  
Following sacrifice, murine thoracic aortas were isolated, dissected into 2mm thickness rings 
and mounted on a wire myography system (Multi-Wire Myography System 610M, DMT).  
Aorta rings were maintained at 37ºC under 95% O2 and 5% CO2, and washed with 
physiological salt solution (NaPSS) pH 7.4 containing 118.4mM NaCl, 4.7mM KCl, 1.2mM 
MgSO4, 1.2mM KH2PO4, 24.9mM NaHCO3, 2.5mM CaCl2, 11.1mM glucose and 0.023mM 
EDTA to allow basal tension recordings.  Maximum tensions were also recorded following 
treatment with potassium salt solution (KPSS) pH 7.4 containing 125mM KCl, 1.2mM MgSO4, 
1.2mM KH2PO4, 24.9mM NaHCO3, 2.5mM CaCl2 and 11.1mM glucose. Aorta rings were 
treated with incremental concentrations of phenylephrine (Sigma) and tensions recorded.  
Incremental sodium nitroprusside (SNP) (Sigma) and acetylcholine (Sigma) treatments were 
carried out following KPSS treatment and tension recordings made.  Basal tension was 
established in between treatments by washing aorta rings with NaPSS.  Measurements were 
recorded in duplicate samples from each animal.   
Data collection and analysis was performed using LabChart 6.0 (ADInstruments).  
 
2.2.40 Cardiac ultrasound 
 
Longitudinal assessment of cardiac function was carried out in male mice over six months. 
The animals were scanned by ultrasound at 30MHz (Vevo770 system, Visualsonics) under 
inhaled isofluorane anaesthesia every month between 4 month and 10 month of age to obtain 
measurements of left ventricle mass, left ventricle wall thickness, left ventricle shortening 
fraction, and ejection fraction. 
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2.2.41 Statistical analysis 
 
Bone mineral density data analyzed using Kolmogorov-Smirnov test.  Analysis by ANOVA (2-
way) and student’s t-test were performed using Prism 5 (GraphPad).  All data in figures 
presented as Mean ± Standard Error Mean (SEM) unless otherwise stated.  In Chapter 5, 
statistical analysis of telemetry results was carried out by the Imperial statistics department. 
The methodology used in the analysis was Mixed Model applied longitudinal data. 
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Chapter 3. Global phenotyping 
 
In a previous study, global CaMKKβ KO mice were found to have impaired long term memory 
due to disruptions to the CaMK cascade and no overt physical abnormality (Peters et al. 
2003).  Since, then, conflicting data has been published regarding the food intake and 
glucose metabolism in separate cohorts of global CaMKKβ KO mice (Means et al. 2008; 
Claret et al. 2011).  In addition, LKB1 has been shown to preferentially phosphorylate the α2 
subunit of AMPK, leading to the suggestion that CaMKKβ may preferentially phosphorylate 
the α1 subunit of AMPK (Sakamoto et al. 2005; Sakamoto et al. 2006).  This section aims to 
clarify the role of CaMKKβ in energy metabolism and assess its AMPK isoform preferences in 
various tissues.  
 
3.1 Global Phenotyping Results 
 
3.1.1 Confirmation of Genotype 
 
The absence of exon 5 in the CaMKKβ KO mice was confirmed by PCR genotyping (Figure 
3.1A).  Absence of expressed CaMKKβ protein in specific tissues of KO mice was further 
confirmed by CaMKKβ activity assays of tissue lysates (Figure 3.1B).  The addition of Ca2+ 
and calmodulin is required by CaMKKβ immunoprecipitated from tissue lysates for the 
activation of recombinant AMPK, shown by negligible CaMKKβ acitivity seen without the 
addition of Ca2+ and calmodulin (Figure 3.1B). This is in keeping with published results 
showing activation of CaMKKβ is required for maximum activity in non bacterially expressed 
CaMKKβ (Green et al. 2011; Tokumitsu et al. 2001). 
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Figure 3.1 Confirmation of CaMKKβ exon deletion and loss of CaMKKβ activity in 
tissue. 
A. Primers designed to differentiate between full length CaMKKβ and alleles with exon 5 
deleted were used to amplify DNA from murine ear snip samples by PCR.  Products of the 
expected size, 350bp for the WT allele and 500bp for the KO allele, were detected as shown 
by the representative agarose gel.   B. CaMKK β activity in immunoprecipitates from brain 
and spleen lysates from WT and CaMKKβ KO mice. assayed with (Brain+Ca/CaM and 
Spleen+Ca/CaM) and without calcium and calmodulin (Brain and Spleen). Activity measured 
in CaMKKβ immunoprecipitates from tissue lysates by activation of recombinant AMPK 
α1β1γ1 in the presence or absence of calcium and calmodulin, followed by measurement of 
recombinant AMPK α1β1γ1 activity by SAMS peptide assay. Results presented as AMPK 
activity in nmoles [γ 32P] incorporation into the peptide per minute per milligram tissue lysate. 
Assays carried out in triplicate.  Results shown are means ± SEM. n=2. 
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3.1.2 Body weight and composition 
 
During the course of this study, Claret et al published results showing CaMKKβ KO mice had 
similar dietary intake, glucose tolerance, and plasma insulin concentration to WT mice (Claret 
et al. 2011).   In our study, no difference was seen in the consumption of food pellets 
between the WT and CaMKKβ KO mice.  At 16 weeks old, there was no difference in body 
weight between WT, CaMKKβ KO, or CaMKKα KO mice (Figure 3.2A).  To assess glucose 
metabolism, the mice were fasted overnight and blood glucose concentrations were 
recorded. Consistent with results seen by Claret et al. no significant difference was seen in 
the fasting blood glucose concentrations of CaMKKβ KO mice compared to WT mice (Figure 
3.2B).  Lipid metabolism was initially assessed by quantifying the accumulation of fat mass. 
To assess the contribution of fat and muscle mass to body weight, the mice were scanned by 
Magnetic resonance imaging (MRI) and the percentage body composition of fat and lean 
muscle was quantified.  CaMKKβ KO mice were found to have no significant difference in the 
percentage of fat and lean muscle compared to WT mice (Figure 3.2C).  In addition, no 
difference was seen when the percentage of fat composition was normalized to either body 
weight or percentage body composition of lean muscle (Figure 3.2D). 
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  A.                                                                       B. 
  
   C.                                                                       D.       
 
 
 
 
 
Figure 3.2 Body weight and fat composition of CaMKKβ KO mice.   
A. Body weights of 16 week old mice on standard chow diet.  WT n=18, CaMKKβ KO n=9, 
and CaMKKα KO n=10.  B. Blood glucose concentrations following overnight fast.  WT n=5, 
CaMKKβ KO n=8.  C.  Percentage of fat (Fat) and muscle (Lean) composition in WT and 
CaMKKβ KO mice as quantified by MRI. WT n=5, CaMKKβ KO n=8.  D. Ratio comparing 
percentage body composition of fat against either body weight or muscle. WT n=5, CaMKKβ 
KO n=8.  All results shown in this figure are means ± SEM.  
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3.1.3 Serum metabolites  
 
Lipid metabolism in the CaMKKβ KO mice was further assessed through measuring 
cholesterol synthesis and triglyceride breakdown. Serum metabolites from WT, CaMKKβ KO 
and CaMKKα KO mice were measured.  No significant difference in serum total cholesterol, 
HDL, LDL, triglyceride or free fatty acid concentrations was seen between WT and CaMKKβ 
KO mice (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3  Serum metabolite measurements from WT, CaMKKβ KO, and CaMKKα KO 
mice. Results shown are means ± SEM.  n=6.     
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3.1.4 Primary hepatocyte function 
 
The CaMKKβ KO mice appeared to have normal body weight, fasting glucose, body 
composition and lipid metabolism. However, during the data collection period for this thesis, a 
study was published showing reduced hepatocyte glucose production in the liver specific 
CaMKKβ KO mice (Anderson et al. 2012). AMPK is phosphorylated by CaMKKβ and AMPK 
activity is known to be important for hepatic metabolism, including glucose production and 
fatty acid synthesis (Andreelli et al. 2006; Carling et al. 1989; Viollet et al. 2009).  Therefore, 
the effect of CaMKKβ deletion on liver glucose production and hepatic AMPK activity was 
investigated.   
 
3.1.4.1 Hepatic glucose production 
 
To investigate hepatic glucose production, primary hepatocytes were isolated from both WT 
and global CaMKKβ KO mice by in situ perfusion with collagenase.  Cells were treated with 
or without metformin for 2h to look at short term effects and after 24h treatment for longer, 
possible transcriptional effects. Hepatic glucose production was assessed by measuring the 
glucose output into the media. Metformin treatment was found to reduce hepatic glucose 
production (Figure 3.4). No significant difference was seen after 2 or 6 hour in glucose output 
between WT and CaMKKβ KO hepatocytes in the presence or absence of metformin. (Figure 
3.4). This shows that in this model the deletion of CaMKKβ does not affect hepatocyte 
glucose output. 
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Figure 3.4  Glucose output by WT and CaMKKβ KO cultured primary hepatocytes. 
Glucose output following 2h or 24h treatment with 500µM Metformin, compared to untreated 
controls.  Assays carried out in duplicate.  A. 2 hour metformin treatment.  B. 24 hour 
metformin treatment.  Mean results shown.  n=3-4.   
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3.1.4.2 Hepatic AMPK activity and mitochondrial respiration 
 
The affect of CaMKKβ deletion on both liver and primary hepatocyte AMPK activity was also 
investigated.   Due to the effect of altering nucleotide levels after dissection of liver we also 
investigated AMPK levels in isolated hepatocytes which were harvested in a way as to avoid 
causing alterations in ATP:ADP ratios. However, there was no significant difference in AMPK 
activity in either total liver lysates or isolated primary hepatocyte lysates from WT and 
CaMKKβ KO mice (Figures 3.5 and 3.8).  The cultured primary hepatocytes were treated with 
various compounds known to alter AMPK activity. AMPK activity was similarly increased in 
WT and CaMKKβ KO hepatocytes treated by either sorbitol, AICAR, or Metformin (Figure 
3.5).   
 
AMPK is also known to activate PGC1α in hepatocytes and skeletal muscle cells (Guigas et 
al. 2007; Jäger et al. 2007); therefore the involvement of CaMKKβ in hepatocyte mitochondria 
biogenesis was investigated.  Mitochondrion function was assessed in the WT and CaMKKβ 
KO primary hepatocytes by measuring oxygen consumption at basal levels, through the 
inhibition of ATP synthase by oligomycin, as well as through electron transport inhibition by 
antimycin A and rotenone, using a Seahorse XF24 Analyser to measure oxygen 
consumption. FCCP was added to stimulate mitonchondrial respiration by uncoupling ATP 
synthesis from electron transport, and complex IV activation was confirmed by the addition of 
ascorbate and TMPD. Primary hepatocytes from CaMKKβ KO mice were found to have 
normal mitochondrial function (Figure 3.6). 
 
These results suggest the deletion of CaMKKβ does not appear to affect hepatic AMPK 
activity or hepatocyte mitochondrial function. 
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Figure 3.5  AMPK activity in cultured primary hepatocytes from WT and CaMKKβ KO 
mice following AMPK activation treatment.  
Primary hepatocytes isolated from WT and CaMKKβ KO mice by in situ perfusion with 
collagenase. Cultured hepatocytes were treated as follows: Control: untreated, Sorbitol: 0.6M 
for 10min, AICAR: 500µM for 30min, Metformin: 2mM for 2h.  Cells were lysed rapidly into 
buffer and snap frozen.  AMPK activity was measured in immunoprecipitates by the SAMS 
peptide in a radioisotope incorporation assay. Results are shown as fold AMPK activation 
normalised to total AMPK activity in untreated cells. Assays carried out in duplicate.  Results 
shown are means ± SEM. n=3-4. 
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Figure 3.6  Hepatocyte mitochondrial function. 
 Mitochondrial function of primary hepatocytes isolated from WT and CaMKKβ KO mice was 
assessed using The Seahorse to measure oxygen consumption rate (OCR) at basal 
respiration and following treatment with 2µg/ml oligomycin, 0.5µM FCCP, 5µM each of 
antimycin A and rotenone, and 20mM ascorbate with 5mM TMPD. Assays carried out in 
triplicate.  Results shown are means OCR normalised to protien concentration ± SEM.  WT 
n=3, CaMKKβ KO n=4.  
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3.1.5 Kinase activity in tissue lysates 
 
In the absence of an obvious global phenotype, the presence of a tissue specific phenotype 
was investigated.  Initially, the activity of CaMKKβ, AMPK and LKB1 was measured in a 
panel of tissues.  
 
3.1.5.1 Tissue specific CaMKKβ activity 
 
CaMKKβ activity was measured in a panel of WT tissues by immunoprecipitation and 
activation of recombinant AMPKα1β1γ1 complex. Brain and testes were found to have the 
highest CaMKKβ activity; with several tissues including spleen, aorta and prostate having 
moderate CaMKKβ activity.  Heart, liver and muscle were found to have negligible CaMKKβ 
activity (Figure 3.7). 
 
 
 
 
 
 
 
Figure 3.7 CaMKKβ activity from WT tissue lysates.  Activity measured in CaMKKβ 
immunoprecipitates from tissue lysates by activation of recombinant AMPK α1β1γ1 in the 
presence of calcium and calmodulin, followed by measurement of recombinant AMPK 
α1β1γ1 activity by incubation with SAMS peptide in a radioisotope incorporation assay.  
Results presented as nmoles [γ-32P] incorporation into the peptide per minute per milligram 
tissue lysate.  Results shown are means ± SEM. n=4; testes and erythrocytes n=3.   
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3.1.5.2 Tissue specific AMPKα1 and AMPKα2 activity 
 
AMPK activity was measured in a panel of tissues from WT and CaMKKβ KO mice (Figure 
3.8A and 3.8B).  To investigate the presence of an AMPKα subunit specific phenotype, 
complexes containing AMPKα1 and AMPKα2 subunits were isolated by immunoprecipitation 
before AMPK activity was measured.  Consistent with published literature, AMPKα2 activity 
was found to be highest in the heart, followed by the liver (Figure 3.8B).  Lung, spleen and fat 
tissue had very little AMPKα2 activity; and AMPKα2 activity was negligible in erythrocytes 
(Figure 3.8B).  In contrast, AMPK α1 activity was found to be significantly higher in spleen 
than all other tissues assayed (Figure 3.8A).  Interestingly, the variation in tissue specific 
AMPKα1 activity appeared to mirror the CaMKKβ activity seen (Figure 3.7 and 3.8A), 
excluding brain with particularly high CaMKKβ activity and spleen with particularly high 
AMPKα1 activity. No significant difference was found in liver, skeletal muscle or adipose 
tissue lysates between CaMKKβ WT and KO.  Strikingly, spleen and erythrocyte lysates from 
CaMKKβ KO mice showed significantly reduced AMPKα1 activity compared to WT mice 
(Figure 3.8A), though no compensatory change in AMPKα2 activity was seen (Figure 3.8B).  
No difference in AMPKα2 activity was seen between WT and CaMKKβ KO mice (Figure 
3.8A). 
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Figure 3.8 Comparing AMPK activity in a panel of tissues from WT and CaMKKβ KO 
mice.  A. Activity of AMPKα1 complexes in WT and CaMKKβ KO murine tissue lysates 
measured by immunoprecipitating AMPKα1 from the respective tissues followed by 
incubation with SAMS peptide in a radioisotope incorporation assay.  ** Comparison between 
WT and CaMKKβ KO spleen lysate.  * Comparison between WT and CaMKKβ KO 
erythrocyte lysate.  B. Activity of AMPKα2 complexes in WT and CaMKKβ KO murine tissue 
lysates measured by immunoprecipitating AMPKα2 from the respective tissues followed by 
incubation with SAMS peptide in a radioisotope incorporation assay. All assays carried out in 
duplicate.  All results presented as pmoles [γ-32P] incorporation into the peptide per minute 
per milligram tissue lysate.  All results shown in this figure are means ± SEM.  n=4; testes 
and erythrocytes n=3.  Student’s t-test: **P<0.01; *P<0.5. 
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3.1.5.3 Tissue specific LKB1 activity 
 
To address the possibility of compensation by increased LKB1 activation of AMPK in the 
absence of CaMKKβ, LKB1 was immunoprecipitated from the panel of WT and CaMKKβ KO 
tissue lysates and LKB1 activity was measured by activation of recombinant AMPK α1β1γ1. 
The highest LKB1 activity was seen in the lysates of testes and brain; with moderate activity 
seen in heart, liver, lung, spleen, kidney, muscle and fat; and low activity seen in 
erythrocytes.  No significant difference was seen in LKB1 activity between CaMKKβ KO and 
WT tissue lysates (Figure 3.9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 LKB1 activity from tissue lysates.   
Activity measured in LKB1 immunoprecipitates from tissue lysates by activation of 
recombinant AMPK α1β1γ1, followed by measurement of recombinant AMPK α1β1γ1 activity 
by incubation with SAMS peptide in a radioisotope incorporation assay. Assays carried out in 
triplicate. Results presented as pmoles [γ-32P] incorporation into the peptide per minute per 
milligram tissue lysate.  Results shown are means ± SEM except for testes.  Testes n=1, all 
other tissues n=2. 
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3.1.6 CaMKK β KO mice have normal bone length and bone density 
 
The suggestion that CaMKKβ may be involved in bone turnover was raised by several 
studies showing associations between the CaMK cascade with the proliferation and functions 
of osteoblasts (Pederson et al. 2008; Oury et al. 2010). In addition, AMPKα1 was also shown 
to be involved in trabecular bone formation (Shah et al. 2010). Both osteoclasts and 
osteoblasts are known to express only AMPKα1 subunit as part of the AMPK complex (Shah 
et al. 2010). As deletion of CaMKKβ appears to only affect AMPKα1 activity (Figure 3.8), we 
thought it worthwhile to investigate the presence of a bone phenotype in the CaMKKβ KO 
mice.   
 
Femurs, tibiae, humeri and radii were isolated from WT and CaMKKβ KO mice, and 
measured for changes to bone length and bone mineral content.  However, no significant 
difference was detected in long bone length, femur cortical thickness or in the tibial ulnar ratio 
(Figure 3.10A).   There was also no significant difference in bone mineral density content 
between WT and CaMKKβ KO mice (Figure 3.10C).   
 
To investigate potential compensation by CaMKKα and LKB1, RNA was extracted from 
crushed murine femurs and gene expression was measured by cDNA synthesis through 
reverse transcription followed by quantitative real-time PCR.  An increase of around two fold 
was seen in the expression of both CaMKKα and LKB1 in CaMKKβ KO bone compared to 
WT (Figure 3.10D); however statistical significance was not reached due to large variations 
within groups. 
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Figure 3.10 Bone mineralization measurements.   
A.  Measurements of tibial ulnar ratio, femoral and humeral length, and femoral cortical 
thickness in WT and CaMKKβ KO mice. n=5 and 7 respectively.   B. Images demonstrate 
conversion from grey scale X-ray image to colour image using a Look Up Table prior to pixel 
counting using ImageJ software.  This process is used to quantify bone mineralisation 
density.  C. Bone mineralization density in WT and CaMKKβ KO mice.  Relative frequency 
and cumulative frequency histograms of mineralization density from femur.  n=5 and 7 for WT 
and CaMKKβ KO respectively.   D. CaMKKα and LKB1 expression in WT and CaMKKβ KO 
mice measured by cDNA synthesis from crushed murine femur extracted RNA through 
reverse transcription followed by quantitative real-time PCR. results shown are gene 
expression in CaMKKβ KO mice normalised to expression in WT mice. Assays carried out in 
triplicate.  n=4.  All results shown in this figure are means ± SEM.  
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3.1.7  Increased osmotic fragility seen in CaMKKβ KO erythrocytes 
 
It has been shown that AMPKα1 KO mice have reduced erythrocyte fragility, leading to 
anaemia and splenomegaly through increased erythrocyte lysis (Wang et al. 2010).  To 
investigate if the reduced AMPKα1 activity seen in the CaMKKβ KO mice resulted in a similar 
phenotype, erythrocyte osmotic fragility was measured in erythrocytes isolated from WT, 
CaMKKβ KO, and CaMKKα KO mice.  In contrast to the AMPKα1 KO mice, erythrocytes from 
both CaMKKβ KO and CaMKKα KO mice showed increased osmotic fragility at 4.5g/l NaCl 
(Figure 3.11A).  At 16 weeks, no splenomegaly is seen in the CaMKKβ KO mice (Figure 
3.11B), and they also do not develop anaemia (Chapter 4, figure 4.6). 
 
Whilst trying to confirm the loss of CaMKKβ expression in the KO, it was noted that CaMKKβ 
activity could not be detected in immunoprecipitations of up to 500ug erythrocyte lysate 
(Figure 3.11C, representative results from 200ug lysate shown). Erythrocyte lysate from 
CaMKKβ KO contained a significant reduction in LKB1 activity compared to WT (Figure 
3.11D), which could account for the reduction in erythrocyte AMPKα1 activity seen. 
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Figure 3.11  Investigating osmotic fragility in erythrocytes from CaMKKβ KO mice.  
A. Erythrocyte osmotic fragility assay showing percentage of cell lysis at NaCl concentrations 
between 3g/L and 6g/L. Results shown are means. WT n=5, CaMKKβ KO n=5, CaMKKα KO 
n=3. B. Murine spleen weights at 16 weeks in WT and CaMKKβ KO mice. n=5-6.  C. 
CaMKKβ activity in WT and CaMKKβ KO erythrocyte lysates, compared to WT spleen lysate.  
Activity measured in CaMKKβ immunoprecipitates from tissue lysates by activation of 
recombinant AMPK α1β1γ1 in the presence of calcium and calmodulin, followed by 
measurement of recombinant AMPK α1β1γ1 activity by incubation with SAMS peptide in a 
radioisotope incorporation assay. Assays carried out in duplicate. D. LKB1 activity in WT and 
CaMKKβ KO erythrocyte lysates (Not statistically significant), n=3, in comparison with 
AMPKα1 activity in WT and CaMKKβ KO erythrocyte lysates (Enlarged from Figure 3.8A).  
Activity measured in LKB1 immunoprecipitates from tissue lysates by activation of 
recombinant AMPK α1β1γ1, followed by measurement of recombinant AMPK α1β1γ1 activity 
by incubation with SAMS peptide in a radioisotope incorporation assay. Assays carried out in 
triplicate. Results presented as pmoles [γ-32P] incorporation into the peptide per minute per 
milligram tissue lysate.   All results shown in this figure are means ± SEM.  n=2-4. Student’s t-
test: *P<0.5. 
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3.1.8 Loss of CaMKKβ confers protection against LPS induced sepsis 
 
AMPK activity was found to be significantly reduced in the spleen lysates of CaMKKβ KO 
mice compared to WT (Figure 3.8A).  As splenectomy is known to result in an increased 
susceptibility to bacterial infections (Styrt 1990), an LPS sepsis murine model was set up to 
assess the immune response in CaMKKβ KO mice.  To investigate the effect of reduced 
AMPK activity seen in the spleens of CaMKKβ KO mice (Figure 3.8A), LPS endotoxin was 
used to induce sepsis in individually caged, 16 weeks old male WT, CaMKKβ KO, and 
CaMKKα KO mice.  In mice, LPS sepsis is known to be associated with a drop in body 
temperature, with a body temperature of below 30ºC associated with non-survival (Saito et al. 
2003; Nemzek et al. 2008). Therefore, body temperature was recorded as a marker of sepsis 
severity as well as the development of qualitative signs including hunched posture, 
piloerection, reduced mobility, and reduced response to external stimuli.  LPS dosage was 
optimized on C57BL/6 mice to produce a consistent significant drop in body temperature at 
12 hours post induction (data not shown).  The temperature drop at 12 hours post LPS 
injection was significantly reduced in the CaMKKβ KO mice compared to WT (Figure 3.12A 
and 3.12B), with WT mice dropping their core temperature by 15.42 ± 0.66 °C compared to a 
10.63 ± 1.17°C temperature drop in CaMKKβ KO mice. In addition, the WT mice also 
appeared physically less well during LPS sepsis, becoming more immobile, shivery, and less 
interested in their environment compared to the CaMKKβ KO mice. This suggests that the 
absence of CaMKKβ activity confers protection against LPS induced sepsis.  Protection was 
not seen in CaMKKα KO mice, dropping their core temperature by 15.29 ± 0.68 °C 12 hours 
post sepsis induction (figure 3.12C), suggesting there may be a CaMKKβ specific mechanism 
for the protection. 
 
To investigate whether the improved body temperature and physiological signs seen in 
CaMKKβ KO mice could be replicated through pharmacological inhibition of CaMKKβ activity 
in WT mice (Tokumitsu et al. 2002), WT mice were treated twice with 10µg/kg STO-609 by 
intraperitoneal injections prior to induction of LPS sepsis.  At 12 hour post LPS induction, the 
body temperature in STO-609 treated WT mice was found to be higher than control treated 
WT mice (Figure 3.12D); indicating STO-609 treatment can also protect against LPS induced 
sepsis.    
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Figure 3.12  The effect of CaMKKβ deletion on LPS induced sepsis.   
A. Temperature drop 12 hours following induction of LPS sepsis by intraperitoneal injection of 
LPS in CaMKKβ KO mice, compared with WT and CaMKKα KO. WT n=21, CaMKKβ KO 
n=12, CaMKKα KO n=10. B. Core temperature measurements prior to induction (T0), and 12 
hours after induction of sepsis (T12) in WT and CaMKKβ KO mice. WT n=21, CaMKKβ KO 
n=12, CaMKKα KO n=10.  C. Similar body weights seen in WT, CaMKKβ KO and CaMKKα 
KO mice. WT n=21, CaMKKβ KO n=12, CaMKKα KO n=10.   D. Body temperature in 
untreated (Control) or STO-609 treated (STO609) WT mice 12 hours following LPS induction 
of sepsis. n=13.  All results shown in this figure are means ± SEM.  Student’s t-test:  
**P<0.01; *P<0.05.  
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3.2 Discussion 
 
3.2.1 Summary of principal chapter findings 
 
Metabolic phenotyping was carried out in global CaMKKβ KO mice to determine the tissue 
specific functions of CaMKKβ, and in particular, its involvement in AMPKα subunit specificity.  
Potential compensation by LKB1 upregulation was also assessed.  The main results are 
summarized below: 
 
1). Global deletion of CaMKKβ does not alter food intake or body weight. 
 
2). No significant change in glucose metabolism is found in CaMKKβ KO mice.  They have 
normal fasting glucose levels and normal hepatocyte glucose production. 
 
3). Isolated CaMKKβ KO primary hepatocytes have normal glycolytic respiration as measured 
by inhibition of ATP synthase (oligomycin) and respiratory chain complexes (rotenone and 
antimycin A).  
 
4). Global deletion of CaMKKβ does not alter lipid metabolism as measured by serum 
cholesterol and triglyceride levels.  
 
5). CaMKKβ KO mice have normal bone length and bone density, indicating normal bone 
turnover with unaltered osteoblast and osteoclast function. 
 
6). In contrast to AMPKα1 KO mice, CaMKKβ KO mice have erythrocytes with increased 
osmotic fragility, not associated with anaemia or splenomegaly. 
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7). Global deletion of CaMKKβ provides protection against LPS induced sepsis. 
 
8). LKB1 can phosphorylate and activate both AMPKα1 and 2 subunits in vivo. 
 
3.2.2 No overt metabolic phenotype in global CaMKKβ KO mice under basal conditions 
 
CaMKKβ does not appear to be involved in metabolism under basal, unstressed conditions.  
No difference was found in body weight, serum cholesterol concentration, or serum 
triglyceride concentration between wild-type and CaMKKβ  KO mice.   Downstream of 
CaMKKβ, no difference was seen in AMPKα1 or α2 activity in liver, skeletal muscle or 
adipose tissue lysates between wild-type or CaMKKβ  KO mice.  The absence of CaMKKβ 
also has no effect on either AMPK activity or glucose production in isolated hepatocytes both 
under basal conditions and when treated with known activators of AMPK.   The results from 
this study support previously published data showing normal food intake,  weight gain and 
glucose tolerance in the CaMKKβ  KO mice (Claret et al. 2011), in contrast to the reduced 
food intake, reduced body weight and improved glucose tolerance reported by Anderson et al 
(Anderson et al. 2008).   In addition to showing reduced body weight and protection against 
impaired glucose tolerance, the study by Anderson et al also showed reduced AMPK activity 
in the hypothalamus of the CaMKKβ  KO mice (Anderson et al. 2008).  The AMPK activity in 
whole brain lysate was found to be the same between WT and CaMKKβ  KO in this study 
(Figure 4A and 4B).   
 
Recently, a separate paper was published by Anderson et al (Anderson et al. 2012) showing 
increased fatty acid turnover resulting in increased serum cholesterol and triglyceride 
concentrations, as well as reduced hepatocyte glucose production in their liver specific 
CaMKKβ KO mice; again, in contrast to the results seen in this study. There is clear 
discrepancy between the results from this study and the findings from the Means lab 
(Anderson et al. 2008 and 2012) but the cause is unknown.  The mice used have been 
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backcrossed onto the same C57/Black6 background.  The kinase domain of CaMKKβ (Figure 
6.1) is the site of deletion for both cohorts of mice used, exon 5 deletion in this study (Peters 
et al. 2003) and exon 2-4 deletion in the Means lab.  
 
 
Figure 3.13 Diagram of murine CaMKKβ illustrating the main functional domains.  (adapted 
from Mutsuko et al. 2011). 
 
Hepatocyte mitochondrial function including basal respiration, ATP turnover, and respiratory 
reserve were all assessed and found to be unaltered in CaMKKβ KO mice, providing further 
evidence that the absence of CaMKKβ does not alter metabolism.  
 
It can be argued that the lack of metabolic phenotype seen in CaMKKβ KO mice could be 
due to compensation of alternative pathways.  However, there is no significant increase in 
AMPKα2 activity to compensate for the changes in AMPKα1 activity, and LKB1 activity also 
remains similar between WT and CaMKKβ KO tissue lysates with the exception of 
erythrocytes where there is a small difference observed.  Nevertheless, it remains possible, 
that the lack of change in AMPK activity seen results from compensation by additional 
unknown upstream activators of AMPK.  In addition, the differences in AMPK activity may be 
masked by the possible full activation of AMPK due to LKB1 activity following the rapid 
depletion of ATP during tissue dissection. 
 
As CaMKKβ does not appear to be involved in the metabolic processes controlled by AMPK, 
it was important to clarify the relationship between LKB1 and AMPK.   AMPKα1  KO mice 
also show no metabolic phenotype, in contrast to AMPKα2 KO mice which have previously 
been shown to exhibit increased body weight, increased adipose tissue mass, impaired 
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glucose tolerance, as well as impaired insulin secretion and sensitivity (Viollet et al. 2003).  In 
vitro, both LKB1 and CaMKKβ can activate AMPK complexes with both α1 and α2 subunits, 
however, it was unclear whether this was also the case in vivo and, more importantly, had 
any physiological function.  The AMPK activity data in the CaMKKβ  KO mice provides 
evidence that LKB1 does phosphorylate both subunits.  In the absence of CaMKKβ, AMPKα1 
activation is similar to that seen in wild-type in most tissues, suggesting CaMKKβ activity is 
not essential for AMPK activity in most tissues under basal conditions.  
 
3.2.3 CaMKKβ  KO mice have normal long bone length and bone mineral density 
 
No difference was seen in the cortical thickness or bone mineral density of 12 week old male 
global CaMKKβ  KO mice.  A possible explanation is compensation at the local level and 
redundancy at the global hormonal level. CaMK I was shown to be involved in the 
proliferation of osteoblasts in vitro, with deletion by siRNA in osteoblasts leading to reduced 
osteoblast proliferation (Pedersen et al. 2008).  AMPK also regulates osteoblast proliferation 
and bone formation: activation of AMPK by AICAR in primary osteoblasts led to increased 
bone formation; and conversely inhibition of AMPK reduced bone formation (Shah et al. 
2010).   In keeping with this, studies have shown reduced trabecular bone density in global 
AMPKα1  KO mice (Jeyabalanet et al. 2012).  However, no evidence of altered osteoblast 
proliferation and increased bone formation was seen in the global CaMKKβ KO mice. This 
may be explained by compensation through increased CaMKKα and LKB1 gene expression 
as seen in CaMKKβ KO bone.  Although statistical significance was not reached, the relative 
expression of both CaMKKα and LKB1 was almost doubled in CaMKKβ KO bones.  
Assessment of protein expression was considered and found to be outside the scope of this 
project as the extraction and isolation of protein from bone is a complex process due to bone 
mineralization.  
 
The control of bone density is also known to be regulated by hormones.  Recently, an in vivo 
murine study where CaMKKβ was deleted in SF1 neurons in the ventromedial nucleus of the 
hypothalamus showed reduced trabecular density in both vertebrae and long bones at 12 
weeks (Oury et al. 2010).  CaMK IV was suggested as the downstream mediator, as the 
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same study showed CaMK IV deletion in SF1 neurons produced a similar phenotype to 
CaMKKβ deletion.  However, the significance of bone density regulation by SF1 neurons is 
unclear, as the activity of CaMK IV, a downstream target of CaMKKβ, is known to be reduced 
in CaMKKβ KO hypothalamus (Peters et al. 2003) but no change in trabecular density is seen 
in the global CaMKKβ KO mice.  Further activation of the pathway, such as leptin injections, 
may be required for a bone phenotype to be seen in global CaMKKβ KO mice.  Leptin is 
known to inhibit bone mass accrual through reduced serotonin synthsis and reduced 
stimulation of SF1 neurons (Yadav et al. 2009).  AMPK activity in the hypothalamus can also 
be inhibited by leptin (Minokoshi et al. 2002 and 2004), although under  unstressed 
conditions, CaMKKβ does not appear to be required for AMPK activity in the brain, as seen 
by the unaltered AMPK activity in CaMKKβ KO brain lysates.  It is also possible that the 
changes in AMPK activity in CaMKKβ KO brain may be masked by the activation of LKB1 
during the isolation of brain tissue as this process is limited by procedural speed. 
 
3.2.4 CaMKKβ KO erythrocytes have increased osmotic fragility 
 
Erythrocytes have been shown to contain AMPK complexes with α1 subunits only.   Anaemia 
as well as splenomegaly is seen in mice lacking AMPKα1 as a result of reduced erythrocyte 
life span. (Wang et al. 2010).  Reduced osmotic fragility was shown and the reduced 
deformability of these erythrocytes in response to shear stress is proposed as the mechanism 
for the increased haemolysis seen (Foretz et al. 2010).   The same phenotype is not present 
in CaMKKβ  KO mice.  In contrast to the AMPKα1  KO, erythrocytes lacking CaMKKβ were 
shown to have increased osmotic fragility compared to wild-type (Figure 6A).  The altered 
osmotic fragility was seen in both CaMKKβ  KO and CaMKKα  KO cells, suggesting the 
involvement of the CaMK cascade in either the erythrocyte membrane ion transporters or the 
maintenance of cell membrane integrity.   However, the physiological relevance of the 
increased osmotic fragility seen is currently unclear, as neither CaMKKβ  KO or CaMKKα  KO 
mice show anaemia or splenomegaly (data not shown), and the difference was significant at 
a NaCl concentration outside the physiological range.    
As CaMKKβ activity was not detectable in WT erythrocytes, LKB1 appears to be the 
upstream kinase responsible for AMPK activity in erythrocytes.  Deletion of CaMKKβ led to 
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both reduced LKB1 activity (Figure 11C) and AMPKα1 activity in erythrocytes through an 
unknown mechanism.  LKB1 is known to be constitutively active (Lizcano et al. 2004), 
suggesting  the reduction in LKB1 activity likely results from reduced LKB1 expression, 
perhaps in the bone marrow haematopoietic stem cells responsible for erythrocyte production 
and protein synthesis.  The transcription regulator CREB is known to be activated by CaMKK 
in neurons (Peters et al. 2003; Wayman et al. 2008), and also activated by CaMK IV in T 
lymphocytes (Yu et al. 2001); although the activation of transcription by the CaMK cascade 
has not been shown in haematopoietic stem cells, the data presented in this thesis raises the 
possibility of a novel link between CaMKK activity and LKB1expression that has not 
previously been studied. 
 
3.2.5 Loss of CaMKKβ activity confers protection against LPS induced sepsis 
 
Sepsis describes a clinical syndrome characterized by systemic inflammation occurring in 
response to known or suspected infections.  Bolus injection of LPS is used in murine models 
of sepsis as studies in human volunteers have shown injection of LPS can induce signs and 
symptoms similar to those reported in septic patients (Buras et al. 2005). Interestingly, the 
loss of CaMKKβ appears to protect mice against LPS induced sepsis, as shown by reduced 
temperature drop in not only the CaMKKβ KO mice and also WT mice treated with the 
CaMKKβ inhibitor, STO-609.   
 
The inhibition of CaMKKβ by STO-609 is not very specific (Tokumitsu et al. 2002).  At 2 hour 
following intraperitoneal injection of 10µg/kg STO-609 in mice, the plasma concentration of 
STO-609 was previously shown to be between 200 and 400ng/g (Massie et al. 2011), which 
is equivalent to a plasma concentration of 6 to 12 µg/ml STO-609 assuming an average 30g 
mouse with 2 ml of plasma.  The tissue availability of intraperitoneally injected STO-709 is 
unclear.  In addition to inhibition of CaMKKβ, STO-609 may also inhibit CaMK I, CaMK IV, 
AMPK, CaMK II and MLCK at the plasma concentration of 6 to 12µg/ml. 
 
 98 
Recently both CaMK I and IV, when activated by CaMKKα and β, have been implicated in 
LPS induced sepsis through macrophage cytokine release.  CaMK IV was shown to be 
required for the release of High-Mobility Group Box 1 (HMG B1), a late stage pro-
inflammatory cytokine, in LPS treated murine primary peritoneal macrophages (Zhang et al. 
2008). CaMK I was found to be involved in the production of Interleukin-10 as well as the 
release of HMG B1 in both LPS treated murine primary peritoneal macrophages and in mice 
undergoing a caecal ligation and puncture model of sepsis (Zhang et al. 2011).  The loss of 
CaMKKβ could lead to reduced activation of CaMK I and CaMK IV, and result in reduced 
inflammatory cytokine production through the above mechanisms.  However, it does not 
explain the lack of protection seen in CaMKKα  KO mice.  Protection through the CaMK 
pathway could occur if it involves tissue with minimal CaMKKα activity; or alternatively, the 
protective effect could be masked in the CaMKKα  KO mice by a compensatory mechanism 
such as increased CaMKKβ activity.   
 
The inflammatory response during sepsis is potentially regulated by CaMKKβ through not 
only the CaMK cascade but also AMPK.  Inhibition of AMPK activity in macrophages has 
been shown to inhibit the LPS induced production of IL6 and TNFα (Sag et al. 2008; Yang et 
al. 2010), both potent pro-inflammatory cytokines and pyrogens (Netea et al. 2000).  Similar 
to the reduced AMPK activity seen in erythrocytes, the loss of CaMKKβ could potentially 
reduce AMPK activity in macrophages leading to reduced LPS induced pro-inflammatory 
cytokine production and therefore limit sepsis progression. 
 
A second possible mechanism for the protection against LPS induced sepsis seen in 
CaMKKβ  KO mice involves the production of NO, a mediator of septic shock.  During sepsis, 
iNOS can be upregulated by both endotoxins and inflammatory cytokines, leading to the 
overproduction of NO, resulting in vasodilation, myocardial toxicity, and mortality.   In 
macrophages, iNOS expression and further NO production has been shown to be dependent 
on the presence of NO produced by eNOS (Connelly et al. 2003).  As eNOS has been shown 
to be activated by AMPK (Chen et al. 2009), it is possible the loss of CaMKKβ could lead to 
reduced iNOS expression, NO production, and therefore improved circulation during sepsis.   
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Improved circulation during sepsis could also occur through vascular resistance to 
vasodilation and hypotension.  AMPK was found to be involved in vessel contractility by 
phosphorylation and inhibition of the MLC kinase, MLCK (Horman et al. 2008); and recently it 
has also been shown to activate the MLC phosphatase regulatory subunit, MYPT1, leading to 
vasodilation (Wang et al. 2011).  CaMKKβ could potentially regulate vessel contractility 
through AMPK, with increased blood pressure seen in CaMKKβ KO mice compared to WT. 
Investigations into possible mechanisms will be further discussed in the next two chapters of 
this thesis. 
 
3.2.6 Comparing LPS and the Caecal ligation puncture model of sepsis 
 
The LPS sepsis model used in this study does not fully represent the conditions present in 
bacterial sepsis.  Unlike bacteria, the LPS used to induce sepsis contains only the 
components of bacterial cell wall and will not replicate within the host organism. The 
production of NO is known to be important for the bactericidal properties of macrophages 
(Vazquez-Torres et al. 2008).  Reduced production of NO in a global CaMKKβ  KO mice 
could potentially lead to reduced phagocytosis by macrophages on exposure to bacteria, and 
result in overwhelming sepsis through bacterial replication and destruction of host tissue.  
Induction of sepsis through caecal ligation puncture (CLP) (Hubbard et al. 2005), which 
releases gut bacteria into the murine peritoneum from the caecum, can provide an alternative 
model to LPS injection.  This model has previously been validated to allow adjustment of the 
resulting sepsis severity through the size of needle puncture and the number of punctures 
made (Buras et al. 2005).  The CLP model may be a more clinically relevant model of 
peritonitis for the investigation of sepsis, however it is technically more challenging than the 
LPS sepsis model and is its use is limited by animal numbers and the technical availability. 
 
In summary it appears that under basal conditions CaMKK plays an undetectable role in 
general homeostasis and metabolism. However under conditions of extreme stress, such as 
found during sepsis, the absence of CaMKK activity appears to be advantageous. This will 
be investigated in detail in the next chapter. 
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Chapter 4. The function of CaMKKβ in inflammation 
 
In the previous chapter, the function of CaMKKβ in general metabolism was explored.  One of 
the striking findings was the reduced deterioration in physical condition seen in CaMKKβ KO 
mice during LPS induced sepsis.  In this chapter, the effect of global CaMKKβ deletion on the 
main inflammatory pathways involved in sepsis will be investigated in order to elucidate the 
possible mechanisms involved, including inflammatory mediator production, white blood cell 
proliferation, macrophage activation and altered vascular permeability.   
 
4.1 Investigating the function of CaMKKβ in inflammation 
 
4.1.1 Measurement of serum cytokine production following LPS treatment 
 
Cytokines and inflammatory mediators are the main components of sepsis progression.  The 
binding of LPS to TLR receptors on leukocytes results in the release of both pro-inflammatory 
cytokines including IL1β or TNFα, as well as the anti-inflammatory cytokine IL10 (Poltorak et 
al. 2000; Nduka and Parrilo. 2009).  The severity of the inflammatory response directly 
correlates with the concentration of the pro-inflammatory cytokines and inversely correlates 
with IL10 (Blackwell and Christman. 1996; Damas et al. 1997; Banchereau et al. 2012).  To 
compare the inflammatory state between WT and CaMKKβ KO mice during LPS sepsis, 
serum was collected at 12 hour post LPS injection and cytokine levels were measured using 
a multiplexed cytokine ELISA kit. Serum cytokine concentrations from control mice were 
below the level of detection and unable to be measured.  12 hours after the LPS injection, the 
serum concentration of IL6 was found to be higher in CaMKKβ KO compared to WT mice; no 
difference was seen in the serum concentration of IL10 or the pro-inflammatory cytokines: 
IL1β, IL6 or TNFα (Figure 4.1).  The serum concentration of granulocyte-macrophage colony 
stimulating factor (GM-CSF) was also measured as an indicator of macrophage proliferation.  
The serum concentration of GM-CSF in CaMKKβ KO mice was found to be similar to WT 
mice following LPS treatment (Figure 4.1).  
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Figure 4.1 Serum cytokine concentrations 12 hour post LPS injection.   
Serum was collected from WT and CaMKKβ KO mice 12 hours after intraperitoneal LPS 
injection, the concentration of a panel of cytokines was measure using a magnetic 
multiplexed ELISA assay kit. Results shown are means ± SEM.  WT n=17, KO n=10.  
Student’s t-test: *P<0.5.  
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4.1.2 Serum NO production following LPS treatment 
 
During sepsis, NO plays an important role in both the activation of leukocytes as well as the 
control of vascular blood flow.  The presence of LPS and increased concentrations of pro-
inflammatory cytokines lead to the expression of iNOS in both endothelial cells and 
macrophages, resulting in increased production of NO. In addition to cytokine measurements, 
the amount of NO released as measured in serum nitrite concentration provides an 
alternative indication of inflammation severity (Petros et al. 1991; Cauwels. 2007).  To 
investigate whether NO synthesis was involved in the sepsis protection, the nitrite 
concentration was measured in serum samples collected from untreated and LPS treated 
mice.  The nitrite in serum is often present in the oxidized nitrate form, therefore prior to 
measurement of nitrite concentration, all serum samples were deproteinated and treated with 
a reducing agent to convert the nitrate back to nitrite. 
 
LPS treatment caused a significant increase in serum NO production (Figure 4.2A). However, 
there was no difference seen in either untreated or 12h LPS serum nitrite concentration 
between the WT and CaMKKβ KO mice (Figure 4.2A), indicating similar NO production 
following LPS treatment.   
Following its production, NO is able to diffuse into vascular smooth muscle cells where it 
binds to and activates guanylyl cyclase which catalyses the conversion of GTP to cGMP.  
Therefore, changes in the concentration of NO correlates with changes in cGMP 
concentration.  When the concentration of cGMP was measured in the serum of  12h LPS 
treated mice, no difference was seen between WT and CaMKKβ KO (Figure 4.2B), 
supporting the lack of difference seen in serum nitrite concentration. 
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Figure 4.2  Serum NO and cGMP concentration following LPS treatment.   
A Serum was collected from WT and CaMKKβ KO mice 12 hours after intraperitoneal 
injection of saline (control) and LPS (12h LPS), nitrite concentration was measured by Greiss 
assay.  *** Comparison of serum nitrite concentration between control and LPS treated mice. 
ANOVA: ***P<0.01.  Control n=4-5, 12h LPS n=12-13.   B Serum was collected from WT and 
CaMKKβ KO mice 12 hours after intraperitoneal LPS injection, serum cGMP concentration 
was measured using the cGMP complete Enzyme ImmunoAssay Kit. n=6. All results shown 
in this figure are means ± SEM. 
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4.1.3 Leukocyte count following 6 hour LPS treatment   
 
As the lack of difference seen in both cytokine concentration and NO production in the WT 
and CaMKKβ KO mice following LPS treatment could be masked by a difference in the 
proliferation of neutrophils and macrohpages, the percentage population of these cells were 
measured by flow cytometry of blood leukocytes isolated from both untreated and 6h LPS 
treated mice.  As would be expected, Neutrophilia is seen following 6h LPS (Figure 4.3).  
However, no difference is seen in the percentage blood population of either macrophages or 
neutrophils, in both untreated and LPS treated WT and CaMKKβ KO mice.  
 
4.1.3.1 Leukocyte populations in blood and the lymphoid organs 
 
The CaMK cascade, and in particular CaMKIV, has previously been implicated in the 
activation of T lymphocytes by promoting gene transcription (Ho et al. 1996; Yu et al 2000).  
Therefore, T lymphocyte and B lymphocyte populations were measured in blood and the 
lymphoid organs including CD4+ T lymphocytes, CD8+ T lymphocytes, CD25+ regulatory T 
lymphocytes, as well as CD44+ activated T lymphocytes  by flow cytometry. No difference is 
seen in any of the leukocyte populations measured between WT and CaMKKβ KO mice 
(Figure 4.5). As would be expected, lymphocytes predominate in the lymphoid organs, and 
only T lymphocytes are present in the thymus (Figure 4.5). 
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Figure 4.3 Macrophage and neutrophil count in blood. Percentage blood population of 
macrophages and neutrophils from 6 hours post saline (Control) and LPS treated WT and 
CaMKKβ KO mice were measured by flow cytometry.  Results shown are means ± SEM.  
n=3-6. 
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Figure 4.4 Leukocyte count in blood and lymphoid organs.  
No significant difference in percentage leukocyte populations in blood and lymphoid tissues in 
6 hour LPS treated WT and CaMKKβ KO mice when measured by flow cytometry. T 
lymphocyte populations include CD4+, CD8+, CD25+, CD44+ and combinations of these seen 
during development.  A. Blood. n=3-6.   B. Spleen. n=2.   C. Lymph nodes. n=2.  D. Thymus. 
n=2.  All results shown in this figure are means ± SEM. 
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4.1.4 CaMKKβ function in macrophage migration 
  
To further determine the role of CaMKKβ in leukocyte activation, peritoneal macrophages 
were isolated from untreated WT and CaMKKβ KO mice, cultured for 24 hours and 
characterized.  Cultured macrophages maintain F4/80 receptor staining for up to 8 days in 
culture following isolation as shown by flow cytometry of a representative sample (Figure 
4.5A).   
  
4.1.4.1 AMPK activity in LPS treated macrophages 
 
As AMPK activity was found to be reduced in CaMKKβ KO erythrocytes, AMPK activity was 
measured in cultured macrophages and also found to be significantly reduced in CaMKKβ 
KO.  To assess AMPK activity in LPS activated macrophages, the cultured macrophages 
were primed with 100ng/ml IFNγ overnight before activation with 10ng/ml LPS treatment.  
Following 24 hour LPS treatment, AMPK activity was found to be similarly reduced in both 
WT and CaMKKβ KO mice (Figure 4.5B). Therefore, the loss of CaMKKβ appears to reduce 
macrophage AMPK activity but does not appear to be involved in LPS induced reduction in 
AMPK activity.   
 
4.1.4.2 LPS induced macrophage activation  
 
The activation of macrophages was assessed by NO production and macrophage 
phagocytosis.  NO production as measured by media nitrite concentration was increased by 
24 hour after 10ng/ml LPS treatment following IFNγ priming; no difference was seen in NO 
production between WT and CaMKKβ KO macrophages with or without LPS treatment 
(Figure 4.5C).  Correspondingly, macrophage phagocytosis as measured by uptake of 
fluorescent conjugated E.coli bioparticles was increased by increasing concentrations of LPS 
treatment, but no difference is seen between the WT and CaMKKβ KO macrophages when 
treated for 24 hours with 100ng/ml LPS (Figure 4.5D).  Without priming by overnight 
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treatment with IFNγ, the uptake of bioparticles by LPS treated macrophages is similar to 
untreated macrophages, indicating IFNγ priming is essential for LPS induced macrophage 
activation.  
 
4.1.4.3 CaMKKβ regulates VEGF dependent macrophage migration 
 
Many of the signalling and cytoskeletal proteins involved in the regulation of macrophage 
phagocytosis are also involved in macrophage migration (Jones. 2000; Swanson and Hoppe. 
2004; Beemiller et al. 2010).   To investigate if CaMKKβ is involved in the regulation of 
macrophage migration, Transwell assays were set up with and without the chemoattractant 
VEGF in the lower wells.  Following macrophage migration through the Transwell membrane, 
only a proportion of the macrophages would detach from the underside of the membrane and 
fall into the lower wells, therefore, the number of macrophages in the lower wells was found 
to be poorly representative of actual number of migrated macrophages. Instead, the 
conversion of tetrazolium salt to formazan by macrophage mitochondria as used in MTT 
assays was found to correlate well with the number of macrophages (Figure 4.5E), and was 
used to measure the number of remaining non-migrated macrophages from which the 
percentage of non-migrated macrophages was calculated.  VEGF induced migration was 
found to be significantly reduced in CaMKKβ KO macrophages compared to WT as shown by 
the greater number of non-migrated CaMKKβ KO macrophage (Figure 4.5F). However the 
significance of this difference is unclear. No difference was found in the number of 
macrophages in blood from LPS treated WT and CaMKKβ KO mice.  It is possible the 
number of tissue macrophages may be reduced in CaMKKβ KO mice, if this is the case, the 
tissue macrophages do not appear to affect LPS sepsis severity as no reduction in cytokine 
or nitrite concentration is seen in CaMKKβ KO mice following LPS treatment.  
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Figure 4.5 Macrophage function.   
A. Representative flow cytometry result of cultured peritoneal macrophages 8 days post 
isolation.  F4/80 staining shown in green (P2, 96%).   B. AMPK activity in 24 hour LPS 
treated cultured macrophages measured by immunoprecipitation of AMPKβ followed by 
incubation with SAMS peptide in a radioisotope incorporation assay.  Assays performed in 
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duplicate. Results presented as pmoles [γ-32P] incorporation into the peptide per minute per 
milligram cell lysate.  n=5-7  C. NO production from untreated (Control) and 24 hour 10ng/ml 
LPS treated (LPS) cultured macrophages as measured by Greiss assay. n=5-7. D. 
Phagocytosis of fluorescent conjugated E.coli bioparticles by macrophages: untreated 
(Control), 24 hour 10ng/ml LPS only (LPS control), and 24 hour LPS following IFNγ priming 
(LPS 10ng/ml and LPS 100ng/ml). n=3.   E. MTT assay showing relationship between 
number of cultured macophages and optical density measured. F. Macrophage motility  
measured by transwell assay.  Results presented as percentage of remaining non migrated 
CaMKKβ KO macrophages. Assay performed in triplicate.  n=3.  All results shown in this 
figure are means ± SEM.  ANOVA: ***P<0.001; **P<0.1; *P<0.5. 
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4.1.5 Loss of CaMKKβ activity does not affect endothelial permeability 
 
The endothelium is an important barrier for macrophage tissue access as well as for the 
distribution of invading pathogens.  The production of NO through iNOS by endothelial cells 
drives the inflammatory process during the progression of sepsis. Bradykinin, thrombin and 
VEGF have all been shown to induce CaMKKβ dependent AMPK activation in endothelial 
cells (Stahmann et al. 2006; Mount et al. 2008; Stahmann et al. 2010); and activation of 
AMPK in human aortic endothelial cells has been shown to increase NO synthesis (Morrow et 
al. 2003).  Therefore, the affects of CaMKKβ inhibition on AMPK activation and endothelial 
permeability was investigated. 
 
4.1.5.1 CaMKKβ inhibition does not affect endothelial permeability under basal conditions 
 
Human umbilical vein endothelial cells (HUVEC) were cultured and treated with both 
activators and inhibitors of CaMKKβ to investigate the effects on AMPK activity as well as 
HUVEC monolayer permeability, AMPK activity was increased by 3 fold following ionomycin 
treatment (Figure 4.6A). This increase in AMPK activity was found to be CaMKKβ dependent.  
Treatment of the cells with ionomycin in the presence of STO609 prevented activation of 
AMPK (Figure 4.6A).  The establishment of human umbilical vein endothelial cell monolayers 
on matrigel coated Transwell membranes was established through the significant reduction in 
fluorescein isothiocyanate (FITC) bound dextran permeability across the membranes.  The 
FITC bound dextran permeability was not significantly different between untreated HUVEC 
monolayer and STO609 treated HUVEC monolayer (Figure 4.6B), suggesting that CaMKKβ 
inhibition by STO609 does not affect HUVEC monolayer permeability by FITC bound dextran. 
 
4.1.5.2 Loss of CaMKKβ does not affect haematocrit increase during LPS sepsis 
 
In addition to the production of inflammatory mediators, the endothelium also functions to 
increase macrophage tissue infiltration during sepsis through increased permeability.  The 
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increased permeability contributes to the development of hypotension seen during sepsis as 
proteins move out of the intravascular compartment followed by water leading to a reduction 
in the intravascular volume; resulting in haemoconcentration and an increase in haematocrit 
(van Lambalgen et al. 1988).  When haematocrit was measured in control and LPS treated 
WT and CaMKKβ KO mice, no difference was seen in basal haematocrit or 6 hour post LPS 
haematocrit in both WT and CaMKKβ KO mice (Figure 4.6C); suggesting the loss of 
CaMKKβ does not affect the change in endothelial permeability following LPS treatment. 
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Figure 4.6 Human umbilical vein endothelial cell monolayer permeability and in vivo 
LPS induced haematocrit change. 
A. AMPK activity in treated cultured HUVEC measured by immunoprecipitation of AMPKβ 
followed by incubation with SAMS peptide in a radioisotope incorporation assay. All assays 
carried out in duplicate.  All results presented as pmoles [γ-32P] incorporation into the peptide 
per minute per milligram cell lysate.  Control: untreated, STO609: 10ng/ml STO-609 for 40h,  
Iono: 1µM Ionomycin for 10min, STO609+Iono, 10ng/ml STO-609 for 40h with 10min 1µM 
Ionomycin. n=2.  B. FITC-dextran Fluorescence of Transwell flow through in untreated 
(Control) and 40 hour 10ng/ml STO-609 treated (STO609) cultured HUVEC monolayers. 
Fluorescence of flow through shown for matrigel only Transwell without HUVEC monolayer 
(FITC-dextran) for comparison as positive control.  n=3.   C.  Haematocrit measurements in 
untreated (Control) and 6 hour LPS treated (6h LPS) WT and CaMKKβ KO mice. n=3-7.  All 
results shown in this figure are means ± SEM. ANOVA: ***P<0.001. 
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4.1.6 Loss of either AMPKα1 or AMPKα2 does not confer protection against LPS 
induced sepsis 
 
The previous chapter presented data showing the loss of CaMKKβ but not CaMKKα appears 
to improve LPS sepsis severity; however the loss of CaMKKβ does not appear to reduce 
either the systemic inflammation or macrophage activation caused by the presence of LPS.  
To further investigate if the protection against LPS sepsis seen in CaMKKβ KO mice is 
mediated through AMPK, LPS induced temperature change was recorded from both global 
AMPKα1 KO and AMPKα2 KO mice.  At 10 hours following LPS treatment, no significant 
difference was seen in the LPS induced temperature drop in either AMPKα1 or AMPKα2 KO 
mice compared to WT (Figure 4.7B and 4.8B). An added complication of looking at the 
AMPKα1 mice however is that they are known to have anaemia and splenomegaly (Foretz et 
al. 2010) which may complicate any phenotype, and therefore may not be comparable to the 
CaMKKβ KO mice.  Anaemia is known to be associated with reduced tissue oxygen delivery 
and has been shown to independently contribute to sepsis mortality (Reade et al. 2010). 
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Figure 4.7 LPS sepsis study in global AMPKα1 KO mice.  
A. Body temperatures prior to (T0) and 10 hour following LPS induction (T10) in WT and 
global AMPKα1 KO mice.  B. 10 hour LPS induced temperature drop. C. Body weight 
measurements.  All results shown in this figure are means ± SEM.  n=6. 
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Figure 4.8 LPS sepsis study in global AMPKα2 KO mice.  
A. Body temperatures prior to (T0) and 10 hour following LPS induction (T10) in WT and 
global AMPKα2 KO mice.  B. 10 hour LPS induced temperature drop. C. Body weight 
measurements.   All results shown in this figure are means ± SEM. WT n=3, AMPKα2 KO 
n=5. 
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4.2 Discussion 
 
4.2.1 Summary of principal chapter findings 
 
Protection from LPS sepsis in the CaMKKβ KO mice was shown in the previous chapter.  
Possible mechanisms including NO and cytokine production, white blood cell proliferation, 
macrophage activation and vascular permeability were investigated.  The loss of CaMKKβ 
does not appear to confer an anti-inflammatory phenotype.  Results from investigations into 
the inflammatory pathways are summarized here: 
 
1). AMPK activity is reduced in CaMKKβ KO primary macrophages compared to WT primary 
macrophages under basal conditions and and reduced further by LPS treatment to a similar 
amount compared to WT mice, implying that the reduction in AMPK activity following LPS 
treatment is not dependent on CaMKKβ activity. 
 
2). Concentration of the cytokine IL6 was found to be higher in the serum of CaMKKβ KO 
mice 12 hours following LPS sepsis induction compared to WT. No difference was seen in 
the serum concentration of IL1β, IL10, TNFα, GM-CSF or NO. 
 
3). CaMKKβ is required for VEGF induced macrophage migration. 
 
4). CaMKKβ is not essential for macrophage activation by LPS treatment or the resulting NO 
production and phagocytosis.   
 
5). CaMKKβ is not essential for neutrophil and macrophage proliferation during LPS induced 
sepsis. 
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6). CaMKKβ is not essential for lymphocyte development in the thymus. 
 
7). Global deletion of CaMKKβ does not appear to affect vascular permeability as measured 
in human umbilical vein endothelial cells with or without STO609 treatment, or in vivo by 
haematocrit count under control conditions or following LPS treatment. 
 
8). Pharmacological treatment with STO609 appears to confer protection from LPS sepsis in 
mice.   
 
9). Global AMPKα 1 or AMPKα2 KO mice do not appear to be protected from LPS sepsis. 
 
 
4.2.2  LPS inhibits AMPK activity independently of CaMKKβ 
 
In this chapter, data presented show CaMKKβ independent inhibition of AMPK activity by 
LPS treatment in primary macrophages.  This is evident as AMPK is inhibited following LPS 
treatment in cell with CaMKKβ from WT mice as well as in CaMKKβ depleted cells from 
CaMKKβ KO mice (Figure 4.5B).  Although basal activity of AMPK is lower in CaMKKβ KO 
cells there is an equivalent fall in AMPK activity following LPS treatment as there is in WT 
cells. Sag et al previously showed that 100ng/ml LPS treatment reduced AMPK 
phosphorylation in murine bone marrow derived macrophages by around 70% within 1 hour 
of treatment (Sag et al. 2008).  More recently, Yang et al found 100ng/ml LPS treatment of 
RAW264.7 cell line macrophages not only reduced AMPK phosphorylation and activation 
relative to total AMPK after 2 hours, but also inhibited both LKB1 and AMPKα1 gene 
expression (Yang et al. 2010).  The NFκB pathways by which LPS induces gene expression 
has been well studied (Guha and Mackman, 2001); more recently LPS has also been shown 
to inhibit insulin gene expression via TLR4 signalling (Amyot et al 2012).  The inhibition of 
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AMPKα1 gene expression is particularly relevant as α1 is the predominant AMPK subunit 
present in macrophages (Sag et al. 2008).  As AMPK activation is known to promote 
macrophage proliferation and phagocytosis (Bae et al. 2011). The inhibition of AMPK 
expression and activation by LPS appears to be another bacterial mechanism for combating 
the host immune system.  The LPS induced reduction in AMPK activity appears to be 
CaMKKβ independent, but could possible be explained if the change in AMPK activity was 
mediated by reduced gene expression of AMPKα1 and the constitutively active LKB1. 
 
4.2.3 CaMKKβ regulates LPS induced NFκB activation but does not affect PI3K 
signalling 
 
CaMKKβ has pro-inflammatory functions as shown by the increased serum IL6 concentration 
in CaMKKβ KO mice following LPS treatment.  Transcription of inflammatory cytokines 
including IL6 is induced by NFκB following its activation and translocation into the nucleus 
(Cinel et al. 2009).  The binding of LPS to TLR4 on the cell membranes leads to recruitment 
of MyD88 which activates IκB kinase (IKK); resulting in the degradation of the NFκB inhibitory 
protein and release of NFκB into the nucleus (Karin and Delhase. 2000).   The reduced 
AMPK activity in CaMKKβ KO primary macrophages suggest that the regulation of AMPK 
may be mediated at least partly through CaMKKβ.  AMPK has been reported to negatively 
regulate the LPS induced NFκB pathway activation with increased IL6 and also TNFα 
expression seen in macrophages transfected with dominant negative AMPK and reduced 
cytokine expression in a constitutively active AMPK transfected macrophage cell line (Sag et 
al. 2008; Yang et al. 2010).  The mechanism for the regulation is unclear, though AMPK 
activation of Sirtuin 1 (SIRT1) has been suggested leading to deacetylation and inhibition of 
NFκB (Yang et al. 2010).   
 
Interestingly, the loss of CaMKKβ does not appear to affect LPS induced production of the 
anti-inflammatory cytokine IL10, suggesting the production of IL10 is regulated by a  CaMKKβ 
independent pathway. Independent from IL6 production, LPS induced IL10 production in 
macrophages is known involve p38 activation downstream of PI3K/AKT (Ma et al. 2001).  In 
addition, LPS induced TNFα expression is also known to be mainly regulated by the 
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activation of PI3K/AKT followed by activation of the MAPK/ERK pathway in macrophages 
(Van der Bruggen et al. 1999).  The unaltered serum IL10 and TNFα expression seen in 
CaMKKβ KO mice suggests CaMKKβ is not required for LPS induced activation of the 
PI3K/AKT and downstream cytokine production.  AMPK has been shown to regulate LPS 
induced IL10 expression in a macrophage cell line (Sag et al. 2008), suggesting that LKB1 is 
the likely upstream regulating kinase involved.  Downstream of CaMKKβ, CaMK I has been 
reported to be involved in LPS induced IL10 production, with increased IL10 release in a 
macrophage cell line transfected with constitutively active CaMK Iα and reduced IL10 release 
in RNAi treated macrophages (Zhang et al. 2011). Indicating CaMKKα activity is sufficient for 
the regulation of the CaMK cascade in cytokine production by macrophages. 
 
4.2.4 CaMKKβ regulates VEGF induced macrophage migration 
 
VEGF activation of tyrosine kinase receptors induced migration was found to be reduced in 
primary macrophages from CaMKKβ KO mice compared to WT, suggesting CaMKKβ is 
involved in the regulation of macrophage chemotaxis.  Chemotaxis in response to bacterial 
components, cytokines or chemokines is an important function for leukocytes including 
neutrophils and macrophages.  The cell motility involved in chemotaxis is a complex process 
involving the transmission of the chemotaxis signal to the cytoskeletal proteins.  The 
chemotaxis attractants bind receptors on the plasma membrane and activate a complex 
signalling network resulting in the activation of the cell motility proteins: Cdc42, Rac and 
RhoA GTPases.  In brief, chemotaxis attractants bind to specific serpentine receptors as well 
as tyrosine kinase receptors, colony stimulating factor 1 receptors (CSF1R) on macrophages 
and activates PI3K signalling, resulting in the production of phosphatidylinositol triphosphate 
(PIP3) and the activation of guanine nucleotide exchange factors (GEFs) which in turn 
activates Cdc42, Rac and RhoA (Jones. 2000).   Cdc42 and Rac regulates the extension of 
filopodia and lamellipodia respectively; whereas activation of RhoA induces the formation of 
stress fibers, actin filaments associated with myosin fibres important for cell contraction 
(Ridley and Hall.1992; Nobes and Hall.1995 ). Cdc42, Rac, and RhoA have also been shown 
to activate each other sequentially in a cascade, with Cdc42 activating Rac, and Rac 
activating RhoA (Ridley et al. 1992).  For cell motility to occur, the generation of lamellipodia 
through actin polymerization is required in the direction of movement, followed by contraction 
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of the cell body to detach the rear of the cell and complete the movement (Jones. 2000; 
Ridley. 2001).  The activation of cell contraction by RhoA is essential for cell motility, shown 
by loss of motility in a macrophage cell line treated with a pharmacological inhibitor of Rho 
(Jones. 2000). The  mechanisms by which RhoA regulates cell contractility is not entirely 
clear.  RhoA has been shown to activate Rho kinase (ROCK) leading to the phosphorylation 
of non muscle myosin light chain regulatory units (NMLC), potentially through the 
phosphorylation and inhibition of MYPT1 by ROCK (Kimura et al. 1996; Totsukawa et al. 
2004). In addition to inhibition, constitutive activation of RhoA also led to the loss of 
macrophage motility, indicating RhoA medicated cell contraction and macrophage motility is 
dependent on the temporal activation of RhoA in response to ligand stimulation (Allen et al. 
1998). 
 
It is unclear where CaMKKβ may exert its regulatory effects on the complex network of 
signals involved in the control of macrophage chemotaxis.  Recent work by Wang et al show 
that AMPK activates MLCP through reduced phosphorylation of MYPT1 in human smooth 
muscle cells as well as vascular smooth muscle cells isolated from AMPKα1 and α2 KO mice 
(Wang et al. 2011).  They further show the activation of AMPK promotes the binding of RhoA 
to p190 GTP activation protein (GAP) leading to the inhibition of RhoA activity, reduced 
ROCK activity, reduced MYPT1 Thr696 phosphorylation, and also decreased activity of 
smooth muscle myosin light chain regulatory units (Wang et al. 2011).  Through the 
regulation of MYPT1, MLCP is able to dephosphorylate MLC (Somlyo and Somlyo. 2003); 
thus raising the possibility of a negative regulatory mechanism between CaMKKβ activity and 
MLC contraction through AMPK, RhoA and MYPT1.  
 
To test this hypothesis, extensive western blotting was carried out to assess the 
phosphorylation of MYPT1. Unfortunately, none of the total and various phospho antibodies 
for MYPT1 tested were sufficiently sensitive to detect MYPT from primary macrophage 
lysates, aorta lysates or human embryonic kidney cell lysates.  The optimisation of an assay 
for the quantification of ROCK activity from aorta lysates is currently ongoing. 
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4.2.5 CaMKKβ is not involved in macrophage phagocytosis 
 
Phagocytosis of pathogens is an important function for macrophages. The activation of TLR4 
by LPS has been shown to stimulate macrophage phagocytosis (Anand et al. 2007); however 
the signalling mechanisms are currently not clear.  Macrophage phagocytosis is known to be 
initiated through the recognition of pathogen antigens by membrane Fc receptors and 
signalled through PI3K (Beemiller et al. 2010), with the rearrangement of the cytoskeleton 
mediated by the Rho GTPases: Cdc42 and Rac, as well as their downstream effectors 
including p21 activate protein (PAK1) (Swanson and Hoppe. 2004; Beemiller et al. 2010).  
Cdc42 and RAC are required for actin filament rearrangement: with Cdc42 recruited to the 
leading edge of the phagocytic cup where it is activated to stimulate actin polymerization; and 
RAC regulating phagosome closure to induce particle uptake (Beemiller et al. 2010).   
 
Data presented in this thesis show CaMKKβ does not appear to be involved in either the 
regulation of macrophage phagocytosis or the stimulation of phagocytosis by LPS.  This is in 
contrast to results from a recent study by Racioppi et al. showing reduced phagocytosis in 
untreated and LPS treated primary macrophages isolated from their cohort of global CaMKKβ 
KO mice (Racioppi et al. 2012). The reason for the discrepancy is unclear.  Racioppi et al. 
also showed resistance to LPS induced sepsis by their global CaMKKβ KO mice; however 
they contribute it to a novel mechanism of increased phospho proline-rich tyrosine kinase 2 
(PYK2) degradation, reduced NFβB activation, and resulting reduced serum cytokine 
concentrations of IFNγ, TNFα, IL6 and IL10 following LPS treatment (Racioppi et al. 2012).  
PYK2 is a member of the focal adhesion kinase (FAK) family, and pharmacological inhibition 
of PYK2 was previously shown to inhibit TNFα expression through the MAPK/ERK signalling 
in adherent monocytes but had no affect on nonadherent monocytes (Rosengart et al. 2002).  
Interestingly, a separate study showed reduced LPS induced NFκB activation and IL1β 
production following PYK2 knockdown by microRNA transfection in an LPS treated 
macrophage cell line (Xi et al. 2010); however comparison with the study by Racioppi et al is 
not possible as no data is presented for either serum IL1β cytokine concentration or 
macrophage mRNA expression following LPS treatment (Racioppi et al. 2012).     
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In summary, the protection conferred by the depletion of CaMKKβ against LPS induced 
sepsis does not appear to be mediated through significantly altered inflammatory response to 
the LPS in the global CaMKKβ KO mice in comparison to WT mice.  As the occurrence of 
septic shock is a significant cause of mortality in sepsis (Sakr et al. 2006; Esteban et al. 
2007), the study investigates the affects of CaMKKβ depletion on blood pressure regulation in 
the following chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 123 
Chapter 5. The regulation of blood pressure by CaMKKβ 
 
Clinically, one of the major causes of mortality following bacterial infection is the development 
of septic shock, which describes severe sepsis induced hypotension which is resistant to fluid 
treatment.  The activation of eNOS by AMPK resulting in the release of nitric oxide has been 
shown in human aortic endothelial cells (Morrow et al. 2003), suggesting the possible 
involvement of AMPK in vasodilation and blood pressure regulation. AMPK has also 
beenshown to phosphorylate MLCK in vitro leading to reduced Ca2+/calmodulin binding which 
is required for its activation (Horman et al. 2008).  So far, there is no data on the involvement 
of CaMKKβ on the regulation of blood pressure. This chapter investigates the effect of global 
CaMKKβ deletion on blood pressure and its contribution to sepsis induced hypotension.   
 
5.1. Investigating the regulation of blood pressure by CaMKKβ 
 
5.1.1 CaMKKβ KO mice have higher baseline systolic and diastolic blood pressure 
compared to WT mice 
 
Initially, cardiovascular parameters were assessed using telemetry transmitters surgically 
inserted into the descending thoracic aorta of both WT and CaMKKβ KO mice. Once the mice 
have recovered from surgery, heart rate, blood pressure and activity levels were recorded 
using telemetry receivers.  The 24 hour baseline telemetry recordings show significantly 
higher systolic and diastolic blood pressure in CaMKKβ KO mice compared to WT mice, 
particularly during night time when the mice are more active (Figure 5.1A and 5.1B).  No 
difference in heart rate was found between WT and CaMKKβ KO mice (Figure 5.1C). 
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A.           B. 
 
 
 
 
 
       C.        
 
 
 
 
 
 
Figure 5.1   Baseline telemetry results.   
Surgically inserted telemetry transponders were used to measure various parameters over a 
24h period in WT and CaMKKβ KO mice.   A. shows systolic blood pressure in millimetres of 
mercury (mmHg).  B. shows diastolic blood pressure in millimetres of mercury (mmHg).  C. 
shows heart rate in beats per minute.  
Results are shown as mean±SEM.  WT n=9, CaMKKβ n=12.  Statistical analysis carried out 
by Imperial statistics department. The methodology used in the analysis was Mixed Model 
applied longitudinal data.  *P<0.05.  
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5.1.2 CaMKKβ KO mice are resistant to LPS induced hypotension 
 
To investigate whether blood pressure control is involved in the protection against LPS sepsis 
seen in CaMKKβ KO mice, heart rate, blood pressure and activity levels were recorded 
before and during the progression of sepsis.  During the 7 hours following LPS injection, the 
systolic and diastolic blood pressure drops in both WT and CaMKKβ KO mice, this drop in 
blood pressure can be explained as vasodilation occurs following the release of NO from 
leukocytes and endothelial cells (Figure 5.2A and 5.2B).  The drop in systolic blood pressure 
is initially similar between WT and CaMKKβ KO mice, until a certain time point following LPS 
injection (350 minutes, p<0.05), then the drop in systolic blood pressure slows down in 
CaMKKβ KO mice compared to WT mice (Figure 5.2A).  The change in diastolic blood 
pressure follows a similar pattern to systolic blood pressure, where a slower drop in diastolic 
blood pressure occurs in CaMKKβ KO mice compared to WT mice after a certain time point 
(330 minutes, p<0.05) (Figure 5.2B).  Heart rate was also found to slow down during the 7 
hours following LPS injection in both WT and CaMKKβ KO mice; and higher heart rate was 
seen in CaMKKβ KO mice compared to WT mice after LPS injection (after 210 minutes, 
p<0.05) (Figure 5.2C). 
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    C.       
 
 
 
 
 
 
Figure 5.2 LPS telemetry results.  
Surgically inserted telemetry transponders were used to measure various parameters over 7 
hours following intraperitoneal LPS injection in WT and CaMKKβ KO mice. A. shows systolic 
blood pressure in millimetres of mercury (mmHg).  B. shows diastolic blood pressure in 
millimetres of mercury (mmHg).  C. shows heart rate in beats per minute.  
Results are shown as mean±SEM. n=5. Statistical analysis carried out by Imperial statistics 
department. The methodology used in the analysis was Mixed Model applied longitudinal 
data.  *P<0.05.  
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5.1.3 Investigating CaMKKβ and downstream affects in vasculature 
 
CaMKKβ expression and kinase activity were assessed in aorta lysates. As shown in figure 
5.3, there is measureable CaMKKβ activity and detectable CaMKKβ protein in aorta lysates 
from WT mice which is almost undetectable in CaMKKβ KO mice.  This raises the possibility 
that CaMKKβ expressed in blood vessels could underlie the mechanism of increased blood 
pressure seen in CaMKKβ KO mice.  
 
 
  A.        B.  
 
 
 
 
 
 
Figure 5.3  CaMKKβ expression and activity in the aorta.  
A. CaMKKβ activity in WT and CaMKKβ KO aorta lysates as measured by 
immunoprecipitation of CaMKKβ from aorta lysates; followed by activation of recombinant 
AMPK α1β1γ1 in buffer containing calcium and calmodulin (WT and CaMKKβ KO), calcium 
only (Ca only), Calmodulin only (CaM only), or without calcium or calmodulin (No Ca/CaM); 
and measurement of recombinant AMPKα1β1γ1 activity. Assays carried out in duplicate. 
Results presented as nmoles [γ-32P] incorporation into the peptide per minute per milligram 
tissue lysate.  Results are shown as mean±SEM. n=2.  B.  A western blot of aorta lysates 
from WT and CaMKKβ KO mice probed with antibodies against CaMKKβ and β actin. 
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5.1.4 Loss of CaMKKβ increases myosin light chain phosphorylation in aorta lysates 
 
To investigate the possible mechanism of blood pressure control by CaMKKβ in the 
vasculature, blood vessel contraction was assessed by comparing the phosphorylation of 
MLC in WT and CaMKKβ KO aorta lysates. Aorta myosin light chain Ser19 phosphorylation 
leads to shortening of the smooth muscle cells, contraction of the blood vessel and results in 
increased blood pressure.  In aorta lysates from untreated mice, the phosphorylation of MLC 
was found to be significantly increased in CaMKKβ KO aorta lysates compared to WT (Figure 
5.4).  MLC phosphorylation is similarly decreased following LPS treatment in both WT and 
CaMKKβ KO aorta lysates (Figure 5.4); this may be explained by an increase in MLC 
dephosphorylation as a result of LPS induced NO release.  In keeping with the increased 
MLC phosphorylation seen in untreated CaMKKβ KO aorta lysates, MLC phosphorylation 
was also higher in the CaMKKβ KO aorta lysates following LPS treatment compared to WT 
aorta lysates (Figure 5.4), suggesting that the increased MLC phosphorylation results from 
loss of CaMKKβ and this is sustained through LPS sepsis.  
 
 A.         B. 
 
 
 
 
 
Figure 5.4 MLC phosphorylation in aorta lysates.  
MLC phosphorylation in aorta lysates from untreated (Control) and 6 hour LPS treated (6h 
LPS) WT and CaMKKβ KO mice.  A.  Representative western blot of aorta lysates from 
untreated (Control) and 6h LPS treated (LPS) WT and CaMKKβ KO mice. Blots were probed 
with antibodies against pSer19 MLC (pMLC), total MLC (tMLC) and β actin. B. Quantification 
of Ser19 MLC phosphorylation as a ratio of pS19 MLC and total MLC expression 
(pMLC/tMLC) from western blots. Results are shown as mean±SEM. Control n=6, 6h LPS 
n=9.  ANOVA: ***P<0.001, *P<0.05. 
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5.1.5 Loss of CaMKKβ increases myosin light chain kinase activity in aorta lysates 
 
The phosphorylation of MLC is determined by the balance between phosphorylation by 
MLCK and dephosphorylation by MLCP. To investigate whether MLCK is a downstream 
target of CaMKKβ in the control of MLC phosphorylation, MLCK activity was measured in 
aorta lysates from WT and CaMKKβ KO mice.   LPS treatment significantly increased MLCK 
activity in both WT and CaMKKβ KO aorta lysates (Figure 5.5A).   Following 6 hours LPS 
treatment, higher MLCK activity was present in the CaMKKβ KO aorta lysates compared to 
WT; whereas no significant difference was seen between MLCK activity between WT and 
CaMKKβ KO mice in aorta lysates from untreated mice.  Total MLCK protein expression is 
similar between WT and CaMKKβ KO aorta lysates when compared to β actin expression 
(Figure 5.5B). 
MLCP activity as measured by MYPT1 phosphorylation could not be assessed due to 
technical difficulties (See section 4.2.4).  
 
 A.       B.  
 
 
 
 
 
Figure 5.5 Aorta MLCK activity.    
A. MLCK activity in aorta lysates from untreated (Control) and 6 hour LPS treated (6h LPS) 
WT and CaMKKβ KO mice. MLCK was immunoprecipitated from aorta lysates and incubated 
with recombinant MLC peptide to assess MLCK activity.  Assays carried out in duplicate. 
Results presented as pmoles [γ-32P] incorporation into the peptide per minute per milligram 
tissue lysate.  Results are shown as mean±SEM. Control n=3, 6h LPS n=8.  ANOVA: 
***P<0.001, *P<0.05.   B. A western blot of aorta lysates from LPS treated WT and CaMKKβ 
KO mice probed with antibodies against total MLCK and β actin. 
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5.1.6 Loss of CaMKKβ has no effect on nitric oxide activity in aorta lysates 
 
The expression of iNOS is induced by LPS binding to TLR4, leading to the production of NO 
by macrophages and endothelial cells during sepsis.  NO diffuses into vascular smooth 
muscle cells and induces the production of cGMP, leading to the activation of MYPT1 by 
PKG, resulting in dephosphorylation of MLC and vasodilation.  In keeping with the similar 
reduction in MLC phosphorylation seen in WT and CaMKKβ KO aorta lysates during LPS 
sepsis (Figure 5.4), no change was seen in the serum NO and cGMP concentrations of 
CaMKKβ KO mice following LPS treatment compared to WT (Figure 4.2). Both cGMP 
concentration and PKG expression in aorta lysates were also assessed and found to be 
comparable between WT and CaMKKβ KO mice (Figure 5.6). 
 
 
 
 A.         B.  
 
 
  
 
 
 
Figure 5.6 cGMP concentration and PKG expression in the aorta.   
A.  Aorta cGMP concentration as measured using an immunoassay kit in 6h LPS treated WT 
and CaMKKβ KO aorta lysates.  Assays carried out in duplicate. Results are shown as 
mean±SEM. n=3.  B.  Western blot of untreated (Control) and 6h LPS treated (LPS) WT and 
CaMKKβ KO aorta lysates probed with antibodies against PKG and β actin. 
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5.1.7 AMPK activity in aorta lysates 
 
As AMPK has previously been shown to be involved in the regulation of blood pressure 
(Wang et al. 2011) and is known to be phosphorylated by CaMKKβ, AMPK activity was 
measured in WT and CaMKKβ KO aorta lysates from both untreated and 6 hour LPS treated 
mice to assess its involvement in the blood pressure phenotype seen in CaMKKβ KO mice. 
AMPKα1 subunit activity was found to be significantly reduced following 6 hour LPS 
treatment compared to untreated in both WT and CaMKKβ KO mice aorta lysates; AMPKα2 
subunit activity and total AMPK activity as measured in immunoprecipitates of AMPKβ 
complexes were reduced in 6 hour LPS treated aorta lysates but did not reach statistical 
significance (Figure 5.7).  These results are in keeping with that seen in LPS treated cultured 
macrophages where LPS treatment significantly reduced AMPKα1 subunit activity (Figure 
4.5B).  No significant difference was seen in AMPK activity between WT and CaMKKβ KO 
aorta from either untreated or 6 hour LPS treated mice (Figure 5.7).  
 
   A.                        B.          C. 
 
 
 
 
 
Figure 5.7 AMPK activity in the aorta.   
The activity of AMPKα1 and AMPKα2 subunit complexes as well as total AMPK activity were 
measured in aorta from untreated (Control) and 6h LPS treated (6h LPS) WT and CaMKKβ 
KO mice by immunoprecipitation of the respective complex from aorta lysates and incubation 
with SAMS peptide in a radioisotope incorporation assay. A. shows AMPKα1 activity.  B. 
shows AMPKα2 activity.  C. shows total AMPK activity.  
All assays carried out in duplicate. Results presented as pmoles [γ-32P] incorporation into the 
peptide per minute per milligram tissue lysate.  Results are shown as mean±SEM. Control 
n=3, 6h LPS n=4.   ANOVA: **P<0.01. 
 132 
5.1.8 CaMKKβ KO mice have normal aorta histology  
 
The aorta wall is composed of three concentric layers including tunica intima, tunica media 
and tunica adventitia. Tunica intima is composed of an innermost endothelial layer in contact 
with blood flow, as well as a layer of connective tissue between the endothelial layer and 
tunica media. The tunica media in the aorta is the thickest of the three layers; it is composed 
of organised smooth muscle cells and appears to be the major contributor to aorta 
contractility. The structure of the tunica media layer has been shown to be importance for 
transmitting the force generated by the movement of phosphorylated myosin fibres across 
actin filaments to aorta wall contraction (Standley et al. 2002). The smooth muscle actin 
filaments are known to form a helical pattern spiralling around the aorta to optimise force 
generation during vessel contraction (Standley et al. 2002); with alterations to actin structure 
leading to loss of contraction and vessel wall weakness, resulting in aneurysms (Bergeron et 
al. 2011).  Smooth muscle cells express elastin and collagen into the extracellular matrix 
which form circular bands around the aorta, providing stretch and stiffness respectively to 
maintain the basal vessel tone (Wagenseil and Mecham. 2012).   The outer layer, tunica 
adventitia, is mainly composed of myofibroblasts which also produce collagen. 
 
To investigate the possibility that the loss of CaMKKβ may increase blood pressure through 
altered aorta structure, perfused aortas were isolated and fixed in formaldehyde prior to 
paraffin embedding, sectioning and staining.  Representative images at 2.5x and 10x 
magnification of aorta sections stained with haematoxylin and eosin (H&E), elastin van graffin 
(EVG), smooth muscle actin (SMA), and picosirius red are presented in figure 5.8.  No 
difference was seen in any of the following measurements: aorta wall thickness, tunica media 
thickness, tunica adventicia thickness, or the number of elastin bands in CaMKKβ KO mice 
compared to WT mice (Figure 5.9A and 5.9B).  Aortas from CaMKKβ KO mice also had 
normal medial thickness as calculated by the ratio of tunica media thickness to the number of 
elastin bands (Figure 5.9A). 
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Figure 5.8 Aorta histology.   
Representative images of formaldehyde fixed, sectioned and stained aorta from WT and 
CaMKKβ KO mice at 2.5x and 10x magnification. 
A. Haematoxylin and eosin stain (H&E). B. Elasin staining with elastin van graffin (EVG). C. 
Staining with smooth muscle actin antibody (SMA). D. Collagen staining with picosirius red. 
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A.        B. 
 
 
 
 
 
Figure 5.9  Aorta histology measurements.   
A.  WT and CaMKKβ KO aorta images were taken at 10x magnification and the following 
measurements quantified using ImageJ software.  AW: Aorta wall thickness, TM: tunica 
media, TA: tunica adventitia, MI: medial interval. B.  Number of elastin bands present in the 
WT and CaMKKβ KO aorta wall on histology.  All measurements made in quadruplicate from 
2 aorta sections from each mouse. Results are shown as mean±SEM. n=4 mice. 
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5.1.9 CaMKKβ KO mice have normal kidney function 
 
As AMPK is known to phosphorylate the renal tubule sodium potassium channel NKCC2 and 
alter kidney salt reabsorption (Fraser et al. 2005 and 2007), urinary electrolyte concentrations 
were measured in CaMKKβ KO mice to investigate the contribution of kidney function to the 
high blood pressure seen.  No difference was found in either sodium, potassium or chloride 
concentrations between urine samples from WT and CaMKKβ KO mice (Figure 5.10A). In 
addition, phosphorylation of AMPK at Thr172 and the phosphorylation of NKCC2 at Ser126 
were found to be similar between WT and CaMKKβ KO kidney lysates as shown by western 
blotting (Figure 5.10B).   
 
Produced in the adrenal glands in response to stress and activation of the sympathetic 
nervous system, the hormone adrenaline is a potent vasoconstrictor that is excreted by the 
kidneys.  To investigate the potential involvement of the sympathetic nervous system, urinary 
adrenaline concentration normalised to creatinine was measured and found to be similar 
between WT and CaMKKβ KO mice (Figure 5.10C); suggesting the increased blood pressure 
seen in the CaMKKβ KO mice does not result from increased adrenaline  production.  
However the increased activation of the sympathetic nervous system cannot not be excluded, 
as the noradrenaline concentration could not be measured due to assay unavailability.  
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Figure 5.10 Comparing kidney function in WT and CaMKKβ KO mice.   
A. Urinary sodium, potassium and chloride concentration in WT and CaMKKβ KO mice on 
normal diet.  Results are shown as mean±SEM. WT n=5, CaMKKβ KO  n=4.  B. Western 
blots of kidney lysates from WT and CaMKKβ KO mice on a normal diet probed with 
antibodies against pSer126 NKCC2 (pNKCC2), total NKCC2 (tNKCC2), pThr172 AMPK 
(pAMPK), total AMPK (tAMPK) expression using an antibody against AMPKβ, as well as β 
actin.  C. Urinary adrenaline concentration in WT and CaMKKβ KO mice normalised to 
urinary creatinine concentration.  Results are shown as mean±SEM. WT n=5, CaMKKβ KO  
n=4.   
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5.1.10 Aged CaMKKβ KO mice have reduced cardiac function 
 
High blood pressure is a known risk factor for the development of heart failure due to 
increased development of both left ventricular hypertrophy and coronary heart disease 
(Haslett et al. 2002; Houser et al. 2012).  To assess the physiological significance of the high 
blood pressure seen in CaMKKβ KO mice under basal conditions, echocardiogram was 
carried out at regular intervals over a six month period until the mice were 12 month old to 
determine the affect of CaMKKβ loss on long term cardiac function. By 10 month, CaMKKβ 
KO mice were found to have significantly reduced ejection fraction as well as left ventricular 
shortening compared to WT (Figure 5.11C and 5.11D respectively); indicating reduced left 
ventricle function and reduced overall cardiac output.  Cardiac hypertrophy was not seen in 
up to 12 month old CaMKKβ KO mice, as shown by similar left ventricle mass and left 
ventricular wall thickness between WT and CaMKKβ KO mice (Figure 5.11A and Figure 
5.11B). 
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Figure 5.11 Comparing cardiac function in 6 to 12 month old WT and CaMKKβ KO 
mice.  
WT and CaMKKβ KO mice were assessed by cardiac ultrasound under isoflurane 
anaesthesia monthly until 12 month old.   A. Left ventricular mass of WT and CaMKKβ KO 
mice were measured on cardiac ultrasound and normalised to body weight to determine left 
ventricular mass index (LVMI).  B. Left ventricle wall thickness was measured on cardiac 
ultrasound and normalised to left ventricle diameter during diastole to determine the relative 
wall thickness (RWI). C. Percentage ejection fraction was measured on cardiac ultrasound in 
WT and CaMKKβ KO mice. D. Percentage shortening fraction was measured on cardiac 
ultrasound in WT and CaMKKβ KO mice. All results in this figure are shown as mean±SEM.  
WT n=5, CaMKKβ n=8.  Student’s t-test: **P<0.01, *P<0.05. 
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5.2 Discussion 
 
5.2.1 Summary of principal chapter findings 
 
In the previous two chapters, the loss of CaMKKβ activity was shown to protect against LPS 
induced sepsis without inhibiting macrophage activation or reducing inflammatory cytokine 
production. In this chapter, we have tried to investigate the possible mechanism of the 
protection against LPS seen in CaMKKβ KO mice via a vascular phenotype. CaMKKβ KO 
mice were found to have higher blood pressure compared to WT mice and increased blood 
vessel MLC phosphorylation resulting in increased vessel contraction. The main results are 
summarized below: 
 
1). CaMKKβ KO mice were found to have higher blood pressure compared to WT mice under 
basal condition.  At 12 month, CaMKKβ KO mice were found to have reduced ejection 
fraction and ventricular shortening compared to WT mice, indicating worse cardiac function. 
 
2). Loss of CaMKKβ confers resistance against LPS induced hypotension. 
 
3). Absence of CaMKKβ results in increased phosphorylation of MLCK and MLC in aorta 
lysates from CaMKKβ KO mice both under basal conditions and following LPS treatment 
compared to WT mice.  
 
4). No difference was seen in serum NO concentration or cGMP concentration in aorta 
lysates indicating that CaMKKβ is not involved in NO production or aorta cGMP expression. 
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5). AMPK activity was found to be reduced in aorta lysates from LPS treated mice; however 
similar reduction in AMPK activity was seen in aorta lysates from both WT and CaMKKβ KO 
mice. 
 
6). No obvious difference was seen on CaMKKβ KO aorta histology compared to WT aorta.  
 
7). Loss of CaMKKβ does not affect kidney function or NKCC2 phosphorylation in kidney 
lysates.  No difference was seen in urinary creatinine or electrolyte concentration between 
WT and CaMKKβ KO mice. 
 
5.2.2 LPS reduces aorta MLC phosphorylation 
 
The phosphorylation of MLC on Ser19 regulates the formation of myosin cross bridges on 
actin filaments and controls smooth muscle cell contration (Adelstein andConti 1975; 
Rembold et al. 1992; Somlyo and Somlyo. 1994).  Although TLR4 receptors are known to be 
expressed on vascular smooth muscle cells (Pryshchep et al. 2008); little is known regarding 
the affect of LPS on the contractile function of smooth muscle.  One recent study showed a 
dose dependent contractile dysfunction in human colonic smooth muscle cells following TLR4 
activation by LPS which was partially prevented by treatment with pharmacological inhibition 
of NFκB (Scirocco et al. 2010).   Data presented in this chapter show reduced aorta MLC 
phosphorylation despite activation of MLCK activity following LPS treatment.  In keeping with 
the reduction in aorta MLC phosphorylation; telemetry recordings show decreases in both 
systolic and diastolic blood pressure following LPS treatment. The difference between MLCK 
activity and MLC phosphorylation can be explained by increased dephosphorylation of MLC 
due to increased serum concentration of NO in LPS treated mice. Leukocytes and the 
endothelium are known to produce NO following LPS induced expression of iNOS (Ding et al. 
1990; Vo et al. 2005).   Although LPS induced iNOS expression and NO production has been 
shown in vascular smooth muscle cells (Ohta et al. 2011); its physiological significance is 
unclear as isolated aortic rings with the endothelium removed are resistant to LPS induced 
vasodilation (Vo et al. 2005).   
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So far, investigation of LPS induced MLCK activity has concentrated on the regulation of tight 
junctions in both epithelium and endothelium.  Through pharmacological inhibition of MLCK, 
activation of TLR4 by LPS has been shown to cause tight junction dysfunction through 
activation of MLCK leading to increased permeability of airway epithelium, intestinal 
endothelium and vascular endothelium (Eutamene et al. 2005; Moriez et al. 2005; 
Bogatcheva et al. 2011).  In keeping with this, data in the previous chapter show increased 
murine haematocrit following LPS sepsis indicating increased vascular endothelial 
permeability.  Little is known regarding the effect of LPS on aortic smooth muscle function, 
this chapter presents evidence supporting the activation of MLCK by LPS in the aorta which 
may antagonise the dephosphorylation of MLC by induced NO which in turn contributes to 
the regulation of blood pressure during sepsis.  
 
5.2.3  CaMKKβ regulates aorta MLCK activation of MLC during LPS sepsis 
 
During LPS sepsis, CaMKKβ appears to reduce MLC phosphorylation through inhibition of 
MLCK activty in the aorta.  The protection conferred to STO609 treated WT mice against LPS 
sepsis is consistent with that the loss of CaMKKβ activity rather than its expression is 
important for the protection seen.  Interestingly, although an increase in MLCK activity is seen 
in aortas from LPS treated CaMKKβ KO mice compared to WT mice, no difference was seen 
in aorta MLCK activity from untreated WT and CaMKKβ mice. One explanation would be 
activation of CaMKKβ by LPS, therefore accentuating the difference in MLCK activity 
between WT and CaMKKβ KO aorta following LPS treatment.  An increase in vascular 
endothelial cell intracellular calcium concentration is seen following LPS induced TLR4 
activation (Bogatcheva et al. 2011); a similar mechanism could lead to activation of CaMKKβ 
in vascular smooth muscle cells. In keeping with the increased MLCK activity seen in aorta 
from LPS treated CaMKKβ KO mice compared to WT, the phosphorylation of MLC was also 
found to be increased as shown by data presented in this chapter. 
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The inhibition of MLCK by CaMKKβ provides an important internal brake on the activation of 
MLCK by increasing calcium concentrations.  Increased vessel calcium sensitivity is a known 
risk factor for coronary artery vasospasms, along with polymorphism in the eNOS gene 
(Stern and Bayes de Luna. 2009; Morikawa et al. 2010).   Calcium channel blockers and long 
acting nitrates are both used in the treatment of coronary artery vasospasms (Stern and 
Bayes de Luna. 2009); however, the cause of vessel calcium sensitivity leading to 
vasospasms remains unclear. Data presented in this chapter provides a novel regulatory 
mechanism for calcium activation of smooth muscle MLCK (Figure 5.12).  
Figure 5.12 Proposed mechanism of MLC regulation by CaMKKβ through MLCK to 
control blood pressure during LPS sepsis.  TLR4 activation in vascular smooth muscle 
cells potentially increase cytosol calcium concentration resulting in activation of MLCK and 
CaMKKβ.  The activation of MLCK by calcium is limited by CaMKKβ activation, potentially 
through activation of AMPK by CaMKKβ and phosphorylation of MLCK, resulting in controlled 
phosphorylation of MLC. The activation of MLC is antagonized by the production of NO 
during LPS sepsis by immune cells and the endothelium, leading to increased activation of 
MLCP and dephosphorylation of MLC, resulting in overall smooth muscle relaxation and 
vasodilation.  AMPK has been shown to inhibit MLC phosphorylation through inhibition of 
ROCK, dephosphorylation of MYPT1 and activation of MLCP (Wang et al. 2011).  Loss of 
CaMKKβ leads to increased MLCK activity and MLC phosphorylation during LPS sepsis, 
resulting in reduced smooth muscle relaxation and reduced hypotension. 
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5.2.4 CaMKKβ regulates vessel contraction through activation of MLC 
 
CaMKKβ KO mice were found to have increased baseline blood pressure compared with WT 
mice, suggesting CaMKKβ not only regulates blood pressure during LPS sepsis but also 
functions to maintain baseline blood vessel tone.  Data presented in this chapter show 
increased MLC phosphorylation in the aorta of untreated CaMKKβ KO mice compared to WT 
mice.  As aorta MLCK activity does not significantly differ between WT and CaMKKβ KO mice 
at baseline, the difference in MLC phosphorylation seen may be explained by altered MYPT1 
dephosphorylation of MLC.   
 
Unfortunately, MLCP activity could not be assessed due to technical difficulties (See section 
4.2.4).  However, the involvement of CaMKKβ in MLC dephosphorylation by MLCP through 
the MLCP regulatory subunit MYPT1 is supported by a recent study by Wang et al. showing 
the activation of AMPK in vascular smooth muscle cells leads to inhibition of ROCK, 
dephosphorylation of MYPT1, activation of MCLP and dephosphorylation of MLC (Wang et 
al. 2011).   
 
5.2.5 Loss of CaMKKβ does not significantly alter aorta structure  
 
Within the blood vessel wall, the layers of smooth muscle are arranged in the form of 
concentric helices spiralling around the lumen of the vessel (Standley et al. 2002). Studies 
indicate the alignment of vascular smooth muscle cells results from the cyclic nature of vessel 
stretch resulting from the arterial pressure generated by the left ventricle (Kanda and 
Matsuda. 1993; Standley et al. 2002); although the mechanisms by which this is 
accomplished remain unclear.  In vivo, vascular smooth muscle cells are arranged in  layers 
within the aorta wall to achieve maximal vessel contraction or dilation with minimal smooth 
muscle cell shortening or lengthening, respectively (Fultz et al. 2000). Between the layers of 
smooth muscle cells, bands of extracellular matrix composed of elastin and collagen provide 
stretch and stiffness respectively to maintain the basal vessel tone (Wagenseil and Mecham. 
2012). Therefore, in addition to the contractility of smooth muscle cells, the control of vessel 
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lumen size and consequently blood pressure is also dependent on the alignment of the 
vascular smooth muscle cells as well as the structure and composition of the extracellular 
matrix.    
 
To assess blood vessel structure and investigate the possibility of a mechanical cause for the 
high blood pressure seen in CaMKKβ KO mice, immunohistochemistry of formaldehyde fixed 
aorta sections from WT and CaMKKβ KO mice was carried out to stain for smooth muscle 
cell alignment, smooth muscle actin composition, and the distribution of extracellular matrix 
proteins.  No difference was seen in either muscle layer thickness or the number of elastin 
bands within the WT and CaMKKβ KO mice.  Similar staining was also seen for the 
distribution pattern of elastin, smooth muscle actin and collagen within the aorta wall; 
suggesting the loss of CaMKKβ does not significantly alter aorta structure.  Smooth muscle 
cell alignment was difficult to assess due to the helical nature of the smooth muscle layers 
around the aorta wall which causes variations within the pattern of smooth muscle cells seen 
on each aorta section. Therefore, the possibility of altered smooth muscle cell alignment 
within blood vessel walls contributing to the high blood pressure seen in CaMKKβ KO mice 
cannot be excluded. 
 
5.2.6 Loss of CaMKKβ does not affect kidney function 
 
Abnormal NaCl handling by the kidneys is known to contribute to the development of high 
blood pressure through sodium and water retention (Haslett et al. 2002; Meneton et al. 2005).   
Significantly reduced urinary excretion of sodium has been shown to be present during the 
development of hypertension in several hypertensive rat strains (Meneton et al. 2005).  The 
ascending limb of loops of Henle in the kidneys reabsorbs 25-30% of filtered NaCl from the 
tubule lumen via the kidney specific NKCC2 cotransporters, and NKCC2 activity have been 
shown to contribute to sodium retention and the development of high blood pressure 
(Gliménez 2006; Ares et al. 2011).  In humans, mutations in the gene coding for NKCC2 
result in decreased or absent activity characterized by the severe NaCl loss and decreased 
blood pressure seen in Bartter syndrome type 1; conversely, increased NKCC2 activity is 
associated with the development of hypertension (Ares et al.2011).  
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To investigate the role of kidney function and NKCC2 activity in the development of high 
blood pressure seen in CaMKKβ KO mice, urinary electrolyte were analyzed as an indirect 
measurement of baseline kidney NaCl handling and NKCC2 activity.  CaMKKβ KO mice were 
found to have similar urinary sodium, potassium and chloride excretion compared to WT mice 
indicating CaMKKβ KO mice have normal kidney function.  Total NKCC2 expression was also 
unchanged in kidneys from CaMKKβ KO mice compared to WT mice; with similar NKCC2 
Ser126 phosphorylation, the site known to be phosphorylated by AMPK (Fraser et al. 2007), 
seen in kidneys from WT and CaMKKβ KO mice. 
 
5.2.7 Loss of CaMKKβ affects long term cardiac function 
 
To assess the physiological significance of the high blood pressure seen in CaMKKβ KO 
mice under basal conditions, cardiac echo was carried out at regular intervals in up to 12 
month old mice to determine the affect of CaMKKβ loss on long term cardiac function.  
Fractional shortening describes the reduction in left ventricle diameter during systole 
compared to diastole whereas ejection fraction describes the percentage of blood volume 
pumped out of the left ventricle during systole; providing quantitative measures of left 
ventricular contractility and cardiac output respectively (Hoit et al. 1997; Rottman et al. 2007).  
By 10 month old, CaMKKβ KO mice were found to have  significantly reduced ejection 
fraction as well as left ventricular shortening compared to WT; suggesting the development of 
hypertensive heart disease and heart failure.  
 
High blood pressure is a well known risk factor for the development of heart failure (Haslett et 
al. 2002; Houser et al. 2012).  The classical paradigm of hypertensive heart disease is that 
persistently elevated blood pressure leads to a degree of compensated ventricular 
hypertrophy with ventricular wall thickening but normal ejection fraction; which eventually 
transitions to heart failure with reduced ejection fraction and fractional shortening (Levy et al. 
1990).  Data presented in this chapter show reduced cardiac function in the older CaMKKβ 
KO mice with no indication of cardiac hypertrophy as shown by normal left ventricular mass 
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and wall thickness; providing support for the alternative theory suggesting the development of 
either left ventricular hypertrophy or failure in response to high blood pressure in the absence 
of transitional cardiac injury in hypertensive heart disease (Drazner 2005). 
 
5.2.8 The benefits and limitations of mouse models  
 
During this study, several different transgenic mouse models of gene deletions were used to 
investigate the function of CaMKKβ in metabolism, LPS sepsis and the regulation of blood 
pressure.  Rodents are used to model human diseases as they have the same organ and 
systemic physiology as humans; in addition, they have the benefit of high reproductive rates, 
ease of handling, and relatively low cost of use.  The mouse (Mus musculus) in particular, is 
the most common mammal used for genetic phenotyping (Simmona. 2008). The mouse 
genome has a similar number of protein producing genes compared to the human genome 
and eighty percent of genes are present in both genomes (Emes et al. 2003). 
 
One of the main disadvantages of using mouse models is the limited technology available for 
physiological measurements due to the size of the animals. The measurement of arterial 
stiffness by pulse wave velocity was not possible in the mouse models due to technical 
limitations. For the measurement of blood pressure in mice, use of radiotelemetry in 
conscious animals was used in preference to tail cuff sphygmomanometer both for its 
sensitivity (Bubb et al. 2012), as well as allowing the measurement of conscious blood 
pressure. However, the surgical techniques involved requires a high degree of expertise and 
is both time and labour intensive which reduced the feasibility of large numbers of animals. 
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Chapter 6. Summary and future directions 
 
CaMKKβ is known to activate AMPK as well as the CaMK cascade, however, little is known 
of the physiological functions of CaMKKβ outside the nervous system.  To investigate the 
functions of CaMKKβ and its involvement in the control of metabolism by AMPK, the global 
CaMKKβ KO mice were characterized both under baseline conditions and also during LPS 
sepsis to model activation of the immune system as well as sepsis induced hypotension.  
This thesis provides evidence for the regulation of blood pressure by CaMKKβ both under 
baseline conditions and during sepsis induced hypotension.  
 
6.1 Conclusions 
 
1). Globally, CaMKKβ does not appear to be required for the metabolic functions of AMPK 
measured in this study as shown by the lack of metabolic phenotype seen in CaMKKβ KO 
mice, suggesting that LKB1 is the main upstream regulator for the metabolic pathways 
controlled by AMPK.  AMPK is a key regulator of metabolism and is known to control the 
energy production and utilisation in an organism on multiple levels including mitochondrial 
function, tissue glucose and fatty acid metabolism, as well as food intake and energy 
expenditure (Kahn et al. 2005; Carling. 2005; Schneeberger and Claret. 2012).  The 
regulation of metabolism by LKB1 activation of AMPK is in keeping with previous findings in 
skeletal muscle specific LKB1 KO mice showing impaired contraction stimulated glucose 
uptake (Sakamoto et al. 2005); and indicates LKB1 may be involved in the regulation of 
mitochondrial function as well as the hormonal control of energy balance. 
 
2). The loss of CaMKKβ in mice protects against the physical deterioration and temperature 
drop that occurs during LPS sepsis as shown in both CaMKKβ KO  mice and STO-609 
treated WT mice. This protection is likely to be mediated through the maintenance of 
systemic blood pressure.  Pretreatment of the CaMKKβ KO mice with blood pressure 
lowering pharmacological agents such as inhibitors of β-adrenergic receptors prior to LPS 
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treatment could clarify the involvement of blood pressure in the LPS sepsis seen; however 
interpretation of the results may be complicated by the effect of the pharmacological agent on 
cardiac function.   
 
3). In the immune system, the involvement of CaMKKβ in macrophage migration as well as 
LPS induced cytokine production and macrophage activation were investigated. The 
regulation of MLC by CaMKKβ in macrophages was suggested by reduced VEGF induced 
migration of primary macrophages isolated from CaMKKβ KO mice compared to WT mice.  
Loss of CaMKKβ appears to increase LPS induced IL6 but not IL10 production; indicating the 
regulation of NFκB activation by CaMKKβ. CaMKKβ is not required for LPS induced 
macrophage activation, nitric oxide production or phagocytosis. In addition, CaMKKβ is not 
required for the production of nitric oxide both under baseline condictions and following LPS 
treatment. 
 
4). CaMKKβ regulates blood pressure both under baseline conditions and during sepsis 
induced hypotension; as shown by increased systemic blood pressure in the CaMKKβ KO 
mice compared to WT matched littermates persisting through sepsis induced hypotension. 
Over time, the high blood pressure resulting from loss of CaMKKβ leads to impaired cardiac 
function as shown by reduced cardiac output and contractility in the CaMKKβ KO mice 
compared to WT matched littermates.  Blood vessel contraction, kidney function, and aorta 
histology were investigated to look for causes of the high blood pressure seen in CaMKKβ 
KO mice.  CaMKKβ does not appear to be required for either sodium reabsorption or the 
phosphorylation of NKCC2 by AMPK in the kidneys.  Aorta histology was also similar 
between the WT and CaMKKβ KO mice.  Blood vessel contraction was assessed through the 
quantification of aorta MLC phosphorylation; and was found to be significantly increased in 
the CaMKKβ KO mice compared to WT both under baseline conditions and during sepsis 
induced hypotension. 
 
Under baseline conditions, the mechanism for regulating aortic MLC phosphorylation by 
CaMKKβ is not entirely clear. CaMKKβ activity does not affect MLCK phosphorylation and 
activation without LPS treatment; although the reduction in MLC phosphorylation can 
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potentially occur through a chain of phosphorylation events following AMPK activation, 
including ROCK activity inhibition and MYPT1 activation resulting in MLC dephosphorylation, 
previously shown in vascular aortic smooth muscle cells (Wang et al. 2011).   Following LPS 
treatment, CaMKKβ activation causes the phosphorylation and inhibtion of MLCK in the aorta 
resulting in reduced MLC phosphorylation.  It is unclear if CaMKKβ phosphorylates MLCK 
directly or through the activation of AMPK.  The availability of transgenic AMPK mice for 
blood pressure measurement following LPS treatment would provide important information 
regarding the involvement of AMPK in this pathway.   
 
 
6.2 Future directions 
 
The mechanism through which CaMKβ controls MLC phosphorylation requires clarification.  
Further evidence is needed to confirm the involvement of AMPK in the regulation of MLC 
phosphorylation by CaMKKβ.  Plans are underway for blood pressure telemetry recordings in 
global AMPKβ1 KO mice both under basal conditions and during LPS sepsis.  In contrast to 
the AMPKα1 KO mice, the AMPKβ1 KO mice do not display either anaemia or splenomegaly; 
therefore provides a better haemodynamic model for the investigation of the role of AMPK in 
blood pressure regulation.   
 
The regulation of blood pressure by CaMKKβ has been shown to persist during reductions in 
blood pressure as shown by LPS sepsis induced hypotension.  An area for future 
investigation would be the effect of the development of high blood pressure on its regulation 
by CaMKKβ.  High dietary salt intake is a well described risk factor for high blood pressure in 
salt sensitive individuals (Luft and Weinberger. 1982).  A European prospective follow up 
study showed 44% of their healthy recruited participants were salt sensitive; and the salt 
sensitive individuals were 75% more likely to develop hypertension over fifteen years 
compared to salt resistant individuals (Barba et al. 2007). The CaMKKβ KO mice have been 
backcrossed onto the C57BL/6 background; as the C57BL/6 mice are known to be salt 
 150 
sensitive (Leonard et al. 2006), the CaMKKβ KO mice may provide a good model for the 
investigation of salt sensitive hypertension.  
 
Another area for future investigation is the clinical implications of blood pressure regulation by 
CaMKKβ, in particular, the pharmacological inhibition of CaMKKβ during sepsis induced 
hypotension.  Currently, treatment of sepsis induced hypotension involves fluid treatment 
followed by the use of vasopressors to raise blood pressure and improve organ perfusion. 
Common vasopressors include catecholamines, such as norepinephrine and dopamine, 
which act on the adrenergic receptors; as well as vasopressin and its analogues acting on the 
vasopressin receptors.  A recent Cochrane review found none of six commonly used 
vasopressors superior to any other when used alone or in combination in the treatment of 
septic shock, sepsis induced hypotension resistant to fluid resuscitation (Havel et al. 2011).  
More significantly, despite the multiple vasopressors currently available for the treatment of 
hypotension, septic shock carries a high mortality rate of 45-50% (Sakr et al. 2006; Esteban 
et al. 2007). Data from a large European prospective multicentered observational study found 
the incidence of septic shock to be 31 cases per 100,000 people per year with 1 in 12 cases 
of hospital admissions for sepsis developing septic shock after 2-5 days (Esteban et al. 
2007). It is clear that improved treatments for septic shock are urgently needed, particularly 
when epidermiological studies show that the incidence of septic shock appears to be rising 
(Martin et al. 2003).  Although much more investigation is clearly required to clarify the 
underlying mechanisms of blood pressure regulation by CaMKKβ, the inhibition of CaMKKβ 
provides a novel target for the treatment of septic shock. 
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Appendix 1.  Substrates of AMPK containing the α1 or α2 subunit (Kodiha and Stochaj 
2011). 
Substrates 
for 
AMPKα1 
Function 
 
Effect of 
phosphorylation 
 
Primary 
intracellular 
localization 
Acc1; 
Subunit of 
acetyl-CoA 
carboxylase, 
ACC 
Carboxylates acetyl-CoA, 
thereby generating 
malonyl-CoA; this step is 
rate-limiting for FA 
biosynthesis. 
inhibition cytoplasm 
 
Acc2; 
Subunit of 
acetyl-CoA 
carboxylase, 
ACC 
Carboxylates acetyl-CoA, 
thereby generating 
malonyl-CoA; this step is 
rate-limiting for FA 
biosynthesis. 
inhibition 
 
mitochondria 
(outer 
mitochondrial 
membrane) 
 
AMPKβ1  
 
Catalytic subunit of AMPK potential 
autoregulation 
cytoplasm, 
nucleus 
AMPKγ1 
 
Regulatory subunit of 
AMPK 
 
enzymatic 
activity, 
localization 
cytoplasm, 
nucleus 
 
 
CFTR 
chloride channel 
 
 
Cystic fibrosis 
transmembrane 
conductance regulator, 
 
inhibits PKA dependent 
stimulation of 
CFTR 
 
plasma membrane, 
ER, 
cytoplasmic 
vesicle; early 
endosome 
ChREBP 
 
Transcription factor; 
repressor 
inactivation of 
DNA binding 
nucleus, 
cytoplasm 
CK1-ε 
(CK1 
epsilon) 
 
Ser/thr kinase; member of 
the casein kinase 1 (CK1) 
family; phosphorylates 
mPer2 
increase of 
CK1-ε activity; 
control of 
circadian clock 
cytoplasm, 
nucleus, cell 
junction, 
centrosome 
CRY1 
(cryptochrome) 
 
DNA photolyase, regulates 
circadian rhythm 
 
phosphorylation 
leads to 
destabilization 
nucleus, 
mitochondria, 
cytoplasm 
CRTC-1 
 
 
 
CREB-regulated 
transcriptional coactivator 
 
phosphorylation 
causes 
cytoplasmic 
retention 
nucleus, 
cytoplasm 
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eEF2K 
(eEF2 
kinase) 
Protein kinase; eEF2K 
modifies and thereby 
inactivates eEF2 
activation of 
kinase activity 
 
cytoplasm 
 
eNOS  
 
 
 
 
 
Endothelial nitric oxide 
synthase (constitutive), EC 
1.14.13.39; 
regulation of 
cytoskeletal 
reorganization 
activation, 
promotes 
deacetylation 
by SIRT1 
 
plasma 
membrane, 
Golgi 
 
GABAB-R1 
 
 
 
 
 
GABAB receptor subunit; 
G-protein coupled receptor 
 
increase in 
receptor function, 
promotes 
functional 
coupling to K+ 
channels 
plasma 
membrane, 
ER, dendrite, 
axon, 
postsynaptic 
membrane 
GABAB-R2 
 
 
 
 
 
GABAB receptor subunit; 
G-protein coupled receptor 
 
increase in 
receptor function, 
promotes 
functional 
coupling to K+ 
channels 
plasma 
membrane, 
ER, dendrite, 
axon, 
postsynaptic 
membrane 
GBF1; 
Golgispecific 
brefeldin A 
resistance 
factor 
Guanine nucleotide 
exchanger for ARF5; 
mediates ARF5 activation; 
Golgi to ER trafficking 
 
triggers 
disassembly of 
Golgi 
apparatus 
 
Golgi 
membrane 
 
GFAT 
 
 
 
 
glutamine-fructose-6- 
phosphate transaminase 1; 
EC 2.6.1.16; regulates 
glucoseflux to hexosamine 
pathway 
1.4 fold 
increase in 
enzymatic 
activity 
 
cytoplasm 
 
GYS1 
 
Glycogen synthase; EC 
2.4.1.11 
inhibits enzymatic 
activity 
cytoplasm 
 
H2B  
 
Histone H2B activates 
stress-induced 
transcription 
nucleus 
 
HDAC5 
 
 
 
 
Histone deacetylase 5; 
EC3.5.1.98; transcriptional 
regulator, cell cycle 
progression, development 
 
reduced binding 
to GLUT4 
promoter → 
enhanced 
GLUT4 expression 
nucleus 
(cytoplasm) 
 
 196 
HNF4 
alpha 
 
Hepatocyte nuclear factor 4 
alpha; transcription factor, 
control of gene expression 
in hepatocytes 
reduced DNAbinding 
 
nucleus 
 
HSL 
 
Hormone sensitive lipase; 
EC 3.1.1.79; involved in 
triglyceride lipolysis 
inhibition; change in the 
association 
with lipid 
droplets 
cytoplasm, 
lipid droplets 
 
IRS1; 
adaptor 
protein 
Insulin receptor substrate 
1, adaptor protein 
modulation of 
PI3 kinase 
signaling 
cytoplasm 
 
KCNMA1 
iso4; 
α subunit 
of BKCa 
channel 
Potassium channel, activated 
in response to membrane 
depolarization, 
oxygen sensing in carotid 
body 
inhibition of 
potassium 
currents 
 
integral 
membrane 
protein, 
plasma membrane, 
axon 
Kir6.2 
(KCNJ11) 
 
Potassium channel, voltage 
dependent, inward 
rectifying 
might play a 
role in insulin 
secretion 
plasma 
membrane 
 
KNS2 
 
 
Kinesin 2; kinesin light 
chain 1, motor protein 
 
biological role 
of modification 
not known 
cytoplasm, 
microtubules 
KPNA2, 
importin- 
α1 
Adaptor for classical 
nuclear import 
 
interferes with 
nuclear import 
of HuR 
cytoplasm, 
nucleus, nuclear 
envelope 
mTOR 
 
 
Ser/thr kinase; EC 2.7.11.1; 
catalytic subunit of 
mTORC1 and mTORC2 
links nutrient 
supply to 
translation 
cytoplasm 
 
NKCC2 
(SLC12A1) 
 
Electroneutral transporter; 
reabsorption of Na+ and 
Cl¯; controls cell volume 
regulation of 
transporter 
activity 
plasma 
membrane 
 
p27Kip1 
(CDKN4) 
 
 
Cyclin-dependent kinase 
inhibitor 1B, controls cell 
cycle progression at G1 
 
stabilization of 
p27; linked to 
autophagy 
 
nucleus 
 
p300 
 
 
 
 
Protein (histone) 
acetyltransferase; 
EC2.3.1.48; transcriptional 
co-activator 
inhibits 
interaction 
with nuclear 
receptors, such 
as PPARγ 
nucleus 
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p53 
 
Tumor suppressor, 
transcription factor, cell 
cycle arrest, DNA repair, 
apoptosis 
 
stabilization of 
p300-p53 interaction; 
controls 
cell cycle 
progression 
nucleus 
 
PFKFB2 
 
 
 
 
6-Phosphofructo-2-kinase/ 
fructose-2,6- 
bisphosphatase 2; EC 
2.7.1.105 or EC 3.1.3.46; 
glycolysis 
activation; 
stimulation of 
glycolysis 
 
cytoplasm 
 
PFKFB3; 
 
 
iPFK2 
similar to PFKFB2; 
inducible in monocytes 
activation cytoplasm 
 
PPP1R3C 
(R5/PTG) 
 
 
 
Regulatory subunit of 
protein phosphatase PP1; 
controls PP1 activity; 
targets PP1 to glycogen; 
stimulation of glycogen 
synthase 
promotes 
ubiquitination 
and thereby 
degradation 
 
glycogen 
granules 
 
PPP2R5C 
(B56 γ) 
 
 
Regulatory subunit of protein 
phosphatase PP2A; 
possible role in the regulation 
and targeting of PP2A 
increases 
PP2A activity 
 
nucleus, 
chromosomes 
 
Raf1 
 
 
 
Ser/thr kinase; EC 2.7.11.1; 
component of 
Ras→Raf→MEK1/2→ERK 
1/2 signaling pathway 
 cytoplasm, 
plasma 
membrane 
 
Raptor 
 
 
 
Regulation of mTORC1 
(mammalian target of 
rapamycin complex 1); 
functions as scaffold 
inhibition of 
mTORC1; cell 
cycle arrest 
 
cytoplasm 
 
Rb 
 
 
 
 
 
Retinoblastoma protein; 
regulates cell cycle 
progression 
at G1; functions as 
transcriptional co-regulator; 
tumor suppressor 
control of brain 
development 
 
nucleus 
 
smMLCK 
 
 
Smooth muscle myosin 
light chain kinase; ser/thr 
protein kinase; EC2.7.11.18 
reduces 
activity of 
smMLCK 
cytoplasm 
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TBC1D1 
 
 
GTPase activating protein 
Rab family members; 
regulates glucose transport 
induces 
binding to 14- 
3-3 proteins 
ER 
 
TIF-IA 
 
Transcription initiation 
factor for RNA-pol I 
reduced rDNA 
transcription 
nucleolus 
 
TORC2 
(CRTC2) 
 
 
Transducer of regulated 
CREB protein 2; 
transcriptional regulator 
 
phosphorylation 
causes 
cytoplasmic 
retention 
nucleus, 
cytoplasm 
 
TSC2 
(tuberin) 
 
 
Generates heterodimer 
with hamartin (TSC1); 
TSC1/TSC2 functions as 
GTPase activator of Rheb 
enhances TSC2 
activity → 
inhibition of 
mTOR 
cytoplasm 
 
ULK1 
 
 
 
Ser/thr kinase; EC 2.7.11.1; 
binds to mTORC1 via 
raptor, binding controlled 
by nutrient supply 
control of 
autophagy 
 
cytoplasm 
 
VASP 
 
 
Vasodilator-stimulated 
phosphoprotein; actin 
regulator 
impairs endothelial 
actin 
assembly 
cytoplasm, 
cytoskeleton 
 
ZNF692 
(AREBP) 
 
Transcriptional regulator, 
contains zinc finger 
 
reduction in 
DNA binding 
 
nucleus 
 
 
 
Substrates 
for 
AMPKα2 
Function  
 
Effect of 
phosphorylation 
Primary 
intracellular 
localization 
ACC1 
 
See above description of 
AMPKα1 targets 
 cytoplasm 
 
AS160 
(TBC1D4; 
Akt 
substrate of 
160k) 
GTPase activating protein for 
Rab; implicated in GLUT4 
exocytosis in skeletal muscle 
 
not fully 
understood; 
may regulate 
glucose uptake 
cytoplasm 
 
HAS2 
 
 
Hyaluronic acid synthase 2; 
EC 2.4.1.212; integral 
membrane protein 
inhibition of 
enzymatic 
activity 
plasma 
membrane 
 
HDAC5 
 
See above description of 
AMPKα1 targets 
 nucleus 
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p53 
 
See above description of 
AMPKα1 targets 
 nucleus 
 
PGC1α 
 
PPAR γ coactivator-1; 
transcriptional 
co-activator; association with 
PPARγ; 
binds to CREB and nuclear 
respiratory factors; controls 
mitochondrial biogenesis 
phosphorylation 
alters 
activity as 
transcriptional 
regulator 
 
nucleus 
 
PLD1 
 
Phospholipase D1 
phophatidylcholine 
specific; EC 3.1.4.4; linked 
to Ras signaling; involved 
in membrane trafficking 
 
activation of 
enzymatic 
activity 
 
Golgi, ER 
 
 
 
 
 
